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ABSTRACT 
 
Lamins A and C, also known as A-type lamins, are type V nuclear intermediate 
filament proteins which form an interlacing meshwork of filaments subjacent to the 
inner nuclear membrane termed the nuclear lamina. A-type lamins have been 
implicated in DNA replication, gene transcription regulation, apoptosis, regulation 
of growth promoters and nuclear migration. Traditionally, expression of A-type 
lamins has been associated with differentiated cells. As such, mutations in A-type 
lamins have been associated with a diverse range of genetic diseases, including 
premature ageing syndromes and with increased proliferation, especially in 
tumours.  
In colorectal cancer, expression of A-type lamins, have been shown to impart an 
adverse prognosis. In order to understand the underlying biological processes 
responsible for this adverse outcome in patients with colorectal cancer, I sought to 
clarify the expression profile of A-type lamins and their binding partners in normal 
colonic/rectal mucosa, prior to investigating the expression of A-type lamins in 
colorectal cancers. I used fresh tissue specimens obtained from patients with 
colorectal cancer for my experiments. A unique finding was the expression of 
lamin A in the putative stem cell niche of colonic / rectal mucosal crypts.  
Further studies in the form of a microarray analysis, revealed a very complex 
picture of up regulation involving various signalling cascades in the cancer 
samples expressing A-type lamins. There was no evidence to suggest a direct 
involvement of A-type lamins influencing the Wnt signalling cascade, however, 
direct involvement of other signalling cascades, such as the IGF signalling 
cascade, Shh signalling cascade and TGF-β signalling cascades were noted. 
These signalling cascades were known to influence the Wnt signalling cascades 
and hence could play a crucial role in the pathogenesis of colorectal cancers 
expressing A-type lamins. 
In addition to these important signalling cascades, other key genes involved in 
apoptosis, growth promoters, cell adhesion, stem cell regulation, oncogenes and 
tumour suppression, were noted to have a unique expression profile in the cancer 
12 | P a g e  
 
sample expressing A-type lamins, not observed in the cancer sample lacking A-
type lamin expression. These observations were suggestive of A-type lamins 
having a diverse range of actions via, as yet, undefined pathways. It would appear 
that A-type lamins were imparting a more motile, less adherent phenotype with 
stem cell like features in colorectal cancers expressing A-type lamins. This could 
explain the observed poor prognosis of patients with colorectal cancers expressing 
A-type lamins. 
Creatine kinase brain (CKB), was also identified as an additional, potential, 
prognostic indicator in the Duke’s B group of patients with colorectal cancer 
expressing A-type lamins. This potential marker, in conjunction with A-type lamin 
expression could be used to identify a sub group of Duke’s B patients at high risk. 
Whether adjuvant therapy in this group would help improve their long term survival 
is unknown since no study has been done to assess this. 
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PSA   Prostate Specific Antigen 
PTEN   Phosphate and Tensin Homolog 
PUFA   Polyunsaturated Fatty Acids 
RD   Restrictive Dermopathy 
RECQL2 DNA helicase-like / Werner syndrome ATP-dependent 
helicase 
rhBMP  Recombinant Human BMP 
RNA   RiboNucleic Acid 
ROBO1 Roundabout, axon guidance receptor, homolog 1 (Drosophila) 
21 | P a g e  
 
rpm   Revolutions per minute 
RT   Room Temperature 
RT-PCR  Reverse Transcriptase – Polymerase Chain Reaction 
SCC   Squamous Cell Carcinoma 
SD   Standard Deviation 
SDS   Sodium Dioecyl Sulphate 
SDS-PAGE Sodium Dioecyl Sulphate – Polyacrylamide Gel 
Electrophoresis 
Shh   Sonic hedgehog  
SLR   Signal Log Ratio 
SMAD4 Mothers Against Decapentaplegic (Drosophila) Homolog 4 
SOC   Super Optimal Broth [Catabolite Repression] 
SOM   Self Organising Maps 
SPSS   Statistical Package for the Social Sciences 
SREBP-1  sterol regulatory element binding protein 1 
STA   Emerin gene 
STK11  Serine/Threonine Kinase 11 
SUN   Sad1 / UNC-84 homology 
SVD   Singular Value Decomposition 
SVM   Support Vector Machines 
T   Thymine nucleotide 
t   Time 
TAE   Tris-Acetate-EDTA 
Taq   Thermus aquaticus 
TBE   Tris-Borate-EDTA 
TBS   Tris Buffered Saline 
Tcf   T-cell Factor 
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TE   Tris / EDTA 
TEMED  N,N,N’N’-tetramethylethylendiamine 
TGFα   Transforming Growth Factor α 
TGFβ   Transforming Growth Factor β 
TGFβIIR  Transforming Growth Factor β Receptor II 
Tm   Melt Temperature 
TNM   Tumour Node Metastsis 
TP53   Tumour Protein 53 
Ub   Ubiquitin 
UC   Ulcerative Colitis 
UK   United Kingdom 
US   United States 
USA   United States of America 
UV   Ultraviolet 
V   Volts 
v/v   volume / volume 
-ve   negative 
v-EGF   vascular endothelial growth factor 
vs.   versus 
w/v   weight / volume 
Wg   Wingless 
WHO   World Health Organisation 
WISP3  WNT-1 inducible signalling pathway protein 3 
XL   X-linked 
yr   year 
β-TrCP  β-Transducin repeat containing protein 
δH2O   Distilled Water 
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δδH2O  Ultrapure Water 
µg   microgram 
µl   microlitre 
µm   micrometre 
µmol   micromole 
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CHAPTER 1 
INTRODUCTION  
 
1.1 Cancer of the colon and rectum Epidemiology 
 
Around the world there were 11 million cases of cancer diagnosed in the year 
2002 (cancer research 2008). In the UK there are around 285,000 new cases of 
cancer diagnosed each year. Breast, lung, bowel and prostate cancers account for 
over half of all these cases (Figure 1.1). Colorectal cancer is the third most 
common cancer to affect the population in the UK. In 2004, there were 36,209 
cases of bowel cancers registered in the UK, two thirds of these affected the colon 
and the rest were in the rectum. The male to female ratio stands at 1.2 : 1.0. From 
1979 up to 1999, there has been on average a 1% rise per annum in the incidence 
of male bowel cancer. Thereafter recently there has been a slight decline. During 
the same period, the incidence of female bowel cancer has remained pretty much 
the same. There has been a gradual decline in the mortality associated with 
colorectal cancer (Figure 1.2). However, nearly 16,000 people died in the year 
2006 from this cancer. Colorectal cancer is the second most common cause of 
death after lung cancer in the UK (Figure 1.3). Despite a gradual increase in 
incidence, the mortality related to this cancer has declined. The five year survival 
rate for men with colon cancer has increased from 22% (23% for women) in the 
1970s to 47% (48% for women) in the late 1990s. A similar trend is seen with 
rectal cancer over the same time period (cancer research UK 2008). 
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Source: http://info.cancerresearchuk.org/cancerstats/types/bowel 
Figure 1.1 
The 20 most commonly diagnosed cancers in the UK 
 
 
 
Source: http://info.cancerresearchuk.org/cancerstats/types/bowel 
Figure 1.2 
Age standardized incidence and mortality rates by sex in the UK. 
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Source: http://info.cancerresearchuk.org/cancerstats/types/bowel 
Figure 1.3 
Mortality rates associated with the twenty most common cancers in the UK 
 
 
1.1.1 Staging of Colon and Rectal Cancer 
 
An important determinant of survival is stage of the disease. Various staging 
systems are in place. The earliest of these is Dukes’ staging system (Dukes, 
1932), which takes into account the spread of cancer through various layers of the 
bowel wall. Dukes’ originally proposed three stages, A, B and C. Stage A cancer is 
limited to the mucosa; stage B cancer indicates spread to the muscular layer and 
stage C cancer indicates spread to at least one lymph node. Stage C cancer was 
later modified to include stage C1, which indicates involvement of localised lymph 
nodes close to the bowel and stage C2, which indicates spread to the highest 
lymph node in the sample of tissue removed (Gabriel et al., 1935). Stage D was 
added on later by Turnbull (Turnbull et al., 1967) to indicate distant spread of 
disease (Figure 1.4).  
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Figure 1.4 
Diagrammatic representation of various tumour stages in colorectal cancer. 
A window shows greater detail of the various layers seen in the colonic / 
rectal wall.       
Source: www.annistononcology.com  
Stage 0 corresponds to Dukes’ stage A 
Stage I and II corresponds to Dukes’ stage B 
Stage III corresponds to Dukes’ stage C 
Stage IV corresponds to Dukes’ stage D 
 
This modified Dukes’ staging system is still widely used throughout the UK. In 
addition, there is the TNM staging system (AJCC, 1997) where T stands for 
tumour, N stands for nodes and M stands for metastasis. TNM comprises of stage 
0, 1, 2, 3 and 4 depending on the extent of tumour spread, node deposits and 
metastasis (Figure 1.5). Early stage disease has a much better outcome in terms 
of five year survival figures as compared to late stage disease. The correlation 
between various stages and approximate five year survival levels has been 
demonstrated in tables 1.1, 1.2 and 1.3. Early stage bowel cancer i.e. Dukes’ A 
(equivalent to Stage 1 disease in the TNM system) has an 83% survival rate at 5 
years whereas Dukes’ D stage has a 3% survival rate at five years. Obviously, the 
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earlier bowel cancer is diagnosed and treated, the better it is for improving 
survival. 
 
Figure 1.5 
Diagrammatic representation of the TNM classification system 
Source: www.annistononcology.com  
Tumour Node Metastasis (TNM) Definitions agreed by the 
American Joint Committee on Cancer (AJCC) 
Primary Tumour  
TX: Primary tumor cannot be assessed 
TO: No evidence of primary tumor 
Tis: Carcinoma in situ (intraepithelial or intramucosal carcinoma) 
T1: Tumor invades the submucosa 
T2: Tumor invades the muscularis propria 
T3: Tumor invades through the muscularis propria into the subserosa or into the 
       nonperitonealized pericolic or perirectal tissues 
T4: Tumor directly invades other organs or structures (T4a) or perforates the visceral 
peritoneum (T4b) 
 
Regional Lymph Nodes  
NX: Regional lymph nodes cannot be assessed 
NO: No regional lymph node metastasis 
N1: Metastasis in 1 to 3 lymph nodes 
N2: Metastasis in 4 or more lymph nodes 
 
Distant Metastasis (M) 
 
MX: Presence of distant metastasis cannot be assessed 
M0: No distant metastasis 
M1: Distant metastasis 
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Stage TNM Stage Groupings Modified Astler-Coller Stage Dukes Stage - Modified 
Stage 0 Tis  No  Mo Stage A Stage A 
Stage I T1  No  Mo 
T2  No  Mo 
N/A 
Stage B1 
Stage B 
Stage B 
Stage II T3  No  Mo 
T4  No  Mo 
Stage B2 
Stage B3 
Stage B 
Stage B 
Stage III Any T  N1  Mo 
Any T  N2  Mo 
Stage C1(T2); C2(T3); C3(T4) 
Stage C1(T2); C2(T3); C3(T4) 
Stage C 1 
Stage C 2 
Stage IV Any T  Any N  M1 Stage D Stage D 
Table 1.1 
Comparison of various colorectal cancer staging protocols in clinical use 
 
 
Table 1.2 
Correlations between TNM stage and survival in colorectal carcinoma  
 
 
Dukes Stage Approximate Frequency at 
Diagnosis 
Approximate Five Year 
Survival 
A 11% 83% 
B 35% 64% 
C 26% 38% 
D 29% 03% 
Table 1.3 
Correlation between Dukes’ stages of colorectal cancer and survival figures 
      Source: Cancer research UK 
         http://info.cancerresearchuk.org/cancerstats/types/bowel/survival 
TNM Stage 5 Year Survival (%) 
Stage 0, I (Tis, T1; No; Mo) >90 
                 Stage I (T2; No; Mo) 80 – 85  
                 Stage II (T3; T4; No; Mo) 70 – 75  
                 Stage III (T2; N1 – 3; Mo) 70 – 75  
                 Stage III (T3; N 1 – 3; Mo) 50 – 65  
                 Stage III (T4; N 1 – 3; Mo) 25 – 45  
                 Stage IV (M1) <3 
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1.1.2 Detection and Screening for Bowel cancer 
 
Symptoms related to early bowel cancer can be fairly innocuous and hence by the 
time significant symptoms do develop, this cancer can be fairly advanced. Various 
symptoms are attributable to bowel cancer. A change in bowel habit over the last 
few weeks or months is significant, especially a history of alternating loose stools 
with episodes of constipation. Passage of dark red blood, either mixed with stools 
or on its own is also significant. Passage of bright red, rectal blood in the absence 
of other anal disease such as haemorrhoids, anal fissures, etc, is also a significant 
symptom. Tenesmus or a feeling of incomplete evacuation of faeces after a bowel 
motion is highly significant and could signify a low rectal cancer. Various signs are 
attributable to bowel cancer but anaemia proves to be a fairly common feature of 
this cancer and can be detected early on. A whole host of investigations are 
usually carried out if bowel cancer is suspected. Investigations such as 
examination of the bowel with an endoscope (sigmoidoscopy / colonoscopy) are 
usually invasive and carry a small but finite risk of damaging the bowel. There are 
other non invasive modalities to investigate bowel cancer such as computerised 
tomography (CT), magnetic resonance imaging (MRI) and ultrasound scans, but 
none of them are capable of yielding a histological diagnosis of bowel cancer and 
hence they are used mostly for staging and follow up of bowel cancer patients. 
Some newer, non invasive, tests are available in a few centres such as CT 
colonography, but their routine use has significant financial constraints (Regge et 
al., 2009a; Regge et al., 2009b; Robertson et al., 2005). 
The early detection and treatment of bowel cancer leads to a reduction in mortality 
and morbidity. To this end various screening tools have been evaluated. The use 
of faecal occult blood (FOB) testing as a screening tool has been investigated in 
randomised control trials. The Minnesota Colon Cancer Control Study assessed 
the efficacy of annual FOB against FOB testing every two years and a control 
group (Mandel et al., 1993). They showed a 33 percent decline in mortality 
associated with annual screening. In addition they also showed an increase in 
Dukes stage D cancers amongst the control group. In Nottingham, UK, a 
randomized control trial was undertaken between 1981 and 1991, to assess fecal 
occult blood testing as a screening tool for colorectal cancer (Hardcastle et al., 
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1996). They demonstrated a 15 % reduction in mortality from colorectal cancer in 
the screened group. The authors’ recommendations from the Nottingham study 
were for the establishment of a national screening program. The UK Department 
of Health subsequently instituted a UK Colorectal Cancer Screening Pilot study in 
2000. The results from this pilot study were in keeping with improved survival and 
an overall cost benefit. This led to the development of a national bowel screening 
program, instituted in 2006 using FOB testing. 
 
1.1.3 Treatment of Bowel Cancer 
 
This is dependant on a multitude of factors. Stage of the disease and factors 
relating to the patients general health are crucial in deciding appropriate 
management. The decision to offer treatment for bowel cancer is the remit of “Multi 
Disciplinary Teams” which take into consideration various factors before deciding 
on various treatment options. Surgery is the mainstay of treatment for bowel 
cancer. In addition, adjuvant therapy in the form of chemotherapy and in cases of 
rectal cancer, chemo / radio therapy, are also offered to patients as these have 
been shown to improve survival. These adjuvant therapies may be given pre or 
post operatively. In advanced cases, surgery may not be possible and palliative 
chemo / radio therapy is all that can be offered. According to national guidelines 
(Association of Coloproctologists of Great Britain and Ireland – ACPGBI), the 
treatment of Dukes stage A cancers is limited to surgery alone. In cases of Dukes 
C and D, this is a combination of Surgery and chemo / radio therapy. It is in cases 
of Dukes B cancers in which there is great debate about which patient will benefit 
from adjuvant therapy (IMPACT B2, 1999). The decision to offer patients with 
Dukes B cancers adjuvant therapy is open to debate as there has been no trial 
which conclusively shows an increase in survival in patients with Dukes’ B tumours 
who receive chemo / radiotherapy. The decision to offer such patients adjuvant 
therapy is usually based on local hospital policies and the decision of the MDT 
panel. Various prognostic factors have been studied but as yet there is no 
conclusive factor which could sway the decision in favour of or against giving 
patients with Dukes’ B tumours adjuvant therapy (1999). 
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1.1.4 Prognostic Factors in Bowel Cancer 
 
Prior to surgery, all patients have a clinical stage (cTNM) to their disease 
assigned. This stage is then confirmed and modified, if need be, with a definitive 
pathological stage (pTNM) of the disease based on histological findings. During 
histological assessment, other features of the tumour and associated host 
response are also looked at. It is these additional features which are taken into 
consideration when assigning a prognosis (related to survival) and determining 
predictive (related to likelihood of response to adjuvant therapy) values. 
Established histological features with a significant outcome on prognosis are: 
1) Pathological stage of cancer  
a. TNM 
b. Dukes 
2) Histological grade of cancer 
a. Well differentiated 
b. Moderately differentiated 
c. Poorly differentiated 
3) Tumour type 
a. Adenocarcinoma 
b. Medullary carcinoma 
c. Mucinous (colloid) adenocarcinoma  
d. Signet-ring cell carcinoma  
4) Vascular invasion 
 
5) Resection margins 
a. Proximal 
b. Distal 
c. Circumferential resection margins 
 
In addition to these well documented and established prognostic / predictive 
factors, there are other factors which have been reported in the literature but are 
33 | P a g e  
 
awaiting validation prior to being introduced into routine patient care. These factors 
are mostly independent of stage. The following is a list of some important 
prognostic / predictive factors (Cawkwell et al., 1999; Compton, 2003; Parc et al., 
2004; Petersen et al., 2002): 
 
1. Perineural invasion (PNI) 
Perineural invasion is defined as invasion into Auerbach’s plexus (Fujita et 
al., 2007). The significance of this observation is still controversial, 
however, several reports have suggested that PNI adversely influences 
prognosis in patients with colorectal cancer (Burdy et al., 2001; Di Fabio et 
al., 2004; Huh et al., ; Ueno et al., 2001). PNI is also indicative of an 
infiltrating tumour border configuration, which is an adverse prognostic 
factor in its own right, as revealed by other studies (Compton, 2003). 
 
2. Tumour perforation 
Transmural involvement of the colonic wall with free perforation of the 
tumour into the abdominal cavity is a very serious event and is classified as 
a T4b tumour by the AJCC, Version 6 (Greene and Sobin, 2002). This has 
been shown to adversely affect outcome and is a poor prognostic indicator 
(Compton, 2003; Fleming et al., 1997). 
 
3. Host immune response  
The presence of lymphocytes in tumour and/or peri-tumoural tissue is 
indicative of an immunogenic response by the host. Certain studies 
consider this to a favorable prognostic factor (Compton et al., 2000a; 
Compton et al., 2000b). However, other studies have failed to reveal any 
association between host immunogenic response and prognosis. Proctor 
and Horgan et al (Horgan and McMillan, ; Proctor et al.) carried out an 
extensive study looking at inflammatory markers in patients with various 
cancers, including colorectal cancers. Their findings suggest an adverse 
outcome in patients in whom there is evidence of a strong host immune 
response. 
 
4. Total number of lymph nodes examined 
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Assessment of regional lymph nodes forms part of the staging process 
used for colorectal cancer assessment and prognosis. This process is 
carried out using conventional Immunohistological techniques on lymph 
nodes identified macroscopically. It has been shown that many nodal 
metastasis occur in lymph nodes less than 5 mm in diameter and hence a 
thorough search for lymph nodes is essential (Herrera-Ornelas et al., 1987). 
The exact number of lymph nodes needed for accurate assessment is still 
uncertain, however, studies have shown that a minimum of 12 – 15 lymph 
nodes need to be examined to predict accurate regional lymph node 
negativity (Scott and Grace, 1989; Tepper et al., 2001). It is generally 
accepted that a minimum of 12 regional lymph nodes need to be harvested 
and examined for accurate staging. 
 
1.1.5 Molecular Markers 
 
In the last decade, significant research has been carried out in the field of 
colorectal cancer at a molecular and genetic level. During this time, many 
important molecular markers have been identified. The true prognostic value of 
these markers has been difficult to assess as there is a paucity of trials and other 
relevant clinical data. However, there are a few important molecular and genetic 
markers which could, in the near future, be used as prognostic markers in routine 
patient care. The following is a list of the more important of these markers with 
brief comments about them:  
 
a. Microsatellite instability (MSI) 
About 5 – 7% of colorectal cancers are part of an inherited condition 
called Hereditary Non Polyposis Colorectal Cancer (HNPCC). This 
condition arises as a result of a defect in DNA mismatch repair 
(MMR) pathways secondary to mutation(s) in the genes controlling 
these pathways, usually hMSH2 and hMLH1 genes. Tumours with 
mutations in MMR genes exhibit a particular phenotype termed 
‘microsatellite instability’ (MSI). Repeated DNA sequences, termed 
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microsatellites, can be replicated incorrectly. If not corrected by the 
MMR enzymes, this will result in abnormal lengthening or shortening 
of the DNA region. Characteristically, 29% of HNPCC tumours 
assessed show MSI termed as MSI-H (MSI-high). Patients with this 
have been shown to have a good prognosis but a higher than normal 
chance of developing another colorectal cancer in a short space of 
time. There is also some evidence to suggest that these tumours are 
not sensitive to routinely used chemotherapeutic agents for treating 
colorectal cancer. Testing for MSI is time consuming and expensive 
as it requires DNA extraction with subsequent Polymerase Chain 
Reaction. An indirect way to assess MSI in tumours has been 
proposed and tested to very good effect (Parc et al., 2004). This 
involves immunohistochemical analysis using antibodies against 
hMSH2 and hMLH1 genes. There are limitations to this alternate 
method of identifying patients with MSI such as, missing patients 
with MSI due to defects in genes for MMR other than the ones being 
tested for. Despite its limitations, patients with stage II colorectal 
cancer and MSI-H, have a very good prognosis and do not need 
adjuvant chemotherapy. 
 
 
b. DCC / 18q LOH (Deleted in Colon Cancer / Chromosome 18q Loss 
of Heterozygosity)  
DCC is a putative tumour suppressor gene located on chromosome 
18q21. Loss of Heterozygosity at this locus results in a poor 
prognosis with shortened disease free survival time. Patients with 
stage II colorectal cancer and exhibiting 18q LOH, may benefit from 
adjuvant chemotherapy, however appropriate trials are awaited. 
 
c. CEA (Carcinoembryonic antigen) 
CEA was first identified in 1965 by Gold and Freedman, when they 
identified an antigen in fetal colons and colon adenocarcinoma, but 
absent from healthy adult colon. Hence its name carcino and 
embryonic antigen. CEA is a glycoprotein involved in cell adhesion 
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and belongs to the immunoglobulin superfamily. Its main use in 
colorectal cancer is for detection of recurrence after treatment of the 
primary tumour. It is also very useful in detection of metastatic 
spread of colorectal cancer to the liver (Berman et al., 2000; Pietra et 
al., 1998) 
 
d. c-myc 
Myc gene was first discovered in Burkitt’s lymphoma patients. This 
gene was similar to myelocytomatosis viral oncogene (v-Myc) and 
hence it was called c-Myc. The protein product of this gene is a 
transcription factor capable of activating many genes (Gearhart et 
al., 2007). It can also act as a transcriptional repressor and has a 
direct role in DNA replication (Dominguez-Sola et al., 2007). Various 
mitogenic signals, like Wnt, Shh and EGF, are capable of activating 
Myc and result in numerous biological functions, such as cell 
proliferation, cell growth, apoptosis, differentiation and stem cell self 
renewal (Kanazawa et al., 2003; Taira et al., 1999). c-Myc has also 
been identified as a target in the APC pathway of colorectal cancer 
(He et al., 1998) 
e. K-ras 
KRAS is a protein encoded by the K-ras gene, located on 
chromosome 12 (McGrath et al., 1983; Popescu et al., 1985). KRAS 
protein is a GTPase and takes part in many signal transduction 
pathways. Mutated K-ras genes are potent oncogenes that play a 
significant role in many cancers, including colorectal cancer (Burmer 
and Loeb, 1989; Kranenburg, 2005). A K-ras mutation in colorectal 
cancer is also predictive of response to panitumumab and cetuximab 
therapy in colorectal cancer (Lievre et al., 2006). 
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1.2 Development and Structure of the Colon and 
Rectum 
1.2.1 Embryological Development 
 
The primitive gut is divided into three parts, foregut, midgut and hindgut. The adult 
colon and rectum develop from the embryonic hindgut and part of the midgut. In 
the embryo, the midgut extends from the intestinal portal and is, initially, in wide 
communication with the yolk sac. This communication subsequently narrows down 
and the mid gut becomes more tubular and elongated. It eventually develops into 
the remaining duodenum (the proximal part being derived from the foregut), 
jejunum, ileum, caecum, ascending colon and most of the transverse colon. The 
embryonic hindgut extends from the splenic flexure area of the colon up to the 
cloacal membrane (a more distal or caudal area where the ectoderm and 
endoderm are in direct opposition to each other). 
The primitive embryonic gut is composed of cells derived from three layers: 
a) The splanchnopleuric coelomic epithelium forms the outer visceral 
or serosal layer of the gut. 
b) The endodermal epithelium forms the epithelium of the mucosa, 
the lining cells of adjoining ducts and the secretory cells of 
associated glands. 
c) The splanchnopleuric mesenchyme gives rise to all intervening 
structures between the above two layers. These are outer 
connective tissue layers, muscularis externa and submucosal 
connective tissue layer (muscularis mucosae and lamina propria of 
the mucosa).  In addition, blood vessels and lymphatics are also 
derived from this layer. 
Innervation of the gut is via migrating neural crest cells which form the enteric 
plexuses. Lymphoid tissue gets incorporated into the gut by two processes; by 
assimilation of cells within the epithelial layer of the mucosa and by colonization of 
the submucosa by individual germinal centers of lymphoid follicles (Gray’s 
Anatomy, 1995) 
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1.2.2 Anatomical Layers 
 
The colon commences at the caecum and includes the ascending, transverse, 
descending and sigmoid colon. The rectum continues after the sigmoid colon to 
end at the anal canal. The architecture of the colon and rectum is fairly uniform 
throughout. The rectum tends to have a thicker and more uniform muscularis 
externa whereas in the colon, the outer longitudinal part of muscularis externa is 
condensed into three discreet muscle strips, called “taenia coli” that run the full 
length of the colon and are responsible for giving it a haustrated appearance. 
Broadly speaking, the colon and rectum are composed of three layers; mucosa, 
muscularis externa and serosa (Figure 1.6). 
 
 
Figure 1.6 
Tissue layers of the colon with cut-away detailing various layers of the colon
       Source: www.hopkins-gi.org  
 
1.2.2.1  Mucosa 
This forms the innermost layer of the colon and rectum. This, one cell thick 
epithelial layer is composed of columnar cells, mucous secreting cells (goblet 
cells) and microfold cells, at its luminal surface. The luminal surface is devoid of 
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any villi in contrast to the small intestine. Numerous pit-like intestinal crypts are 
present throughout the colon and rectum. These intestinal crypts are the functional 
units of the colon and rectum. They contain entero-endocrine and stem cells (at 
their bases) in addition to the other cell types mentioned. 
Lamina propria is made of connective tissue and gives support to the overlying 
epithelium. Solitary lymphoid follicles are also found in this layer. 
Muscularis mucosa forms a layer of smooth muscle below the mucosa. Occasional 
slips of muscle are also noted running in between individual glands. 
The sub mucosa underlies the mucosa and consists of loose connective tissue 
within which are found blood vessels, nerves and lymphatics. 
1.2.2.2 Muscularis externa 
This forms the muscular coat of the colon and rectum. It is composed of two 
layers, an outer longitudinal layer and an inner circular layer. The outer 
longitudinal layer is concentrated into three discrete bands of muscle in the colon 
but completely invests the rectum. In the colon these longitudinal bands of muscle 
are called the taeniae coli. 
 
1.2.2.3  Serosa 
This layer is also known as the visceral peritoneum. It covers the colon and rectum 
to a variable extent. The transverse colon and sigmoid are completely invested in 
this layer while the ascending and descending colon and the upper rectum are 
only partially covered by this layer. 
 
1.2.3 Physiological Function 
 
The colon and rectum act primarily as a reservoir for undigested food particles 
prior to their evacuation from the anus. Inside this large reservoir, numerous 
bacteria are living in symbiosis with the human host. Bacterial action on the food 
residue helps in fermentation with subsequent digestion of food and release of 
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nutrients, especially minerals. In addition, fermentation of dietary fiber has a 
potential protective role against colorectal carcinogenesis. The exact underlying 
mechanisms are not clear though, however, fermentation of fiber leads to the 
formation of short chain fatty acids (SCFA). Butyrate, a SCFA, is one such by 
product of the fermentation process and has been shown to be protective against 
colorectal cancer in some studies (Lupton, 2004). The exact biological 
mechanism(s) responsible for this protective role of butyrate in colorectal cancer 
are unknown at present; however, recent studies have shown butyrate influencing 
the methylation of promoter sequences in the Mis Match Repair (MMR) genes 
(Dronamraju et al., 2008). 
The colon and rectum are also well equipped to absorb water back into the 
circulation. This process allows the waste products to become more solid and 
compacted. Most of the residue from the small bowel is liquid but by the time it 
leaves the human body, it is more or less well formed. 
In addition, the large bowel produces copious amounts of mucus which help in 
lubricating the luminal surface of the mucosal layer and also mucus at the bases of 
intestinal crypts prevents noxious substances from coming into contact with 
sensitive cells at these locations. This has very important beneficial effects as 
harmful or carcinogenic products are prevented from causing damage at the 
sensitive basal regions of these intestinal glands. The columnar cells lining the 
mucosa have microvilli at their apical (luminal) surfaces which contain secretory 
granule containing immunoglobulins of the IgA variety (Guyton 1991). 
 
1.2.4 The Colon Crypt as a Functional Unit and its 
Genetic Regulation 
 
The mucosal lining of the colon and rectum is characterized by a million pit-like 
invaginations termed intestinal glands (Figure 1.7 and 1.8). These intestinal glands 
form the main functional units of the colon and rectum. Colorectal cancer is 
thought to arise from these intestinal glands, after they undergo mutation. Each 
crypt or gland contains roughly 2000 cells which are renewed, on average, every 
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82 hours. The height of each crypt has been determined to be about 82 cells in 
height but this value is dependant on location in the colon or rectum and has been 
claimed as 40 in other studies. The total number of cells forming the circumference 
of each crypt has been estimated to be in the region of 41 cells (Potten et al., 
1992; Twombly, 2002). 
 
         
                            
 Figure 1.7                 Figure 1.8 
 
Diagrammatic representation of crypts in the colon / rectum illustrating various zones of the crypt in 
profile, including the stem cell niche area, the proliferative compartment and the differentiated 
zones, respectively. Also illustrated is the direction of cell migration. 
Adapted from (Twombly, 2002) 
 
The crypt can be divided into three zones; stem cell niche area, proliferative zone 
and differentiated zone. At the base of each crypt is the stem cell niche ranging 
from 4 to 12 cells. Studies using radiolabelling techniques and other putative stem 
cell markers have shown cells in the basal region of the crypt with properties in 
keeping with stem cells (Potten, 1998; Radtke et al., 2006). Cells above this stem 
cell niche area undergo rapid proliferation and move along the crypt axis towards 
the lumen. Maximum proliferative activity is noted in the lower third of the crypt 
(above the stem cell niche area) and gradually diminishes as these rapidly 
proliferating cells undergo differentiation towards the middle half of the crypt. Cells 
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above the proliferating zone are differentiated and move towards the lumen of the 
large bowel (Figure 1.8). At the luminal surface, these differentiated cells spread 
out like a sheet. Differentiated cells at the luminal surface undergo apoptosis and 
are shed into the lumen of the large bowel.  
Homeostatic control of all three compartments in the crypt is highly complex and 
involves multiple signaling pathways. These pathways are also implicated in the 
embryological development of the gut (de Santa Barbara et al., 2003). A few of the 
more important and better studied pathways are: WNT, Hedgehog, SOX, Notch 
and Bone Morphogenetic Protein (BMP), signaling pathways. The WNT pathway is 
considered highly significant in maintaining homeostasis in the crypt (Bienz and 
Clevers, 2000; Pinto et al., 2003) and is discussed in greater detail below (Figure 
1.9). 
 
Figure 1.9  
A view of the canonical Wnt signalling pathway. 
Wnts bind a receptor complex consisting of LRP5 or LRP6 and one of ten Fz proteins. 
This prevents phosphorylation of β-catenin by GSK3β and other kinases and its 
subsequent degradation. Stabilized β-catenin accumulates and translocates to the 
nucleus, where it interacts with Tcf7 and related transcription factors (Lef1, Tcf7L1, 
Tcf7L2) to regulate gene expression. Outside the cell, molecules that sequester either 
LRP5 (e.g., Dkk1 and sclerostin) or the Wnt ligand (e.g., Sfrp) negatively control the 
canonical Wnt signalling pathway. 
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Wnt genes encode for extracellular signaling molecules called Wnt factors. These 
are secreted glycoproteins responsible for numerous developmental processes 
including development and homeostasis in the gut. The source of these secreted 
Wnt factors is not clear but they are thought to originate at the base of intestinal 
crypts or underlying mesenchymal tissue (Batlle et al., 2002). Although Wnt genes 
are all included in one family, two distinct signaling pathways can be defined: the 
Wnt / β-catenin / Tcf 4 signalling pathway (also called as the canonical Wnt 
signaling pathway) and the Wnt / Ca2+ signaling pathway. Wnt signals act on cells 
by signal transduction pathways which ultimately act on gene expression 
programmes (Peifer, 2002). In the absence of Wnt stimulation, β-catenin is 
phosphorylated by two  
 
serine / threonine kinases: casein kinase I (CKI) phosphoryates β-catenin at Ser-
45, this in turn allows glycogen synthase kinase 3 β (GSK 3 β) to phosphorylate 
the remaining regulatory sites at Trr-41, Ser-37 and Ser-33 (Polakis, 1997). 
Phosphorylation of β-catenin takes place in a multiprotein complex made up of 
APC (Adenomatous Polyposis Coli), Axin (a scaffold protein) and Diversin (the 
ankyrin repeat protein which helps in recruiting CKI). Phosphorylation of β-catenin 
results in ubiquitination by the β-TrCP–E3-ligase complex and subsequent 
degradation by the proteosome (Figure1.9). Stimulation of the canonical Wnt / β-
catenin pathway occurs when Wnt glycoproteins bind to  the frizzled (Fz) seven-
span transmembrane receptors together with the low-density lipoprotein receptor-
related proteins 5 and 6 (LRP5/6) single-span transmembrane co-receptors, 
members of the low-density lipoprotein receptor related family (Pinto and Clevers, 
2005b). Intracellularly, degradation of β-catenin is prevented by inhibition of 
phosphorylation, resulting in its stabilization. In the presence of Wnt factors, 
Dishevelled (Dsh) prevents degradation of β-catenin by recruiting GBP/Frat-1, 
which displaces GSK3β from Axin. This prevents Axin from performing its role as a 
scaffold protein and leads to stabilization of β-catenin in the cytosol from where it 
translocates to the nucleus (Figure 1.9). Translocation of β-catenin into the 
nucleus is a poorly understood process. However, in the nucleus, β-catenin 
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interacts with transcription factors of the T-cell factor / lymphoid enhancing factor 
(TCF/LEF) family, namely Tcf-4, and forms complexes. This in turn results in 
transactivation of transcription genes like c-MYC and cyclin D1, with subsequent 
loss of its repression on the cell cycle inhibitor p21CIP1/WAF1and allows cells to enter 
S phase from G1. Thus nuclear accumulation of β-catenin is seen as a hallmark of 
active Wnt signaling. In the absence of Wnt signaling, β-catenin is exported from 
the nucleus by APC and subsequently degraded (Bienz, 2002). Nuclear 
accumulation of β-catenin decreases as one moves up along the crypt. This forms 
a crucial switch between proliferation and differentiation along the crypt axis (van 
de Wetering et al., 2002). 
Any mutational event which inactivates APC or activates β-catenin has the effect 
of rendering the canonical Wnt signaling pathway permanently on and can lead to 
tumourigenesis in the colon. It has been shown that mutations in the APC gene 
are noted in about 85% of all colorectal cancers (Kinzler and Vogelstein, 1996). It 
has also been noted that in aberrant crypt foci (ACF), which are the earliest, 
benign precursors of colorectal cancer, there is nuclear accumulation of β-catenin 
(van de Wetering et al., 2002). It is thus widely believed that activation of β-catenin 
/ TCF-4 is the earliest event responsible for initiation of colorectal cancer by 
allowing unrestricted proliferation of crypt cells. 
 
1.3 Colorectal Carcinogenesis – A Multistep 
Phenomenon 
 
The initiation, progression and spread of colorectal cancer has been studied 
extensively and proven to involve multiple stages.  Each stage of colorectal 
carcinogenesis has a unique molecular / genetic signature accompanied by well 
defined histological features and properties. The adenoma – carcinoma sequence 
(Fearon and Vogelstein, 1990) sets out a framework of various molecular / genetic 
changes involved in colorectal carcinogenesis (Figure 1.10). Colorectal 
carcinogenesis can be divided into four distinct stages: 
Aberrant crypt foci  Adenoma formation (Early, Intermediate and Late)  
Carcinoma  Metastasis. 
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Figure 1.10 
Adenoma – Carcinoma Sequence in Colorectal Carcinogenesis. 
1.3.1 Aberrant Crypt Foci (ACF) 
 
Aberrant crypt foci (ACF) are generally considered to be the early precursors 
towards cancer of the colon and rectum in terms of histological, immunological, 
biochemical, genetic and epigenetic changes seen in these lesions. ACF is the 
term used to describe abnormally large crypts, either single or multiple, with a 
thicker epithelial lining and a slit like or elliptical opening. These ACF were first 
described by Bird et.al (1987) in the colons of female mice treated with 
carcinogens. A year later it was put forward as a potential pre-neoplastic lesion in 
the colon of mice (McLellan and Bird, 1988). From there onwards further studies 
have shown that ACF, or at least a subset of ACF, might be the earliest precursors 
of colorectal cancer. An increase in the Immunohistochemical expression of 
carcinoembryonic antigen and β-catenin has been noted in ACF (Cheng and Lai, 
2003; Pretlow et al., 1994; van de Wetering et al., 2002). Mutations in APC, K-ras 
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and P53 are well documented in colorectal carcinogenesis. Similar mutations have 
also been observed in ACF (Smith et al., 1994). It has been observed that not all 
ACF are pre destined to become cancerous. The histopathological classification 
as recognized by the WHO, divides ACF into two main groups, hyperplastic ACF 
and dysplastic ACF. In hyperplastic ACF, the crypts are elongated with occasional 
branching and a serrated opening but no layering of epithelium is seen. The nuclei 
are also enlarged and elongated but there is no nuclear atypia. Mucin depletion is 
not seen. Cells with positive expression for proliferation markers are usually 
located at the basal to mid regions of the crypts. On the other hand, ACF with 
dysplasia show different properties. In addition to elongated and enlarged crypts, 
there is depolarization of nuclei, depletion of mucin and layering of cells. 
Expression of proliferative markers were also noted to be higher up in the crypt 
(Cheng and Lai, 2003). 
 
1.3.2 Early Adenomas – Role of APC (5q21) 
 
Adenomata are recognized as pre neoplastic lesions in the colon and rectum. For 
descriptive purposes these adenomata are also referred to as polyps (which 
essentially is a descriptive term describing any elevation in the intestinal mucosa). 
However, not all polyps have the potential towards malignant transformation, e.g. 
hyperplastic polyps, inflammatory polyps and metaplastic polyps. Macroscopically, 
Adenomatous polyps are divided into three categories: tubular, tubulo-villous and 
villous, with increasing malignant potential from the tubular variety towards the 
villous type. The APC gene is located on chromosome 5q21 and encodes a 2,843-
amino acid protein. Β-catenin is its major downstream target. Mutations in the APC 
gene are usually truncating mutations primarily in the first half of the gene (Miyoshi 
et al., 1992). In early adenomas, the APC gene is either mutated or there is loss of 
5q (APC gene). This gene is an essential component of the Wnt signaling pathway 
as discussed earlier. Loss of APC results in nuclear accumulation of β-catenin and 
a drive towards hyperproliferation. This hyperproliferation is noted in the upper 
third of the colon crypts in contrast to normal crypts where the proliferative 
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compartment is usually located in the lower two thirds. This results in an abnormal 
accumulation of cells at the mucosal surface leading to an early adenoma. 
 
1.3.3 Intermediate Adenomas – Proto-oncogene 
mutations 
 
Intermediate stage adenomas are characterized by mutations in proto-oncogenes. 
K-ras is a proto-oncogene and belongs to the ras gene family. They form an 
integral part of the intracellular signal transduction mechanism. Under normal 
conditions, K-ras is GTP bound and its activity is controlled by a GTPase which 
converts GTP to GDP, thus inactivating K-ras. Activating K-ras mutations result in 
decreased GTPase activity leading to a permanent state of K-ras activation with a 
consequent growth advantage conferred upon daughter cells (Navaratnam et al., 
1999). These types of mutations are observed in 35% - 42% of colorectal cancers 
(Worthley et al., 2007) and are responsible for the further progression of an early 
adenoma towards an intermediate stage adenoma. 
 
1.3.4 Late Adenomas – Mutations in tumour 
suppressor genes 
 
The p53 gene, a tumour suppressor gene, is mutated in 70% of colorectal 
cancers. This gene encodes for a protein that acts as an important transcription 
factor that binds to specific sequences of DNA and regulates expression of cell-
cycle retarding genes. These include Bax and the BH3 only proteins puma and 
noxa, which in turn inactivate bcl-2 and bcl-xl, resulting in release of cytochrome c 
from mitochondria (Fridman and Lowe, 2003). This is important in cases of DNA 
damage as it allows DNA repair mechanisms time to correct defects / damaged 
DNA. Should the damage to DNA prove irreparable. p53 induces pro apoptotic 
genes that trigger the apoptotic pathway (Figure 1.11). Mutations in DCC, SMAD2 
and SMAD4 are observed in more advanced adenomas. SMAD2 and SMAD4 are 
involved in TGF-β signaling pathways and hence are involved in regulating growth 
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as well as apoptosis. All three genes are located at 18q21.1. Allelic loss at this site 
is observed in a majority of colorectal cancers. DCC is also involved in apoptosis. 
Presumably, mutations in these genes results in the accumulation of genetic 
defects in cells that would have triggered apoptosis under normal conditions. This 
in turn could result in malignant transformation of these affected cells. Mutations in 
p53 (17p13), usually through allelic loss, is a late feature observed in advanced 
adenomas and colorectal cancers. 
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Figure 1.11 
 
Diagram depicting the downstream effects of mitogenic signals in 
intermediate and late stage colorectal adenomas 
 
Mitogenic signals (including APC mutations) cause activation of Ras. This inhibits 
the retinoblastoma (Rb) protein allowing E2F and Myc to promote cell cycle 
progression. p16INK4a is a tumour suppressor whose mutation permits cyclin D 
dependent kinase (CDK) to inhibit Rb. High levels of E2F or Myc activates 
p14ARF and thereby p53 which has multiple outputs. A series of proapoptotic bcl-
2 family members are stimulated and via PTEN the antiapoptotic actions of AKT 
are inhibited. 
 
Adapted from AJM Watson 2004  
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1.4 Sporadic and Inherited Bowel Cancer types 
 
1.4.1 Sporadic Cancer 
 
80% - 85% of colorectal cancers are sporadic where age is the most important 
determinant of risk (Figure 1.12). The remaining small percentage of CRC 
incidence is accounted for by patients whose risk is higher than the general 
population.  These patients include those with dominantly inherited CRC 
syndromes, e.g. familial adenomatous polyposis (FAP), hereditary non-polyposis 
colorectal cancer (HNPCC).  Other patient groups at risk include those with a 
personal history of CRC, ulcerative colitis (UC) and colonic Crohn’s, primary 
sclerosing cholangitis (PSC) or a liver transplant (LT), and those with familial CRC 
defined as “the presence of one first degree relative who is affected by CRC aged 
<45 years or two affected first degree relatives”. 
 
Figure 1.12 
 
Numbers of new cases and age-specific incidence rates, by sex of bowel 
cancer. 
Source: http://info.cancerresearchuk.org/cancerstats/types/bowel/incidence/ 
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The adenoma – carcinoma sequence as proposed by Fearon and Vogelstein 
(Fearon and Vogelstein, 1990) is based on the accumulation of genetic events 
which confer a growth advantage to a clonal population of cells with a resultant 
shift from adenomas to invasive carcinomas. In this model a number of key 
regulatory oncogenes and tumour suppressor genes acquire mutations which 
results in either activation or loss of function of theses key genes, as discussed 
earlier. This in turn drives normal colonic epithelium towards cancer. In the early 
stages of sporadic colorectal cancer development, somatic mutations are required 
in both APC alleles. For both APC alleles to undergo mutation a longer period of 
time, with appropriate exposure to various risk factors, including carcinogenic 
stimuli, is required and hence sporadic colorectal cancer is usually a disease 
affecting an older population group. 
 
1.4.2 Inherited bowel cancer syndromes 
 
1.4.2.1  Familial Adenomatosis Polyposis (FAP) 
 
Around 1% of colorectal cancers are due to FAP. This is an autosomal dominant 
condition in which one APC allele is inherited with a germline mutation. The 
prevalence of this condition is estimated to be 1 in 8000. Affected individuals are 
heterozygous for the mutated gene and have a 50% chance of passing it on to 
their offspring. Males and females are equally affected. These mutations are 
mostly between codons 169 and 1393 (Spirio et al., 1993). In cases with this 
condition the incidence of colorectal cancer is disproportionately high. Prior to 
adenomas developing, the other, normal APC allele needs to undergo mutation. 
Clinically in these patients, their colons are studded with multiple polyps (Muller et 
al., 2000). These cases usually develop colorectal cancer early in adult life and 
have a very poor prognosis unless a prophylactic colectomy is undertaken. They 
need regular surveillance and appropriate surgical intervention when required. In 
addition to colonic polyps, these patients may also manifest with extra-colonic 
features such as polyps affecting the upper gastrointestinal tract, osteomas, 
epidermoid cysts, desmoids formation, congenital hypertrophy of retinal pigment 
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and other malignant changes such as small bowel cancer, thyroid tumours, 
hepatoblastomas and brain tumours. Patients with these extra-colonic features are 
also classified under Gardner’s syndrome. 
 
1.4.2.2   Hereditary Non-Polyposis Colorectal Cancer (HNPCC) 
 
HNPCC is an autosomal dominant condition and, unlike FAP, most patients 
develop a solitary colorectal tumour. HNPCC accounts for about 3% to 5% of all 
colorectal cancer cases and is also known as Lynch syndrome. HNPCC is caused 
by inactivating mutations of one of several DNA mismatch repair genes. Patients 
with HNPCC have an estimated 80% lifetime risk of developing colorectal cancer 
(Vasen et al., 1996) at an average age of 44years as compared to 64 years for 
sporadic cancers. These patients are also prone to having synchronous and 
metachronus colorectal cancers as well as other extra-colonic malignancies such 
as endometrial, stomach, small bowel, renal, ureteric, ovarian, brain and biliary 
tree cancers. HNPCC may be diagnosed clinically using the modified Amsterdam 
criteria: 
Modified Amsterdam Criteria: 
 There should be at least three relatives with an HNPCC-associated cancer 
(colorectal cancer, endometrial, small bowel, ureter or renal pelvis 
malignancy). 
 One affected relative should be a first-degree relative of the other two. 
 At least two successive generations should be affected. 
 At least one malignancy should be diagnosed before age 50 years. 
 FAP should be excluded in the colorectal cancer case(s). 
 Tumours should be verified by pathological examination. 
1.4.2.3 Other Colon Cancer Syndromes 
 
Peutz-Jeghers syndrome (PJS) is an autosomal dominant condition which is 
associated with multiple gastrointestinal polyps, both hamartomatous and 
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adenomatous. The risk of developing cancer between the ages of 15 to 64 is 93%. 
The highest cumulative risk in these patients is for breast, colon, pancreatic, 
stomach and ovarian cancer. 
Juvenile-Polyposis is an autosomal dominant condition associated with 
hamartomatous polyps throughout the gastrointestinal tract. The underlying defect 
in this condition, in 15% to 20% cases,  is due to a germline mutation in the 
MADH4 gene, also known as SMAD4/DPC4, on chromosome 18q21(Howe et al., 
1998). In 25% to 45% of cases, mutations in the gene-encoding bone 
morphogenic receptor 1A, residing on chromosome band 10q22, are also noted 
(Howe et al., 2001). 
 
1.5 The Mammalian Nucleus 
 
In the mammalian cell, the nucleus forms the largest intracellular organelle. 
Separating the nucleus from the cytoplasm is the nuclear membrane or envelope. 
The main function of this membrane is to separate the delicate nuclear 
transcriptional apparatus and genome from the cytoplasm. This envelope is 
studded with nuclear pore complexes (NPCs) which traverse the full thickness of 
the nuclear membrane and allows selective movement of various molecules 
across it (Franke et al., 1981; Gerace and Burke, 1988). The nucleus contains 
DNA, RNA and proteins and is responsible for transcription and replication of 
DNA. DNA is packaged into chromatin, which is arranged into loops of 30 -100 
kbp, with anchorage of defined DNA sequences to the nuclear matrix (Vogelstein 
et al., 1980). These DNA sequences are known as matrix or scaffold attachment 
regions (MARs or SARs respectively).                       
 
1.5.1 The Nuclear Envelope and its Dynamic Function 
 
The nuclear envelope consists of two layers enclosing a perinuclear space. Both 
layers are made of a bilipid layer and are studded with Nuclear Pore Complexes 
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(NPCs). The outer nuclear membrane (ONM) also incorporates ribosomes on its 
cytoplasmic surface and is continuous with rough and smooth endoplasmic 
reticulum (ER). It is functionally similar to the ER (Gerace and Burke, 1988). The 
inner nuclear membrane (INM), on the other hand, is devoid of ribosomes and is 
lined on its inner or nucleoplasmic surface by the nuclear lamina, composed of 
filamentous units known as lamins (Gerace and Blobel, 1980). Nuclear envelope 
transmembrane proteins (NETs) form another subset of nuclear envelope proteins. 
Both lamins and NETs  are known to have many binding partners (Bengtsson and 
Wilson, 2004; Zastrow et al., 2004) (Figure 1.13). 
Figure 1.13 
Schematic view of the nuclear envelope showing Nuclear Pore Complexes (NPC), 
organization of the nuclear lamina and their associated proteins (in purple): Lamina 
associated polypeptides 1 and 2 (LAP1 and 2), Lamin B receptor (LBR), Emerin, Nesprin 
and MAN1; and transcription fators (in pink): Retinoblastoma transcriptional regulator 
(RB), Germ Cell Less (GCL), Sterol response element and binding protein 1 (SREBP1), 
MOK2 and FOS. Barrier to Autointegration factor (BAF) is a chromatin associated protein 
that also binds to lamins.              Adapted from Coutinhoe et.al 2009 
The importance of these associated binding proteins is significant and, in the form 
of tissue related complexes, they may be responsible for the observed phenotype 
in various Laminopathies. To explain nuclear envelope (NE) disease pathology, 
three mechanisms are suggested – altered gene expression, as regulated from the 
nuclear periphery; mechanical disruption of lamina-cytoskeletal interactions 
leading to mechanical instability and disruption of the cell cycle/stem cell 
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maintenance (Dorner et al., 2007; Malik et al., 2010; Schirmer et al., 2003). 
Because gene regulation and cytoskeleton connections have both been 
implicated, this could easily mean that NE proteins could reside either in the inner 
or outer nuclear membrane. NE proteins have been identified in both inner and 
outer nuclear membranes.  Integral membrane proteins of the ONM are shared by 
the ER whilst those of the INM consist of lamina-associated polypeptides (LAPs) 
and lamin B receptors (LBRs) (Foisner and Gerace, 1993; Georgatos et al., 1994; 
Gerace and Foisner, 1994). 
The perinuclear space is an aqueous environment with functions similar to the 
rough ER. This space also harbours the luminal domains of the integral membrane 
proteins from the ONM and INM, with the possibility of them communicating with 
each other. The NPCs are complex structures with relative molecular masses of 
over 100 mDa (Reichelt et al., 1990) and are composed of many proteins 
collectively known as nucleoporins (Davis and Blobel, 1986). These NPCs are 
linked by pore-connecting fibrils and by the nuclear lamina lying close to the 
nucleoplasmic surface of the INM. These NPCs allow the exchange of molecules 
into and out of the nucleus via either passive diffusion or active transport. 
 
1.5.2 The Cell Cycle 
 
The cell cycle is characterized by four sequential phases: G1, S, G2 and M phases. 
G1, S and G2 are collectively termed interphase. The phase of mitosis or M phase 
is responsible for the creation of two genetically identical daughter cells. During 
mitosis, there is a dynamic sequence of events which can be subdivided into 
prophase, prometaphase, metaphase, anaphase, teleophase and cytokinesis 
(Figure 1.14 and 1.5).  
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Figure 1.14 
The cell cycle 
Diagram to illustrate the sequential phases involved in the cell cycle. Phases 
Gap1, S and Gap2 are collectively known as interphase. The phase of Mitosis is 
further subdivided into Prophase, Prometaphase, Metaphase, Anaphase and 
Telophase / Cytokinesis. 
                                                           Adapted from: http://publications.nigms.nih.gov/insidethecell      
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Figure 1.15 
Current model for regulation of the eukaryotic cell cycle 
Passage through the cycle is controlled by G1, S-phase, and mitotic cyclin-
dependent kinase complexes (CdkCs) highlighted in green. These are composed 
of a regulatory cyclin subunit and a catalytic cyclin-dependent kinase subunit. 
Protein complexes (orange) in the Cdc34 pathway and APC pathway 
polyubiquitinate specific substrates including the S-phase inhibitor, anaphase 
inhibitor, and mitotic cyclins, marking these substrates for degradation by 
proteasomes. These pathways thus drive the cycle in one direction because of the 
irreversibility of protein degradation. Proteolysis of anaphase inhibitors inactivates 
the protein complexes that connect sister chromatids at metaphase (not shown), 
thereby initiating anaphase. 
Adapted from Molecular Cell Biology; 4
th
 Edn 
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At prometaphase there is an abrupt breakdown of the nuclear envelope, which 
includes the nuclear membranes, nuclear lamina and nuclear pore complexes. 
Reassembly of various components of the nuclear envelope, takes place in a very 
well coordinated manner towards late anaphase / telophase. It is during prophase 
that dynein, a minus-end directed microtubule associated motor protein, 
translocates to the mitotic spindle. This spindle in turn is cross-linked to 
invaginated areas of the nuclear membrane via its centrosomes. This results in 
physical disruption of the lamina and nuclear membrane by metaphase (Salina et 
al., 2002). The nuclear lamina plays an important role in the breakdown and 
reassembly of the nuclear envelope. This role is dependant upon the 
phosphorylation status of nuclear lamina (Ottaviano and Gerace, 1985). Upon 
phosphorylation, the nuclear lamina depolymerises and is dispersed throughout 
the cytoplasm as soluble dimers (Gerace and Blobel, 1980). This process of 
nuclear lamina phosphorylation is regulated by M-phase promoting factor (MPF) 
(Murray and Kirschner, 1989) which is a p34cdc2 kinase / cyclin B complex 
activated early in mitosis (Dessev et al., 1991). Studies have shown that both 
lamin A and B types become soluble upon depolymerisation (Beaudouin et al., 
2002; Daigle et al., 2001) 
During telophase each set of daughter chromosomes arrive at the poles of the 
spindle and decondense. At this stage the nuclear envelope reforms around each 
set of chromosomes and effectively marks the end of mitosis. Cytokinesis then 
occurs and each daughter cell then enters into the G1 phase of the cell cycle. 
Reformation of the nuclear envelope is accompanied by dephosphorylation of 
individual lamin components with their subsequent polymerization and recruitment 
to the inner nuclear membrane, where they form a filamentous meshwork. B-type 
lamins are thought to be the first nuclear lamins to get incorporated into this 
polymeric meshwork at the inner nuclear membrane (Moir et al., 2000a). 
Farnesylation of the cysteine residue in the C-terminal isoprenylation signal, the 
CAAX motif, and subsequent endoproteolytic cleavage of the AAX tripeptide and 
carboxymethylation of the terminal cysteine residue, help in allowing anchorage to 
the inner nuclear membrane. Interaction between integral proteins of the inner 
nuclear membrane and nuclear lamins is also facilitated (Farnsworth et al., 1989; 
Firmbach-Kraft and Stick, 1993). The nuclear membrane A-kinase anchoring 
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protein, AKAP149, targets chromatin-bound protein phosphatase 1 (PP1) to the 
NE upon nuclear reformation in vitro, this correlates with assembly of B-type 
lamins into the nuclear lamina (Steen and Collas, 2001). 
 
The exact time at which B-type lamins start accumulating at the inner nuclear 
membrane is not certain however it is thought to be towards the end of late 
anaphase / telophase (Daigle et al., 2001). Broers et al (1999) have shown that A-
type lamins do not migrate to the nuclear periphery until the end of Cytokinesis. 
Soluble A-type lamins have also been noted in the nucleoplasm of cells for a few 
hours into G1 phase of the cell cycle (Moir et al., 2000b). Absence of A-type lamins 
does not appear to have a significant bearing on formation of the nuclear envelope 
as evidenced by their absence during the earliest stages of nuclear envelope 
assembly. However, A-type lamins are very important for the proper functioning of 
the nucleus. This is obvious in diseases wherein there is a mutation of either the 
LMNA gene or in the lamin A/C protein. In essence then, B-type lamins form a 
meshwork of fibers adjacent to the inner nuclear membrane upon which, 
subsequently, A-type lamins get incorporated (Moir et al., 2000a). 
 
1.5.2 The Nuclear Lamina  
 
Intermediate filament proteins are composed of 10 – 13 nm diameter filaments 
found in the cytoplasm and nucleus. These intermediate filament proteins form 
cytoskeletal fibers in metazoan cells. In the nucleus, they form a filamentous 
meshwork lining the inner nuclear membrane and are responsible for providing 
anchorage sites for chromosomes and nuclear pores. Lamins belong to the 
intermediate filament protein family group and are principal components of the 
nuclear lamina. The nuclear lamina is composed of type V intermediate filament 
proteins (Fisher et al., 1986; McKeon et al., 1986) (Figure 1.16). 
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Figure 1.16 
Diagrammatic illustration of a cytoplasmic intermediate filament and lamin 
polypeptide. 
Source: Adapted from Hutchison et al 2004 
 
Individual polypeptides of intermediate filaments consist of elongated molecules, 
48 nm in length, with an extended central α-helical domain. These monomers form 
a parallel coiled coil with other monomers. These dimers then pair with other 
dimers in an anti parallel fashion to form staggered tetramers. This represents the 
soluble subunit of intermediate filaments. These tetramers then stack up in a 
lateral fashion to form the filament. Each filament is composed of eight parallel 
protofilaments. This forms a rope like structure with a cross section revealing 32 
individual α-helical coils and measuring 10 – 13 nm in diameter. This arrangement 
allows the filaments to bend easily but makes it very difficult for them to break 
(Alberts, 2002). The secondary structure of intermediate filaments is composed of 
a central coiled – coil α-helical rod domain. A non helical amino-terminal forms the 
head domain while, a non helical, carboxy terminal forms the tail domain. The rod 
domain is divided into four helical regions, 1A, 1B, 2A and 2B. These are 
characterized by heptad repeats with  three non-helical linker segments separating 
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them (Fuchs and Weber, 1994). Nuclear lamins, in contrast to cytoplasmic 
intermediate filaments, contain a 42 amino acid (six heptad repeat) insertion into 
coil 1B (Erber et al., 1998). Most lamins, except lamin C, have a C-terminal CAAX 
motif. This is a target for isoprenylation and carboxymethylation This is of 
importance in helping lamins to localize at the inner nuclear membrane (Nigg, 
1992). Also, lamins have a nuclear localization sequence (NLS) in their tail domain 
(Loewinger and McKeon, 1988) which helps in directing lamins to the nucleus 
where they line the nucleoplasmic surface of the inner nuclear membrane and 
form a two dimensional lattice  
 
1.5.2.1 Lamin structure and filament assembly 
 
Up to seven lamin subtypes have been identified in mammals. These can be 
divided into two subgroups, A and B-type lamins, based on various characteristics 
such as ultrastructural properties, biochemical properties and mitotic fate (Gerace 
and Blobel, 1980; Gerace and Burke, 1988; Gerace et al., 1984). A-type lamins 
are expressed in most differentiated cell types whereas B-type lamins are 
essential for cell viability and are expressed in virtually all cells. The LMNA gene 
(Figure 1.17), located on chromosome 1q21.1 – 21.3 (Lin and Worman, 1993) 
encodes for lamins A, AΔ10 and C, which are all alternatively spliced variants of 
that gene (Fisher et al., 1986; Furukawa et al., 1994; Machiels et al., 1996; 
McKeon et al., 1986). B-type lamins consist of lamins B1, B2 and B3. The gene 
encoding laminB1 is LMNB1, located on chromosome 5q23.3 – 31.1 (Lin and 
Worman, 1995) lamins B2 andB3 are alternatively spliced variants of the LMNB2 
gene, located on chromosome 19p13.3 (Biamonti et al., 1992). Lamins C2 and B3 
have only been identified in male germ cells (Furukawa and Hotta, 1993). 
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Figure 1.17 
Diagrammatic representation of chromosome 1. The LMNA gene is found at 
location 1q21.2, as marked by the yellow arrow. 
Adapted from www.progeriafamilycircle.com  
 
 
 Gene LMNA 
Gene Location 1q22 
Number of Exons 12 
Alternative splice variants Isoform A; Isoform C and isoform ADelta10 
Protein name Pre lamin A/C which is cleaved into Lamin A/C 
Protein sequence length 664 AA 
Protein mass (Da) 74,139 
Table 1.4 
Table summarizing various properties of the LMNA gene and its isoforms 
 
The LMNA gene (Table 1.4) contains 12 exons. In exon 10 is located codon 566, 
which acts as an alternative splice site for prelamin A and lamin C. this gives rise 
to the 3’ – most amino acid common to both lamin A and C mRNAs (Lin and 
Worman, 1993). Codons 567 to 572 are lamin C specific. The amino acid encoded 
for by Codon 572 marks the termination of lamin C. In the case of prelamin A, the 
remaining nucleotides of exons 11 and 12 adjoin the 3’ – end of codon 566, thus 
making these exons lamin A specific. Lamin AΔ10 lacks all 30 amino acids (90 
nucleotides) encoded by exon 10 (Machiels et al., 1996), however, it retains the 
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lamin A specific tail domain. Hence, lamin A subtypes only differ in the sequence 
of their tail domains (Figure 1.18). 
 
Figure 1.18 
Structure of lamin A/C gene LMNA and of the lamin A/C protein 
Source: Adapted from Taylor, M. R. G. et al. J Am Coll Cardiol 2003 
 
Nuclear lamina assembly is a sequential process in which, initially, parallel, un-
staggered dimers form (Heitlinger et al., 1992). These then associate head to tail 
forming tetramers via highly conserved domains and non-helical amino-terminal 
head domains (Heitlinger et al., 1992). In contrast to intermediate filaments, lamin 
tetramers elongate longitudinally to form 2 nm wide protofilaments prior to 
associating laterally. Lateral growth of these protofilaments are believed to 
represent half staggered, anti parallel associations of lamin head to tail 
protofilaments (Goldberg et al., 1999). This gives rise to the observed two 
dimensional lattice arrangement of 10 nm wide filaments with an average 
crossover spacing of 52 nm (Aebi et al., 1986). 
Hutchison and co workers proposed a model of lamin A and C integration into the 
nuclear lamina (Hutchison et al., 2001). In their model lamin A and C get 
incorporated into the nuclear lamina after B-type lamins associate with the inner 
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nuclear membrane. As lamin C does not possess an isoprenylation signal, it was 
proposed that its incorporation into the nuclear lamina occurs on the back of lamin 
A. A-type lamins form anti parallel, half staggered tetramers which associate with 
B-type lamin tetramers already lying subjacent to the inner nuclear membrane. 
Vaughan et al (Vaughan et al., 2001) have also reported the importance of lamin A 
in localisation of emerin and lamin C to the nuclear envelope. 
 
1.5.2.2 Lamins and chromatin organization 
 
Nuclear lamins play an important role in DNA replication (Jenkins et al., 1993; 
Jenkins et al., 1995; Newport et al., 1990). Prior to having any role in DNA 
replication, nuclear lamins need to interact with the inner nuclear membrane and 
bind chromatin. Goldberg et al. (1995) provided the first direct evidence for the role 
of nuclear lamins in DNA replication. By the addition of purified lamin B3 to 
depleted Xenopus nuclear assembly systems, they were able to reinitiate DNA 
replication. B-type lamins also play an important role in the organisation of 
interphase chromatin. This is born out by the observation of lamin B1’s specific 
interaction with peripheral matrix attachment regions (MARs) of DNA (Luderus, 
1992 #1563). Binding of chromatin by A-type lamins has also been demonstrated 
(Glass, 1993 #537;Glass, 1990 #1564;Shoeman, 1990 #1565;Taniura, 1995 
#1101). By the application of various biochemical studies it has been shown that 
different regions of the lamin A tail domain interact with chromatin. Hoger et al. 
(1991) discovered the region between amino acid residues 598-641 of lamin A, as 
being an area of potential chromatin interaction. Similarly, Taniura et al. (1995) 
identifies the region between amino acid residues 394-430 of lamin A as chromatin 
binding sites. 
At present, the expression of A-type lamins is only associated with differentiated 
cell types. This fact, coupled with the observation that A-type lamins have a 
greater affinity for binding chromatin as compared to B-type lamins (Hoger et al., 
1991; Yuan et al., 1991), has led to the suggestion that chromatin organisation is 
partly regulated by A-type lamins. Lending further support to this suggestion is the 
observation that A-type lamins play an important role in the early events of cell 
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differentiation (Collard et al., 1992; Lourim and Lin, 1992) and in conjunction with 
lamin C, binds with the growth suppressor p110RB (Mancini et al., 1994; Ozaki et 
al., 1994). 
The association of heterochromatin with lamin A inside the nucleus takes the form 
of distinct foci (Bridger et al., 1993), thus giving rise to the proposition that lamin A 
polymerises preferentially on heterochromatin. As A-type lamins relocate to the 
nuclear envelope, this complex of heterochromatin makes close contact with the 
nuclear envelope, thereby allowing it to anchor to the nuclear periphery. It is 
interesting to note that in some cells undergoing rapid proliferation in healthy 
tissue, A-type lamins are not expressed. Differential expression of A-type lamins is 
also noted in some cancers (Broers and Ramaekers, 1994; Willis et al., 2008; 
Worman and Courvalin, 2002). 
 
1.5.2.3 Lamins and Transcription regulation 
 
The mechanisms by which lamins influence transcription regulation are diverse. 
This is a reflection of the different ways in which lamins interact with transcriptional 
processes. Lamins do not always bind to transcriptional factors or their regulatory 
complexes, but act through indirect association with transcription binding partners. 
The nuclear envelope is known to harbour a large number of transcription factors, 
mostly repressors. Retinoblastoma protein (Rb) is an important transcription factor 
and is known to actively repress transcription factor E2F-dependant gene 
transcription by actively binding to E2F and recruiting histone deacetylases. In its 
active form, Rb is hypophosphorylated and forms complexes with lamin A/C and 
lamina associated polypeptide 2 alpha (LAP2α) at the nuclear periphery, during 
G1 phase of the cell cycle (Hutchison and Worman, 2004; Mancini et al., 1994; 
Markiewicz et al., 2002; Ozaki et al., 1994). This tethering of Rb at the nuclear 
periphery is crucial for its normal function and any mutation that disrupts this 
tethering,  results in aberrant function, including development of cancer (Hinds et 
al., 1992). There is direct evidence now showing the importance of this interaction 
between A-type lamins and Rb in preventing the degradation of Rb protein by the 
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proteosome (Johnson et al., 2004), thereby allowing it to function normally in its 
regulation of cell growth and division (Figure 1.19). 
 
 
Figure 1.19 
 
Role of lamin A/C and LAP2α in prevention of Rb degradation by the 
proteosome. 
 Lamin-A–LAP2α complexes are required for Rb function. A complex of lamin A/C 
(green) and LAP2α (blue) tethers Rb (red) and thereby prevents its destruction by 
the proteosome (yellow). In the presence of lamin A/C and LAP2α and the 
absence of Rb phosphorylation, E2F activity is inhibited and cells remain in G1. 
When lamin-A/C–LAP2α function is disrupted, Rb is targeted for destruction by the 
proteosome, thereby de-repressing E2F and allowing cell-cycle progression.           
Source: Adapted from Hutchison et al. 2004 
 
At the inner nuclear membrane are also located the LEM domain proteins (LAP2 
or lamina associated protein 2, Emerin and MAN1) which are the main lamin 
interacting proteins. These LEM domain proteins share a common 43 amino acid 
sequence in their N terminus (Cohen et al., 2001), which bind to DNA-binding 
protein BAF (Barrier to Autointegration Factor) (Furukawa, 1999; Lin et al., 2000). 
BAF is a highly conserved, small protein, with diffuse nuclear localisation in 
interphase cells, which localises to chromosomes during mitosis. There are 
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frequent but transient interactions between BAF and LEM domain proteins. The 
intermolecular bridging properties of BAF cause compaction of DNA resulting in a 
higher order of chromosomal structure (Zheng et al., 2000). Hence, various 
interactions between LEM domain proteins, lamins and BAF can also affect 
chromatin structure and lead to differences in functional outcomes. Octamer-
binding transcription factor (Oct-1) co-localises with B-type lamins at the nuclear 
envelope and actively represses the ageing associated collagenase gene (Imai et 
al., 1997). In ageing cells, there is translocation of Oct-1 from the nuclear envelope 
with loss of transcriptional silencing and increased collagenase activity. 
Collagenase, an extracellular matrix degrading enzyme involved in tissue repair 
and remodelling, has been implicated in many tissue degenerative diseases. 
LAP2β (Lamina Associated Polypeptide 2 Beta) has also been shown to interact 
with chromatin via BAF and its LEM domain (Furukawa, 1999). LAP2β also 
interacts with the transcription factor GCL (Germ-Cell-Less) protein, which 
localises at the inner nuclear membrane, and is bound to E2F/DP heterodimer. 
Together they form a repressor complex at the nuclear envelope against the 
transcriptional activity of E2F/DP3, which is normally under strict control by the Rb 
protein in G1 phase of the cell cycle (Nili et al., 2001). 
Emerin, an integral membrane protein, is known to bind both lamin A/C and BAF 
(Lee et al., 2001). This interaction results in a functional link to chromatin. 
Localisation of emerin to the Nuclear envelope is highly dependant on lamin A 
polymers (Vaughan et al., 2001), the deficiency of which results in emerin being 
translocated to the cytoplasm. The C-terminal domain of emerin is also known to 
bind with GCL. This interaction with GCL is disrupted when BAF interacts with the 
N-terminal LEM domain of emerin (Holaska et al., 2003). 
 
1.5.2.4 Lamins and Apoptosis 
 
Control on the number of cells in a complex, multicellular organism, such as 
humans, is a very intricate process that requires not only control on the rate of cell 
division but also on the rate of cell death – programmed cell destruction or 
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apoptosis. Cells undergoing apoptosis show characteristic features such as, 
shrinkage and condensation of the cell with collapse of the cytoskeleton followed 
by nuclear envelope disassembly and fragmentation of DNA. This is then followed 
by active membrane blebbing and a controlled breakage of the cell into membrane 
enclosed vesicles, called apoptotic bodies. Of interest is the observation that these 
apoptotic bodies express surface makers that act as signals for rapid phagocytosis 
by macrophages or neighbouring cells. The whole process of apoptosis is known 
to be energy dependant and irreversible once initiated. Central to the whole 
process of apoptosis is a family of proteases that harbour a cysteine at their active 
site and cleave target proteins at specific aspartic acids (Alberts, 2002), hence the 
term caspases is used to describe them. Caspases are synthesised inside the cell, 
as pro-caspases, which are inactive and require activation by cleavage at their 
aspartic acid site, usually by other caspases. Nuclear lamins are early targets for 
caspases. PKCδ, activated by caspases 3, is responsible for hyperphosphorylation 
of lamins. This allows caspases access to lamins prior to their cleavage (Cross et 
al., 2000). Caspase 6 cleaves lamins at their α-helical rod domain at position 230 
(Lazebnik et al., 1995; Rao et al., 1996), which is an aspartic acid residue. The rod 
domain in lamins happens to be the site for dimerisation and linking chromatin, 
hence, cleavage at this site represents an extremely effective mechanism for 
breaking down lamina and the subsequent release of chromatin. There are 
differences in the way A-type lamins are broken down as compared to B-type 
lamins. In case of B-type lamins, they are completely cleaved with the cleaved 
products closely associating to the Nuclear Envelope. A-type lamins, on the other 
hand, undergo partial cleavage and are more diffusely dispersed throughout the 
cytoplasm. 
 
1.5.3 Laminopathies 
 
Laminopathies is the term used to describe a group of genetically inherited 
disorders with tissue specific phenotypes as a result of mutations in the LMNA 
gene. They are subdivided on the basis of which tissue is affected and also 
encompass a group of pre-mature ageing syndromes.  
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1.5.3.1 Laminopathies affecting striated muscle 
1.5.3.1.1 Limb girdle muscular dystrophy 1B (LGMD-1B) 
This condition is inherited in an autosomal dominant fashion. The underlying 
defect is a mutation in the LMNA gene, linked to chromosome 1q21.1 – q21.3. The 
results of this mutation manifest themselves as proximal myopathy, affecting the 
lower limb muscles, during the persons late teen years. This slowly progresses 
towards the upper limb muscles by the time they are between 30 and 40 yrs of 
age. Premature death in these people is usually due to defects in their 
cardiological system. 
1.5.3.1.2 Emery – Dreifuss muscular dystrophy (EDMD) 
EDMD is an inherited condition characterized by a triad of clinical features: 
Contractures of tendons, especially at the elbow, Achilles tendon and posterior 
cervical muscles; cardiomyopathy, heart defects, particularly conduction defects in 
the heart; and weakness with wasting of skeletal muscles, especially humeral and 
peroneal muscles. EDMD can be inherited in three different ways: As autosomal 
dominant or autosomal recessive or X-linked. Both autosomal dominant and X-
linked have similar clinical features as described earlier (Dreifuss and Hogan, 
1961; Emery and Dreifuss, 1966). The autosomal forms of EDMD are as a result 
of mutations in the head, rod and tail domains of the LMNA gene, on chromosome 
1q211 – q21.3 (Raffaele Di Barletta et al., 2000). X-linked EDMD manifests itself in 
the second or third decade of life as a result of a mutation at the locus mapped to 
chromosome region Xq28. This is the locus for the EMD gene (also called the STA 
gene) which encodes for a inner nuclear membrane protein, emerin (Bione et al., 
1994). Emerin interacts with lamin A at the nuclear envelope and provides 
anchorage to lamin A (Cartegni et al., 1997). Mutations in emerin are widely 
distributed, however, the majority of these mutations are noted to be in the lamin A 
binding domain area (Lee et al., 2001). In normal tissue, emerin localizes to similar 
areas of the nuclear envelope as do A-type lamins. However, in persons with X-
linked EDMD, there is a marked absence of emerin from skeletal and cardiac 
muscle (Nagano et al., 1996) 
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1.5.3.1.3 Dilated Cardiomyopathy – 1A (CMD-1A) 
This condition is inherited in an autosomal dominant fashion. It is characterized by 
the onset of cardiac conduction defects in the third or fourth decade of life leading 
to heart failure as a primary cause of mortality. The underlying mutation is in the 
LMNA gene, predominantly in the coiled coil regions 1A and 1B of the rod domain 
(Brodsky et al., 2000; Fatkin et al., 1999). The phenotypic appearances of this 
mutation reveal varied skeletal muscular dystrophies.  
 
1.5.3.2 Laminopathies affecting bone, nerve and adipose tissue 
1.5.3.2.1 Familial Partial Lipodystrophy (FPLD) - Dunnigan type – 
laminopathy affecting adipose tissue 
FPLD of the Dunnigan type is an autosomal dominant condition due to 
heterozygous missense mutations in the LMNA gene on 1q21 – q23. The locus of 
this mutation has been isolated to codon 482, in exon 8, which codes for the 
proximal C-terminal domain of lamin A/C. Clinical features manifest with the onset 
of puberty and include loss of fat from the limb and trunk, accumulation of fat on 
the back, groin, neck and face and a predisposition to insulin resistance with 
resultant complications manifesting as high blood pressure, glucose intolerance, 
dyslipidaemia, coronary heart disease and liver steatosis (Dunnigan et al., 1974; 
Vantyghem et al., 2004; Vigouroux et al., 2001). 
1.5.3.2.2 Mandibuloacral dysplasia (MAD) – Laminopathy affecting bone 
This condition is inherited in an autosomal recessive manner and thus its typical 
clinical features are only evident in homozygous individuals. These features 
include growth retardation in the post natal period, hypoplastic mandible with 
dental overcrowding, other cranio-facial malformations, progeria-like skeletal 
abnormalities, atrophic skin with mottled cutaneous pigmentation, hair loss  and 
either type A or B lipodystrophy, accompanied by insulin resistance (Simha and 
Garg, 2002; Young et al., 1971). The underlying homozygous mutation 
responsible for MAD, R527H has been identified in the tail domain of lamin A/C in 
cases suffering from type A lipodystrophy. This mutation affects the normal 
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distribution and localization of lamin A/C at the nuclear envelope (Novelli et al., 
2002). 
1.5.3.2.3 Charcot-Marie-Tooth type 2B1 (CMT2B1) – Laminopathy affecting 
neural tissue 
This autosomal recessive disease affects motor and sensory nerves, usually in the 
second decade of life. It can be divided in two groups: CMT type 1 is the 
demyelinating form of the disease while CMT type 2 affects axons predominantly 
and can be subdivided into CMT 2 subtype 1 and CMT 2 subtype 2. Persons with 
CMT 2 suffer from decreased nerve conduction velocity resulting in weakness and 
wasting of distal lower limb muscles and, in some cases, also proximal muscles. In 
families with the CMT2B1 disorder, the genetic defect has been isolated to 
chromosome 1q21, an area that harbours the LMNA gene (Bouhouche et al., 
1999). Subsequently a homozygous mutation was discovered in the rod domain of 
lamin A/C in persons with CMT2B1. The genetic mutation giving rise to CMT2B2 
has been identified on chromosome 19q13.3 (Leal et al., 2001). 
  
1.5.3.3 Laminopathies and premature ageing syndromes 
1.5.3.3.1 Hutchinson – Guildford Progeria Syndrome (HGPS) 
HGPS, a premature ageing syndrome, is a rare condition. Since its discovery in 
1886, more than 100 cases have been reported worldwide. Its mode of inheritance 
is more likely to be autosomal dominant, however, autosomal recessive cases are 
also known. The underlying mutation in this condition involves the LMNA gene. 
Persons suffering from this condition appear to age ten times faster as compared 
to normal individuals. Clinical features of HGPS include, severe restriction of 
growth in the post-natal period, microganthia, hypoplasia of the mid face region, 
alopecia, wrinkled skin secondary to loss of subcutaneous fat, generalized 
osteodysplasia, hypogonadism, premature atherosclerosis and poor muscle 
development. The average life expectancy in persons with HGPS is 12 – 15 years 
with congestive cardiac failure, secondary to advanced atherosclerosis, being a 
common cause of death. Interestingly, persons with HGPS do not show other 
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features associated with the ageing process i.e. susceptibility to tumour formation, 
diabetes, cataract formation, cerebral degeneration leading to cognitive 
impairment, etc and hence, HGPS is thought to reproduce only partially the ageing 
process (Martin and Oshima, 2000). De Sandre-Giovannoli et al (2003) have 
reported a single base substitution from C to T in the LMNA gene, affecting codon 
608 within exon 11, in a subset of persons suffering with HGPS. This does not 
result in an amino acid change; however, it partially activates a cryptic splice site 
with deletion of 50 amino acids at the C-terminal end of lamin A. This results in 
loss of an endoproteolytic cleavage site as well as loss of a cell-cycle dependant 
phosphorylation site (Ser625). Both these sites play an important role in the post-
translational modification of pre-lamin A into lamin A. Presence of this incompletely 
processed form of prelamin A at the nuclear envelope acts as a dominant mutant 
(Eriksson et al., 2003). Studies on fibroblasts obtained from persons with HGPS 
having a G608G mutation, have revealed defects in nuclear structure, for example, 
thickening of the nuclear lamina, nuclear lobulations and loss of peripheral 
heterochromatin (Goldman et al., 2004). 
1.5.3.3.2 A-typical Werner Syndrome 
Werner syndrome is another premature ageing syndrome characterized by 
atherosclerosis, diabetes, premature graying of hair, subcutaneous calcifications, 
aged facial appearances, early-onset cataracts, scleroderma like skin changes 
and early death (McKusick, 1963). Werner syndrome is inherited as an autosomal 
recessive condition and is due to homozygous mutations in the DNA helicase-like 
gene RECQL2, a 3’ – 5’ RecQ DNA helicase – exonuclease, responsible for 
unwinding and cleaving nucleotides from DNA termini (Wang et al., 2000). Atypical 
Werner syndrome has been identified in a subgroup of patients and represents a 
more severe form. Persons with atypical Werner syndrome were found to have 
normal RECQL2 but were heterozygous for mutations in LMNA (Chen et al., 
2003). Chen et al (2003) noted changes in nuclear morphology and mislocalised 
lamins in fibroblasts of a person with atypical Werner syndrome due to mutation 
L140R in the LMNA gene.  
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1.5.3.4 Laminopathies and Fetal Disease 
1.5.3.4.1 Restrictive Dermopathy (Fetal Akinesia Deformation Sequence-
FADS) 
Restrictive dermopathy was first described by Witt et al in 1986 (Witt et al., 1986). 
This is a fatal condition in which tautness of the skin causes fetal akinesia or 
hypokinesia deformation sequence (FADS). Other manifestations of the condition 
include a thin, tightly adherent, translucent skin with prominent vessels, 
generalized joint contractures, typical facial changes (small mouth, pinched nose 
and microganthia), enlarged fontanels, respiratory insufficiency due to pulmonary 
hypoplasia, clavicular dysplasia and an enlarged placenta with a short umbilical 
cord.  These abnormalities usually appear after 22 – 24 weeks gestation and are 
associated with polyhydramnios and reduced fetal movement. Premature delivery 
usually takes place at around 31 weeks gestation. Live born children usually die 
within the first week of life (Lenz and Meschede, 1993; Mau et al., 1997; Verloes et 
al., 1992). These phenotypic features are similar to those observed in Hutchinson-
Gilford syndrome, a progeria due to mutations in LMNA (De Sandre-Giovannoli, 
2003 #1783;Eriksson, 2003 #51). Work done by Navarro et al in patients with 
restrictive dermopathy (Navarro et al., 2005; Navarro et al., 2004) identified 
truncating splice mutations in LMNA exon 11, leading to the production of 
truncated Lamin A precursors. They also identified a single heterozygous insertion 
mutation in ZMPSTE24 exon 9 in another group of patients with restrictive 
dermopathy not exhibiting mutations in LMNA. Mature Lamin A isoforms are 
processed through a series of post-translational modifications performed on the 
pre-lamin A precursor. The enzyme responsible for these post-translational 
modifications is a zinc metalloproteinase ZMPSTE24, for which lamin A is the only 
known substrate in mammals (Corrigan et al., 2005; Sinensky et al., 1994). 
Mutations in this enzyme and LMNA result in loss of mature lamin A and an 
increase in the amount of unprocessed, full length lamin A precursors. These 
defects are associated with phenotypes that show features similar to those 
observed in Hutchinson-Gilford progeria syndrome (Mounkes and Stewart, 2004; 
Navarro et al., 2005; Novelli and D'Apice, 2003). 
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1.5.4 Lamins and Cancer 
 
The differential expression of lamins in cancers of epithelial, mesenchymal and 
lymphoid tissue has been studied by various researchers and include acute 
lymhoblastic leukemia, non-Hodgkin’s lymphoma (Stadelmann et al., 1990), 
human small cell lung cancer, non-small cell lung cancer (Broers et al., 1993), 
(Kaufmann et al., 1991), metastatic leiomyosarcoma, rhabdomyosarcoma, 
chondrosarcoma (Cance et al., 1992) and basal cell cancer of the skin (Tilli et al., 
2003; Venables et al., 2001). There have been varied reports of lamin A/C 
expression in some cancers. For example, in colorectal cancer, Moss et al. (1999) 
describes a decreased level of lamin A/C expression in colonic adenomas and 
adenocarcinomas as compared to normal tissue. On the other hand, a study by 
Canc et al. (1992) showed a heterogeneous expression of lamin A/C in two colon 
adenocarcinomas. These varied results hint towards a greater role of lamins in 
cancers than was previously believed. 
 
1.6 Stem cells 
 
The human body is made up of many different tissues, many of which are subject 
to rapid proliferation with a continuous turnover of cells. The human large intestine 
is a prime example. In this organ, the lifespan of a mature, well differentiated cell 
can be measured in days. Despite this rapid turnover of cells, the large intestine 
maintains its unique architecture and mass over time through a tightly regulated 
process of renovation. Under physiological conditions, this process is sustained by 
a small minority of cells with extraordinary features, known as stem cells. Stem 
cells can be defined by three main properties: 
1. Differentiation – the ability to give rise to a heterogeneous progeny of 
cells, which progressively diversify and specialize according to hierarchical 
processes, constantly replenishing the tissue of short lived, mature 
elements. 
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2. Self renewal – the ability to form new stem cells with an identical and intact 
potential for proliferation, expansion and differentiation, thereby maintaining 
the stem cell pool. 
3. Homeostatic control – the ability to modulate and balance differentiation 
and self-renewal according to environmental stimuli and genetic constraints. 
Individual stem cells are large, primitive cells that do not express markers of 
lineage differentiation, and are consequently difficult to define and characterize 
morphologically. Stem cells are typically located in a specialized mesenchymal 
‘niche’ and maintain their capacity for limitless self-replication throughout the 
lifetime of their host, and can also divide to produce daughter cells, committed to 
the formation of every adult cell lineage within their tissue of origin (Brittan and 
Wright, 2004). The study of stem cells has its roots dating back to nearly 50 years 
or so and is probably best exemplified by the hematopoietic family of blood and 
immune cells. All the functional cells found in blood and lymph arise from a single 
common parent cell known as the hematopoietic stem cell (HSC), which resides in 
the bone marrow. The HSC pool of cells represents less than 0.01% of cells in the 
bone marrow. Yet, each of these rare cells gives rise to a larger, intermediately 
differentiated population of progenitor cells. These in turn divide and differentiate 
further through several stages into mature cells responsible for specific tasks. By 
the time a cell reaches its final functional stage, it has lost all ability to proliferate or 
to alter its destiny and is said to be terminally differentiated. Fundamentally, stem 
cells provide the foundations of every organ in the body, with their ability for self 
renewal by symmetrical division and their capacity to generate the entire adult cell 
component within their indigenous tissue via asymmetrical cell division. Stem cells 
regulate the rate of cell production in a tissue to maintain homeostasis, and can 
up-regulate cell turnover concurrent to increasing regenerative demand dictated by 
damage or disease. 
A deeper understanding of the role stem cells play in homeostasis of the large 
intestine has also brought to light the significant link between stem cells and their 
possible role in colorectal carcinogenesis. At present our understanding about 
stem cells in the colon / rectum is limited since there are no definitive stem cell 
markers available that can positively identify these stem cells. However, two 
putative stem cell markers have been proposed: Musashi-1 (Msi-1), a neural RNA 
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binding protein required for asymmetric division of sensory neural precursor cells, 
has been proposed by Potten et.al (Potten et al., 2003) as a marker of stem and 
early lineage progenitor cells in murine small intestine. The presence of Msi-1 in 
the human colon crypt cells was also reported by Nishimura et.al (Nishimura et al., 
2003). The second stem cell marker proposed recently by Barker et.al (Barker et 
al., 2007) is the gene, Lgr5 (leucine-rich-repeat-containing G-protein-coupled 
receptor 5). Using lineage-tracing experiments, they were able to show that Lgr-5 
positive crypt base columnar cells were able to generate all epithelial lineages 
over a 60 day period. This was in keeping with observed stem cell characteristics. 
In the adult human colon / rectum, stem cells are known to occupy the basal 
regions of the crypts (Nishimura et al., 2003; Potten, 1998; Potten et al., 2003) and 
vary in numbers but approximately 4 – 6 stem cells exist in this region. Factors 
involved in the maintenance of the stem cell niche are incompletely understood, 
however, two models have been proposed: the Deterministic or Immortal model 
claims that a small number of stem cells reside in a niche, each generating exactly 
one stem cell and one transit-amplifying cell at each asymmetrical division. Each 
stem cell is immortal in this model. Studies done by Potten et.al (Potten et al., 
1992; Potten et al., 2002) have lent support to this model. They have shown that 
stem cells protect their DNA from replication errors by selective retention of the 
template DNA strand. On the other hand, in the Stochastic or Niche model, 
many stem cells exist in a niche, with each stem cell division producing either, two 
stem cells, or one stem cell and a daughter cell or no stem cells and only two 
daughter cells. Studies done by Yatabe et.al (Yatabe et al., 2001) and Kim et.al 
(Kim et al., 2005) have advocated support for the Stochastic model. 
Various signaling pathways have been implicated in regulation of the crypt – 
villous axis and stem cell niche. These pathways include the Wnt pathway, the 
Bone Morphogenetic Protein pathway, the Cdx1 and Cdx2 pathway, the Forkhead 
Fkh6 signaling pathway, the Hedgehog genes(Shh and Ihh) signaling pathway, the 
Homeodomain Nkx2-3 pathway and the platelet-derived Growth factor-A (PDGF-
A) / PDGFR-α pathway (Androutsellis-Theotokis et al., 2006; Berman et al., 2003; 
Chen et al., 2004; Gregorieff and Clevers, 2005; Hardwick et al., 2004; Katoh, 
2007a; Katoh, 2007b; Katoh, 2007c; Katoh and Katoh, 2006b; Lees et al., 2005; 
Logan and Nusse, 2004; Pinto and Clevers, 2005a; Pinto and Clevers, 2005b; 
Reya and Clevers, 2005; van den Brink, 2007; van den Brink and Hardwick, 2006). 
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The most important pathway involved in homeostasis and colorectal 
carcinogenesis, has been the Wnt signaling pathway. It is interesting to note that 
up to date there has been no conclusive direct evidence linking the Wnt signaling 
pathway to stem cells, the reason(s) for this has been the paucity of definitive stem 
cell markers in the colon / rectum. All the evidence available is only supportive of a 
role for these signaling pathways in regulating stem cell function in the colon / 
rectum. 
 
Finally, the role of stem cells in the pathogenesis of colorectal cancer has been 
open to debate and speculation. Aberrations in the Wnt signaling cascade, 
especially mutations in the APC gene, have been shown to lead to tumour 
formation in the colon (Gregorieff and Clevers, 2005; Logan and Nusse, 2004; 
Pinto and Clevers, 2005b). Also, there appears to be increasing evidence to 
suggest that human cancers can be considered a stem cell disease (Dalerba et 
al., 2007a; Jordan et al., 2006; Reya et al., 2001). According to this ‘Cancer Stem 
Cell’ (CSC) theory, tumours are not to be viewed as simple monoclonal 
expansions of transformed cells, but rather as complex tissues where growth is 
driven by small pool of pathologically transformed CSCs that, on the one hand, 
have acquired tumour-related features such as uncontrolled growth with metastatic 
potential, and, on the other hand, are able to self renew and differentiate into a 
phenotypically heterogeneous progeny. In support of this hypothesis, three key 
experimental observations (Al-Hajj et al., 2003; Bonnet and Dick, 1997; Singh et 
al., 2004) have been made: Firstly, only a minority of cancer cells within each 
tumour are capable of tumourigenic potential when transplanted into immune-
deficient mice: Secondly, tumourigenic cancer cells have a distinct profile of 
surface markers and can be differentially and reproducibly isolated from non-
tumourigenic ones by flow cytometry and thirdly, tumours grown from tumourigenic 
cells contain mixed populations of both tumourigenic and non-tumourigenic cancer 
cells, thereby re-creating the full phenotypic heterogeneity of the parent tumour 
(Dalerba et al., 2007b). At present, CSCs have been identified from several solid 
tumours such as head and neck cancers (Prince et al., 2007), brain tumours (Galli 
et al., 2004; Singh et al., 2004), breast cancer (Al-Hajj et al., 2003) and colorectal 
cancer (O'Brien et al., 2007; Ricci-Vitiani et al., 2007). Colorectal CSCs (Co-CSCs) 
are identified by expression of CD133+ (Ricci-Vitiani et al., 2007) in these cells. 
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However, additional markers have been described such as CD44 and EpCAM 
(epithelial cell adhesion molecule) (Dalerba et al., 2007b). The implications of Co-
CSCs in colorectal cancer are proving to have a profound impact on our current 
understanding of this disease process. The CSC model introduces an additional 
conceptual frame for the interpretation of intra-tumour heterogeneity observed in 
colorectal cancer. In addition, the CSC model might also help explain unexpected 
observations in colorectal cancer biology, such as the presence of heterogeneous 
patterns and non-constitutive mechanisms of telomerase activation within both 
primary and metastatic colorectal cancers (Dalerba et al., 2005). The observation 
that colorectal cancer is sustained by a minority subpopulation of CSCs could 
assist in the development of more effective prognostic indicators and treatment 
regimens specifically targeting these CSCs. 
 
 
 
  
1.7 Thesis aims 
 
A-type lamins are implicated in various tissue specific disorders such as 
autosomal inherited EDMD, MAD, etc. Variable expression of A-type lamins has 
also been observed in a broad range of malignancies affecting epithelial, 
mesenchymal and lymphoid tissues. Recently, a retrospective study looking at the 
variable expression of A-type lamins in colorectal cancers has shown an adverse 
prognosis in patients with colorectal cancers expressing this protein. The 
underlying biological processes responsible for this adverse outcome in patients 
with colorectal cancers expressing A-type lamins are still unknown. A-type lamins 
have been implicated in various signaling pathways and are also known to play an 
important role in other functions involving the cell, for example, cell to cell 
adhesion, nuclear chromatin organization, mitosis, cytoskeletal reorganization, cell 
growth regulatory pathways, amongst other functions. 
To try and answer some of the observed features associated with variable A-type 
lamin expression in colorectal cancers, it is important to characterize the normal 
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expression profile of A-type lamins and their binding partners in mucosa of the 
colon / rectum initially followed by a study looking at the expression profile of A-
type lamins in colorectal tumours. In addition, the expression profile of β-catenin in 
the colonic crypts also merits review since this pathway is known to play a key role 
in colorectal carcinogenesis. To this end, a prospective study of patients with 
colorectal cancers undergoing definitive treatment is planned. Further studies 
using microarray based analysis will also be undertaken on tumour samples 
obtained from patients in the study group. 
In colorectal cancer, appropriate treatment of the Duke’s B stage group has 
always posed a dilemma since the benefit of surgery alone or surgery in 
combination with adjuvant therapy (chemotherapy and / or radiotherapy) is still 
unproven. A recent retrospective study has shown A-type lamins to be an 
independent prognostic indicator in colorectal cancer; my work is aimed at trying to 
identify a cause for this observation by utilizing microarray studies, in which I will 
compare a Duke’s B tumour, expressing A-type lamins, with other stages of 
colorectal cancers. I would also like to identify any signaling pathways involved in 
tumours expressing A-type lamins. An attempt will also be made to try and answer 
the age old question of whether colorectal cancer is primarily a stem cell problem 
or not. Finally, I would like to identify any additional prognostic indicators that may 
complement the expression of A-type lamins in colorectal cancer. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 General Materials and Reagents / Chemicals 
 
All plastic ware / glassware were supplied by Greiner Bio-One Ltd, 
Gloucestershire, UK. General reagents and chemicals used were supplied by 
Sigma-Aldrich Company Ltd (Dorset, UK), Melford Laboratories Ltd (Suffolk, UK) 
and BDH Laboratory Supplies (VWR International Ltd, Leicestershire, UK). 
2.2 Patient Selection and Tissue Sampling 
 
2.2.1  Patient selection  
 
After obtaining appropriate Local Research and Ethics Committee approval, 
patients undergoing elective colorectal cancer surgery at the James Cook 
University Hospital in Middlesbrough, UK, were identified and consented for tissue 
sample collection, prospectively. A total of forty two patients were thus identified 
and appropriate tissue samples were taken for further analysis and research.  
 
2.2.2 Tissue samples for immunohistochemical 
analysis 
 
Surgically resected specimens of the colon / rectum were opened up longitudinally 
and thoroughly cleaned with sterile saline. This, in effect, created a rectangular 
shaped specimen with the tumour located centrally and flanked on either side by 
macroscopically normal looking colonic / rectal mucosa. Full thickness samples of 
normal colonic mucosa, tumour and marginal areas between tumour and normal 
colonic mucosa were obtained by sharp dissection. The same process was 
repeated for all patients undergoing surgical resection of their tumours. These 
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samples then underwent an automated process during which they were processed 
and fixed in 10 % formalin before being embedded in paraffin blocks, at the James 
Cook University Hospital following standard pathology guidelines. The orientation 
of samples was crucial to experimental work and so tissue samples were 
specifically orientated in such a manner as to obtain a full thickness profile of 
colonic tissue and tumour sample. On an average, six samples were taken from 
each patient, four samples of normal colonic mucosa from each of the four corners 
of the resected specimen and one sample each from the central tumour area and 
the marginal area respectively. 
 
2.2.3 Tissue samples for RNA analysis 
 
Tissue samples of normal colonic mucosa and central tumour region were 
sampled by sharp dissection. After weighing the samples, an appropriate amount 
of Trizol® reagent was added to the sample prior to manual homogenisation as per 
guidelines issued by invitrogen®(Invitrogen™, Paisley, UK). Homogenised samples 
were aliquoted into 1 ml volumes and stored at minus 80º C in RNAse free 
eppendorfs. Additionally, a sample of normal colonic mucosa was kept in Dispase 
II® solution overnight. This assisted in cleaving the basement membrane prior to 
dissecting the mucosa from the underlying Muscularis. The mucosa was then 
weighed and an appropriate amount of Trizol® reagent was used for 
homogenisation, as per issued guidelines. These samples were then stored in a 
similar fashion.  
 
 
2.2.4 Tissue samples for cryosectioning 
 
Fresh tissue samples of normal colonic mucosa were also obtained for 
cryosectioning. Each sample was snap frozen in liquid nitrogen and then stored in 
a minus 80ºC freezer. 
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2.3 Immunohistochemistry 
 
2.3.1  Colonic tissue samples 
 
All tissue samples used were sectioned at 5 micrometers thickness. These 
samples were then transferred to superfrost® slides and incubated at 37ºC 
overnight to improve adhesion. 
 
2.3.2  Antigen retrieval 
 
Tissue sections were de-paraffinized by immersion in xylene for five minutes, 
repeated twice. The re-hydration process was undertaken using decreasing 
concentrations of ethanol: 100% ethanol – 5 minutes, 100% ethanol – 5 minutes, 
96% ethanol – 5 minutes, 70% ethanol – 5 minutes before being transferred to 
distilled water for 3 minutes. Antigen retrieval was carried out using a modified 
method described by Barker et al. (1999). Tissue sections were immersed in a 3% 
H2O2 in methanol solution, for 10 minutes at room temperature, to suppress all 
endogenous peroxidase activity. This was followed by incubation at 90ºC for 15 
minutes of tissue sections in a 0.01 M citrate buffer (pH 6.0) solution, using a 
water bath. Thereafter, tissue sections were allowed to cool in PBS for at least 10 
minutes. Slides containing the tissue sections were then loaded onto Thermo 
shandon coverplates™ (Thermo Shandon Ltd. UK) and placed into Shandon 
Sequenza® staining racks (Thermo Fisher Scientific Inc. USA). All experimental 
work continued with the slides loaded onto the slide holders. 
 
2.3.3  Peroxidase staining reaction 
 
To block non-specific binding, tissue sections were incubated with 2% goat serum 
– 2% bovine serum albumin in PBS for 20 minutes. After 3 washes with PBS, 
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tissue sections were incubated with primary antibody, diluted to the appropriate 
concentration in 0.1% BSA in PBS. 140 μl of antibody solution was applied to each 
slide and incubated overnight at 4ºC in a dark chamber. Various concentrations 
and other details about the primary antibody used can be seen in Table 2.1. All 
slides were then washed 3 times with PBS. Biotinylated IgG was used as 
secondary antibody at a concentration of 1:400 in 0.1% PBS. 140 μl of this 
solution was used per slide and left for 45 minutes at RT. Slides were then washed 
3 times with PBS. 30 minutes prior to use, StreptABComplex / HRP (Dako 
Cytomation) 
Table 2.1 
Various antibodies and corresponding secondary antibodies used for 
Immunohistochemistry (IHC) 
Primary 
Antibody 
Target Type Reference Assay Dilution Secondary 
Antibody 
Dilution 
1332 A 2 Lamin A Mouse 
monoclonal 
Hozak et al. 
(1995) 
IHC 1:50 Biotinylated 
DαM HRP 
1:400 
Jol 2 Lamin A/C Mouse 
monoclonal 
Dyer et al. 
(1997) 
IHC 1:100 Biotinylated 
DαM HRP 
1:400 
RalC Lamin C Rabbit 
polyclonal 
Venables et 
al. (2001) 
IHC 1:10 Biotinylated 
DαR HRP 
1:400 
Emerin Emerin Mouse 
monoclonal 
Novocastra
® 
IHC 1:50 Biotinylated 
DαM HRP 
1:400 
PCNA PCNA Mouse 
monoclonal 
Immuno-
concepts
® 
IHC 1:100 Biotinylated 
DαM HRP 
1:400 
Lap2α Lap2α Rabbit 
polyclonal 
ImmuQuest
® 
IHC 1:10 Biotinylated 
DαR HRP 
1:400 
β-Catenin β-Catenin Mouse 
monoclonal 
BD 
Biosciences
® 
IHC 1:100 Biotinylated 
DαM HRP 
1:400 
Anti 
Active β-
Catenin 
Active β-
Catenin 
Mouse 
monoclonal 
Upstate
® 
Cell 
Signalling 
Solutions 
IHC 1:10 Biotinylated 
DαM HRP 
1:400 
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was prepared (50 μl Streptavidin and 50 μl biotinylated peroxidase in 5 ml of 0.1% 
BSA in PBS) and 140 μl of this solution was used per slide and allowed to 
incubate for 30 minutes at RT. Slides were washed 3 times in PBS. Activated DAB 
chromogen (Dako Cytomation) was used for immunological detection. Upon 
adequate visualisation, further reaction was stopped by plunging the slide into 
dH2O and the time taken for the reaction was noted. Negative control studies were 
also conducted using 0.1% BSA in PBS instead of the primary antibody. 
 
2.3.4  Counterstaining 
 
Tissue sections were counterstained with either neat Ehrlich’s haematoxylin 
(Raymond A Lamb Ltd, Eastbourne, East Sussex, UK) for 3 minutes and then 
rinsed in tap water for 1 minute. Using 1% acid-alcohol for 1 minute, the stain was 
differentiated and then further matured in 0.04% aqueous ammonia for 30 
seconds. Or with neat Mayer’s Haemalum for five seconds, before being rinsed in 
distilled water and fixing the stain with alkaline alcohol (3 ml ammonia solution in 
100 ml of 70% ethanol). After washing in dH2O for 1 minute, tissue sections were 
de-hydrated by immersing in: 70% ethanol – 1minute, 96% ethanol – 1 minute, 
96% ethanol – 1 minute, 100% ethanol – 1 minute, xylene – 3 minutes and xylene 
– 3 minutes. Cover slips were then applied to the slides using Entellan® (Merck 
kGaA, Darmstadt, Germany) and left overnight to dry. 
 
2.3.5  Image analysis 
 
A Nikon Diaphot 300 inverted microscope (Nikon Corporation, Tokyo, Japan) fitted 
with Plan 4x / 0.13, 10x / 0.25, 20x / 0.4 and 40x / 1.3 lenses, was used for image 
analysis. Images were captured digitally by a Nikon DXM 1200 digital camera 
using Nikon Act – 1, version 2.2 software. Further image processing was carried 
out in Adobe® Photoshop® 7.0 (Adobe Systems Inc. San Jose, CA, USA). 
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2.4 Semi – quantitative RT PCR 
 
2.4.1  Primer design 
 
Specific primers were designed using Primer 3 web interface 
(http://frodo.wi.mit.edu/primer3/primer3_code.html), developed by the Whitehead 
Institute, Cambridge, MA and the Howard Hughes Medical Institute, Chevy Chase, 
MD. This software allows the design of primers from a given DNA sequence based 
on parameters such as primer length, product size, melt temperature (Tm) and GC 
%. Primers between 18 to 27 bases long were designed with a minimum Tm of 
57°C and a maximum Tm of 63°C. GC content was kept between 45 – 70 %. A 
maximum Tm difference of 4°C between sense and antisense primers was also 
ensured. Examination of secondary structures in primer pairs, incorporating hairpin 
loops, cross-dimers, self dimers, palindromes, runs and repeats which could alter 
their function or generate aberrant products, was assessed using Net Primer 
online software (PREMIER Biosoft International, CA / 
http://www.premierbiosoft.com/netprimer/index.html).Table 2.2 shows a list of 
primer sequences specific for the coding sequences (cds) of human genes 
investigated: 
 
2.4.2 RNA Extraction from Colorectal Cancer Tissue 
Samples 
 
2.4.2.1  RNA extraction 
 
After obtaining appropriate samples, as described in section 2.1.3, RNA isolation 
was carried out using TRIzol® reagent (Invitrogen™, Paisley, UK), as per their 
protocol sheet (Technical Manual #15596-026). 1ml of TRIzol® reagent was 
added to every 100mg of tissue sample. All work surfaces and materials used 
were RNAse free. This work was carried out in a laminar flow hood. 
 
86 | P a g e  
 
Gene Accession 
Number 
Primer 
Direction 
Start 
(5’– 3’) 
Deoxyoligonucleotide sequence Product 
Size (bp) 
 
Lamin A/C 
 
 
NM_005572 
 
Sense 
 
Antisense 
976 
 
1235 
GATGCGCTGCAGGAACTGCG 
 
CGGGCCAGTGAGTCCTCCAG 
 
259 
 
Lamin A 
 
 
NM_170707 
Sense 
 
Antisense 
1878 
 
2112 
GGTGCGCTCAGTGACTGTGG 
 
CGTGACACTGGAGGCAGAAGAG 
 
234 
 
Lamin C 
 
 
NM_005572 
Sense 
 
Antisense 
1716 
 
1968 
GAAGGCTGGGCAGGTGGTGA 
 
TCAGCGGCGGCTACCACTCA 
 
252 
 
T Plastin 
 
 
NM_005032 
Sense 
 
Antisense 
2692 
 
2998 
GCATCTTCCCTCTCATACCC 
 
GCAAACAGCTTGACAAAGCA 
 
307 
 
E Cadherin 
 
 
NM_004360 
Sense 
 
Antisense 
4301 
 
4715 
CCAAGTGCCTGCTTTTGATG 
 
CACAATTATCAGCACCCACAC 
 
415 
 
β Actin  
 
 
NM_001101 
Sense 
 
Antisense 
257 
 
1090 
GGCACCACACCTTCTACAATGAGC 
 
CGTCATACTCCTGCTTGCTGATCC 
 
834 
Creatine  
Kinase  
Brain 
 
NM_001823 
Sense 
 
Antisense 
92 
 
768 
CAACAGCCACAACGCACT 
 
TGACCCACACCAGGAAGG 
 
677 
 
Table 2.2 
 Primers for semi-quantitative RT-PCR 
2.4.2.2  Homogenisation 
 
Homogenisation of these samples was carried out in a glass Teflon homogeniser. 
After incubation at RT for 5 minutes, all insoluble material was removed by 
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centrifugation at 12,000 x g for 10 minutes at 4ºC and transferring the supernatant 
to 1.5ml RNAse free eppendorfs (1ml of supernatant was added to each 1.5ml 
RNAse free eppendorfs). At this point, samples were snap frozen in liquid nitrogen 
and stored at minus 80ºC. 
 
2.4.2.3  Phase separation 
 
Frozen samples were allowed to reach RT before adding 0.2ml of Chloroform for 
every 1ml of TRIzol® (Invitrogen™, Paisley, UK) reagent used originally. After 
vigorously shaking the samples to ensure adequate mixing and no obvious phase 
separation, 15 minutes of centrifugation at 12,000 x g and 4ºC was carried out. 
This resulted in a colourless, clear aqueous upper phase with a well defined 
whitish interphase separating it from a pinkish lower phase. The upper, clear 
phase was very carefully transferred to fresh 1.5ml RNAse free eppendorfs to 
continue with RNA precipitation. 
 
2.4.2.4  RNA Precipitation 
 
To this clear aqueous phase, 0.5ml of isopropanol was added for every 1 ml of 
TRIzol® (Invitrogen™, Paisley, UK) used initially. After incubation at RT for 10 
minutes, the sample was centrifuged for 10 minutes at 12,000 x g and 4ºC. RNA 
was precipitated in the form of a small pellet at the base of the tube. 
 
2.4.2.5  RNA Wash 
 
After removal of the supernatant, each pellet was washed with 1ml of 75% RNAse 
free ethanol. After mixing and vortexing the sample, it was centrifuged at 7500 x g 
for 5 minutes at 4ºC. After removal of excess ethanol, the RNA sample was 
allowed to air dry. 
 
88 | P a g e  
 
2.4.2.6  Redissolving the RNA 
 
RNA was dissolved in 25μl of RNAse free water. This was heated up to 55ºC for 
10 minutes and mixed thoroughly by pipetting. 
 
2.4.3  RNA quantification and quality assessment 
 
2.4.3.1  Quantification of RNA 
 
RNA quantification was carried out using a Beckman DU-600 ----- analyser. 2 μl of 
RNA sample was mixed with 98μl of DEPC treated H2O. This sample was then 
loaded onto a 100μl cuvette and analysed. The concentration of RNA in the 
sample was calculated using the formula: 
  A260 reading x 40μg/ml x Dilution factor 
Where:  
 1) A260 is the absorbance of the solution at 260nm 
2) 40 μg/ml is a fixed conversion factor relating absorbance to                       
concentration for RNA 
 3) Dilution Factor was 2 in this case 
 
Knowing the concentration of RNA in the sample, it was easy to calculate the total 
volume of RNA per sample. 
 
2.4.3.2  Quality assessment of RNA using a 1.2% 
Formaldehyde denatured gel 
 
A 1.2% Formaldehyde denatured gel was prepared by dissolving 600 mg of 
Agarose to 40 ml of DEPC treated H2O, using a microwave oven. The sample was 
allowed to cool down to RT before adding 5 ml of 10 x MOPS and 5 ml of 37% 
Formaldehyde. A 50 ml tray, with an appropriate comb, was used to allow the gel 
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to set in. 1 x MOPS was used as the running buffer solution. All RNA samples 
were then prepared for gel electrophoresis using RNA sample loading buffer 
(Sigma®, Sigma-Aldrich Inc, Saint Louise, Missouri, USA), in accordance with the 
manufacturers instructions. Samples were separated alongside RNA size markers 
(Sigma®, Sigma-Aldrich Inc, Saint Louise, Missouri, USA) ranging from 0.2 – 10 
KB. All gels were prepared in a similar fashion and were run at 80mV for one hour. 
Bands were visualised using a Gel Doc ™ 2000 UV transilluminator and Quantity 
One ™, version 4.0.3 software (Bio-Rad). Purity was determined by measuring the 
ratio of absorbance in DEPC-treated δH2O at 260nm and 280nm (A260/A280) in a 
GeneQuest CE2301 Analyser (Cecil Instruments Ltd. Cambridge, UK).  
 
2.4.4 Confirmation of RNA integrity 
 
The human gene β-actin was used to exclude the possibility that geneomic DNA 
(gDNA) may have been co-isolated with total RNA. Primers to an 834bp fragment 
of β-actin (see table 2.1) were used to amplify any contaminating gDNA in 0.5µl 
reaction volume comprising 1 x Reddymix™ PCR Master Mix (ABgene, Epsom, 
Surrey, UK) [25 units/ml Thermoprine Plus DNA Polymerase (Taq), 75mM Tris-
HCl (pH 8.8 at 25°C), 20mM (NH4)2SO4, 2.5mM MgCl2, 0.01% Tween
®20 (v/v) and 
200 µM each dNTPs], 0.4 pmol/µl β-actin sense primer and 0.4 pmol/µl β-actin 
anti-sense primer. Cycling conditions were as described in section 2.4.6. 
The total volume of PCR product (25µl) was electrophoresed on a 1.2% 
Formaldehyde denatured gel. RNA samples showing evidence of gDNA 
contamination were treated with 0.075 units/µl RQ1 RNase-free DNase (Promega) 
in a 1x reaction buffer [40mM Tris-HCl (pH 8.0), 10mM MgSO4, 1mM CaCl2] for 15 
minutes at room temperature. The reaction was terminated by incubating the 
samples with 1µl DNase stop solution (20mM EGTA, pH 8.0) for 10 minutes at 
65°C. RNA was then precipitated with 1/10 of the total reaction volume of DEPC-
treated  3M Sodium Acetate (NaOAc), pH 5.2 and 3 volumes of 100% RNase free 
ethanol (-20°C), vortexed for 5 seconds and incubated overnight at -20°C. To 
recover RNa, samples were centrifuged at 12,000 x g for 10 minutes at 4°C, the 
supernatant removed and pellets washed with 1ml 70% RNase free alcohol (in 
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DEPC-treated δH2O). Centrifugation was repeated 12,000 x g for 5 minutes at 
4°C, the supernatant aspirated and residual ethanol allowed to evaporate for 5-10 
minutes in a laminar flow hood. The resulting pellet was re-suspended in 20µl 
RNase free water and the quality, purity (A260/A280) and concentration (A280) of the 
RNA was re-evaluated as described in section 2.4.3. 
 
2.4.5  RNA storage 
 
All excess RNA samples were immediately snap frozen in liquid nitrogen and 
stored at minus 80ºC. 
 
2.4.6 Reverse Transcription – Polymerase Chain 
Reaction (RT-PCR) 
 
Reverse transcription and amplification of target genes was carried out in 2 stages 
using Promega’s Reverse Transcription system (A3500) and PCR Master Mix 
(M7502). For all samples, RT-PCR was completed in triplicate. 
First, a cDNA library was synthesised in a 40µl reaction using Promega’s Reverse 
Transcription System in exact accordance with their technical bulletin TB099 
(2006). Two –ve controls substituting RNa and the AMV-RT for δH2O were used in 
each run. All resulting cDNA libraries were aliquoted and stored at -20°C.  
Β-actin was amplified from all cDNA libraries and their accompanying AMV-RT 
negative controls, plus negative controls where no RNA was added to show equal 
amounts of cDNA had been reverse transcribed and that reverse transcription and 
PCR reactions were working successfully. 
PCR fragments for the chosen target genes detailed in table 2.1, were amplified 
from all Reverse Transcriptase reactions using a 25µl reaction containing 1 x 
Promega PCR Master Mix [25 units/ml Taq DNA polymerase in buffer (pH 8.5), 
200µM each dNTPs and 1.5 mM MgCl2], 0.4 pmol/µl sense primer, 0.4 pmol/µl 
anti-sense primer, 2µl cDNA library and Nuclease-Free water. Optimisation of 
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PCR profiles was carried out in an Eppendorf Mastercycler™ Gradient Thermal 
Cycler (Eppendorf UK Ltd, Cambridge, UK) using the following conditions; 94°C 
for 2 minutes, 26 cycles of [94°C for 45 seconds, Tm°C ± 5°C for 1 minute, 72°C 
for 1 minute] and finally 72°C for 5 minutes. 
2.4.7 Analysis 
 
All amplified products were run on a 1.2% Formaldehyde denatured gel, at 60V for 
60 minutes. Product size was compared to a 100bp DNA ladder (Promega Cat 
#G2101) and bands were visualised using a GelDoc™ 2000 UV transilluminator 
and Quantity One™ software versin 4.0.3 (Bio-Rad). Differences in expression 
levels were quantified using densitometry and calculated as a ratio against β-actin 
expression. 
 
2.5 Microarray Analysis 
 
Genome wide microarray analysis was carried out on selected, human colorectal 
tumour samples using the Human Genome U133 Plus 2.0 high-density 
oligonucleotide Affymetrix GeneChip array (Affymetrix, Santa Clara, CA, USA). 
Normalisation of expression ratios was carried out in accordance with the 
associated Affymetrix guidelines for the HG U133 GeneChip and a targeted gene 
list was generated by means of a series of relevance thresholds for detection p-
value significance, expression change p-value significance and Signal Log Ratio 
(SLR). Analysis of the targeted gene list and biological interpretation of results was 
carried out using the online NetAffx Analysis Centre from Affymetrix found at 
(http://www.affymetrix.com/analysis/index.affx). Genes of interest were subjected 
to cluster analysis by Gene Ontology including; Biological Processes, Molecular 
Function and Cellular Component. For a detailed description of the online NetAffx 
tools, see http://www.affymetrix.com/support/index.affx.  
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CHAPTER 3 
EXPRESSION PROFILE OF LAMINS A/C AND 
THEIR ASSOCIATED BINDING PARTNERS IN 
HUMAN COLONIC CRYPTS  
 
3.1 Introduction 
3.1.1 Histological characteristics of normal colonic 
and rectal epithelium 
 
As mentioned previously (chapter 1), the mucosal lining of the colon and rectum is 
a highly complex structure which proliferates rapidly and is under tight control of 
various homeostatic mechanisms. This ensures a state of physiological 
equilibrium, essential for the proper functioning of this organ. As described in 
Gray’s anatomy (38th edition), the basic functional units, underpinning the entire 
colon and rectum, are flask shaped invaginations of mucosa called crypts. Each 
crypt has a fairly uniform structure and arrangement of cells. However, there is 
slight variation in the exact number of cells forming any given crypt in the colon 
and rectum in the same individual or between individuals. Irrespective of this 
observation, each crypt strictly adheres to a common histological layout of cells 
which in turn allows the colon and rectum to function properly. Only six types of 
cells are responsible for giving rise to the millions of cells forming the mucosal 
lining of the colon and rectum. These include:  
Columnar cells (vacuolar absorptive cells) – The most numerous of the 
epithelial cell types and responsible for ionic exchange / regulation and water 
resorption. They all bear apical microvilli. Many of these cells also contain 
secretory granules in their apical cytoplasm containing largely mucins but also 
antibodies of the IgA type. They are characterised by typical junctional complexes 
around their apices which limits diffusion from the lumen into the intestine wall. 
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Mucous (goblet) cells – These cells consist of elongated basal nuclei and have 
an apical region containing many membrane-bound Mucin granules. Their 
secretions are important in lubricating the intestinal wall and also in mechanical 
and chemical protection. Their apical surfaces bear a few short microvilli. 
Microfold cells – They are located at sites of lymphoid follicles in the intestinal 
wall. They have long, widely spaced microvilli between which are numerous 
endocytic vesicles. These cells are thought to act as sampling sites for antigens in 
the lumen of the intestine which are then transferred to the underlying lymphoid 
tissue for further processing and production of appropriate antibodies. 
Entero-endocrine cells – These cells are situated mostly at the bases of 
intestinal glands and are part of the gastro-entero-pancreatic (GEP) endocrine 
system. They consist of scattered, often solitary, hormone producing cells. Their 
bases rest on the basal lamina and they produce secretory granules of varying 
sizes and shapes which diffuse across the basal lamina and are absorbed into the 
blood stream. Their actions are usually endocrinal.  
Brush cells – These are infrequent cell types of unknown function. They have an 
apical bundle of long, straight microvilli, giving them a characteristic appearance. 
Stem cells – These cells reside at the basal regions of crypts and are responsible 
for giving rise to all cell types. They have no obvious microscopic features that can 
distinguish them from other cell types in the basal regions of the crypts. They 
undergo periodic mitosis to give rise to a stream of cells which migrate upwards to 
populate the entire crypt and are shed off at the boundaries between crypts 
(Brittan and Wright, 2004; Potten, 1998). 
Located between each crypt is the supporting stroma or mesenchyme. Located in 
the mesenchyme are cells whose functions are poorly understood but appear to 
secrete important factors which play a significant role in crypt homeostasis for 
example Wnt factors. Also located in the mesenchyme are scattered lymphocytes. 
Supporting the mucosa is the muscularis mucosae below which resides the 
submucosa containing the neurovascular plexus to the intestine. The muscularis 
externa consists of two layers of smooth muscle, an inner circular and outer 
longitudinal layer, responsible for peristaltic activity. Surrounding the muscularis 
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externa is the serosa, a layer of adventitial tissue which is absent in the lower two 
thirds of the rectum. 
To date, many studies have been undertaken to elucidate and characterise 
various compartments in the crypt, crypt dynamics, stem cell niche areas in the 
basal region of the crypt and many other crypt characteristics; however there is a 
paucity of data as regards expression profiles for lamin A/C and its binding 
partners in the intestinal crypts. Keeping this in mind, my aims are to, initially, 
characterise the expression profile of A-type lamins and their binding partners in 
the mucosa of the colon and rectum and, subsequently, to investigate and clarify 
the role, if any, of A-type lamins in colorectal cancer. 
 
3.1.2 Expression of lamin A/C in different cancerous 
cells and tissues 
 
The role of lamins in cancer has been studied in a variety of different cancers such 
as basal skin cell cancer (Venables et al., 2001), acute lymhoblastic leukaemia, 
non-Hodgkin’s lymphoma (Stadelmann et al., 1990),  human small cell lung cancer 
and non-small lung cell cancer (Broers et al., 1993), colorectal cancer (Cance et 
al., 1992; Moss et al., 1999) and metastatic leiomyosarcoma, rhabdomyosarcoma 
and chondrosarcoma (Cance et al., 1992).  
In some cancers studied, there are conflicting reports about the expression of 
lamins, for example, in colorectal cancer, Moss et al., (1999) describes a decrease 
in nuclear staining for A-type lamins and lamin B1 in colon adenomas and 
adenocarcinomas when compared to normal colonic mucosa, whereas Cance et 
al., (1992) has previously reported heterogeneous expression of A-type lamins in 
two colon adenocarcinomas. Interestingly, Venables et al., (2001) demonstrates a 
down regulation of lamin A in basal skin cell cancers exhibiting a high proliferative 
index and a loss of lamin C in slower growing tumours.  
In my studies, expression of total lamin A/C, as well as lamin A and C individually, 
in normal colonic / rectal mucosa was undertaken. Samples were oriented to 
obtain full thickness profiles of colonic / rectal crypts. All patients participating in 
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this study underwent expression profiling for lamin A/C, lamin A and lamin C, in a 
similar fashion. When assessing for lamin A/C expression in colorectal cancers, I 
took into consideration previous conflicting reports about lamin A/C expression 
patterns in different patient groups with colorectal cancer. In my studies, I used, 
commercially available, specific monoclonal / polyclonal antibodies against lamin 
A, lamin C and lamin A/C. Appropriate negative control studies were done to 
exclude any bias in the observed results. Similarly, Western blot analysis 
confirmed specificity of antibody used against lamin A/C (Figure 3.1) 
 
Figure 3.1 
 
Western blot (Human) analysis of whole cell lysates from HeLa cells using Jol 2 
(Antibody against lamin A/C). Bands observed at 73 kDa and 64 kDa, 
corresponding to lamin A and C, respectively. 
               Courtesy of abcam® laboratories 
Quantification of antibody expression in the tissue samples selected using 
immunohistochemical methods, was undertaken by me. This involved a structured, 
microscopic analysis of the entire cancer tissue section at 20x magnification. Each 
20x field visible was designated 1power field. The tissue section was then divided 
into rows, corresponding to 1 power field (20x), along the x and y axis. Each row 
was assessed for antibody expression in a left  right fashion. For every power 
field, expression of antibody was categorised into three groups:  
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Present – If more than 90% of the visualised area was expressing 
antibody. 
Absent – If less than 10% of the visualised area was expressing antibody. 
Depleted – If less than 90%, but more than 10%, of the visible area was 
expressing antibody. 
All power fields for each cancer tissue sample were then collated into a single 
figure and a final assessment regarding expression of antibody was made, based 
on the same cut off values as used for each individual power field. Analysis of all 
tissue samples was done by me. 
This method of quantification has well known drawbacks. Inter observer error can 
be seen and reproducibility can be problematic. Similarly, quantification is very 
subjective. Alternate methods that are more objective, such as quantification 
studies using an image analyser are difficult to use for this type of analyses due to 
the patchy areas of antibody expression noted in some cancer tissue samples. 
The method of antibody expression quantification used by me has previously been 
used in a separate study (Cox 2007) with very low inter observer error and god 
reproducibility, hence I opted to use a similar method for my study. 
 
 
 
3.2 RESULTS 
 
3.2.1 Optimization of specimen samples for 
immunohistochemistry 
 
All samples were obtained fresh from appropriately consenting patients 
undergoing bowel cancer surgery. Orientation of the specimen sample was very 
important. All samples were meticulously oriented after appropriate fixation and 
then embedded in liquid paraffin. Half of all specimen samples were oriented flat 
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with the mucosal surface uppermost, the remaining half were oriented at 90° in 
paraffin to give full length profiles of colonic crypts. All embedded specimen 
samples were sectioned as mentioned previously and H&E immunostaining done 
to assess orientation of the sample prior to undertaking immunostaining using 
definitive antibodies. All primary antibodies were carefully assessed using 
gradually increasing dilutions of primary antibody, to assess for optimum 
expression in the samples. Where possible, monoclonal antibodies were used in 
preference. 
 
3.2.2 Normal colonic crypts in human adults  
(Figures 3.2 and 3.3) 
 
The basic functional unit of the large intestine is the crypt. Each crypt is made up 
of various cell types, as mentioned earlier. The connective tissue surrounding 
these glands is called the lamina propria. The connective tissue together with the 
cells forms the mucosa. Separating the mucosa from the sub mucosa is the 
muscularis mucosae. This is made up of a thin layer of smooth muscle cells. 
Beneath this layer is the submucosa. In the submucosa are located numerous 
capillaries, lymphatics, neuro-vascular structures, lymphoid aggregates and 
scattered lymphocytes. The muscularis externa surrounds the submucosa and is 
composed of two layers, an outer longitudinal and inner circular layer. Covering 
the muscularis externa to a  
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Figure 3.2 
 
Cross section of the colon stained with H & E (10x). 
 
This micrograph shows the three main layers making up the colon. The 
mucosal layer is adjacent to the GI tract lumen. Colonic crypts are formed 
by flask shaped invaginations into the mucosal layer. Separating the 
mucosal layer from the sub-mucosal layer is the muscularis mucosae. The 
submucosal layer carries in it capillaries, lymphatics and nerves. The outer 
most layer of the colon is formed by the muscularis externa, composed of 
the inner circular and outer longitudinal layers of muscle, respectively.  
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Figure 3.2   
Cross section of the colon stained with H & E (10x).  
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Figure 3.3 
Normal crypt from mucosa of the human colon 
H & E (20x) 
Scale bar represents 100µm.  
LP – Lamina Propria          SM – Sub Mucosa          MM – Muscularis 
Mucosae 
 
This micrograph shows in greater detail the full crypt profile. Cells lining 
these crypts are columnar in shape with basal nuclei. Mucous secreting, 
goblet cells (indicated by cells with large vacuoles in them) make up a 
large proportion of cells making up the crypt. The muscularis mucosae and 
lamina propria are well represented in this section.  
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Figure 3.3 
Crypt from mucosa of the human colon stained using H & E. (20x) 
Scale bar represents 100µm. 
 
 
 
 
MM 
LP 
SM 
Lumen 
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variable extent is a layer of visceral peritoneum called the serosa (Figure 3.2 and 
Figure 3.3). 
Significant variation was noted in the total number of cells making up a crypt. On 
average, the height of a crypt was 80 cells high. The average diameter of a crypt 
was approximately 200 microns based on serial sections, but this value was highly 
subjective due to variation based on multiple factors, including tissue processing, 
tissue orientation, angle at which the specimen was sliced, etc. The mucosal (or 
luminal) surface of the colon and rectum appeared cribriform, in keeping with 
multiple luminal openings of intestinal crypts. 
 
3.2.3 Expression of lamin A/C in the adult human colon 
crypt (Figures 3.4 and 3.5) 
  
The aim of this study was to characterise the expression of lamin A/C subtypes in 
the human colon crypt. Formalin fixed and paraffin embedded sections of normal 
adult human colon were stained with the appropriate antibody using standard 
immunohistochemical methods. To assess the expression of lamin A/C a 
monoclonal antibody Jol2 (anti lamin A/C) was used. This antibody reacts with the 
common domain of the lamin A/C tail, aa 464 – 572 and identifies both lamins A 
and C (Dyer et al., 1997). 
Lamin A/C expression was observed in three distinct zones along the crypt axis 
(Figures 3.4). In the basal region, this was limited to cells lying adjacent to the 
Muscularis mucosae (figure 3.5 C). On average, the maximum number of cells 
expressing lamin A/C in this region was eight. Lamin A/C expression was mostly 
limited to the nucleus, in a heterogeneous distribution. Very little cytoplasmic 
staining was noted in these cells. 
An abrupt change in lamin A/C expression patterns was observed in cells lying 
above the basal cells. In these cells there was a sudden loss of lamin A/C 
expression (figure 3.5 A). On average, thirty five to forty five cells above the basal 
cells had little or no lamin A/C expression. The number of cells  
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Figure 3.4 
 
Expression of A-type lamins in normal colonic epithelium 
(10x) Scale bar represents 200µm. 
Arrows point towards the basal regions of the crypts 
Arrowheads point towards the top of the crypts. 
 
This photo micrograph shows the expression profile of A-type lamins in the 
crypts of mucosa from the colon. A-type lamin expression in the crypt is 
noted in two distinct zones: 
Firstly, in the basal zone or putative stem cell niche area of the crypts 
Secondly, in cells making up the upper one third of the crypt, this 
corresponds to the differentiated zone. 
A-type lamin expression is also noted in cells making up the muscularis 
mucosae and lamina propria. At all sites, the expression of A-type lamins 
is at the nuclear envelope. 
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Figure 3.4 
Expression of A-type lamins in normal colonic epithelium (10x) 
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Figure 3.5 
Expression profile of lamin A/C in an isolated intestinal crypt from the 
colon  
Figure A 
Expression profile of lamin A/C in an isolated intestinal crypt from the 
colon  (20x) Scale bar represents 150µm 
Figure B 
Expression profile of A-type lamins in cells lining the upper third of 
the crypt (indicated by arrowheads), corresponding to the 
differentiated zone 
(40x) Scale bar set at 50µm 
Figure C 
Expression of A-type lamins in cells forming the basal regions of the 
crypt (indicated by arrows) and corresponding to the putative stem 
cell niche area.  
(40x) Scale bar set at 50µm 
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Figure 3.5 (A, B and C) 
Expression profile of lamin A/C in an isolated intestinal crypt from the colon   
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forming this zone was variable between different crypts from the same section as 
well as between sections taken from different samples, but on average, it 
comprised two thirds of the crypt axis. This corresponded with the known 
proliferative zone of the intestinal crypts. 
A fairly rapid return of lamin A/C expression in the cells populating the upper one 
third of the crypt was noted. In these cells lamin A/C expression was 
predominantly in the nucleus, in a heterogeneous distribution (figure 3.5 B). Lamin 
A/C expression gradually increased along the crypt axis towards the luminal 
surface and was most prominent at the luminal surface. This upper third of the 
crypt was known to be the site for differentiation of cells that moved up from the 
proliferative lower two thirds of the crypt and is known as the differentiated zone of 
the crypt. 
Of interest was the observation that lamin A/C expression in the mesenchymal 
tissue surrounding the crypts revealed a uniform expression of lamin A/C in the 
nuclei of these cells. This expression pattern was observed in all sections from 
different samples analysed. There did not appear to be any gradient to this 
staining pattern when compared to the crypts (figure 3.5 A). The morphology of 
these nuclei expressing lamin A/C in the mesenchymal tissue was very similar to 
that observed in the nuclei of cells located in the upper most areas of the crypt. 
These mesenchymal cells exhibited slightly larger nuclei which appeared 
elongated in some areas. There was variable expression of lamin A/C noted in 
cells of the submucosa. 
 
3.2.4 Expression of lamin A in the adult human colon 
crypt (Figure 3.6) 
 
Lamin A expression in the colon crypts (figure3.6 A and B) mirrored the expression 
pattern seen by lamin A/C in crypts. Expression of lamin A was noted in three 
distinct areas of the crypt and also in the mesenchymal tissue and basement 
membrane regions. At the basal regions, on an average, eight cells exhibited 
expression of lamin A. This was predominantly in the nuclei, in  
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Figure 3.6 
Expression profile of lamin A in the intestinal crypts of the colon and 
rectum. 
Figure A 
Expression profile of lamin A in cells lining the upper third of the crypt 
(indicated by arrowheads), corresponding to the differentiated zone. 
Scale bar is set at 100µm. (40x) 
Figure B 
Expression profile of lamin A in cells at the base of the colonic crypt 
(arrows), corresponding to the stem cell niche area.  
Scale bar is set at 100µm. (40x) 
 
In both figures, expression of lamin A is at the nuclear area predominantly. 
A heterogeneous intranuclear and intra cytoplasmic expression is noted. 
Cells of the muscularis mucosae and lamina propria also exhibit nuclear 
area expression of lamin A. 
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Figure 3.6 (A and B) 
Expression profile of lamin A in the intestinal crypts of the colon and rectum
 (40x) 
  
B 
A 
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a heterogeneous distribution (figure 3.6 B). This region of the crypt is proposed to 
harbour the putative stem cell niche (Potten, 1998). 
As noted with lamin A/C expression, there was an abrupt loss of lamin A 
expression in cells adjacent to the basal cells expressing lamin A, in the crypt. Two 
thirds of the way up along the crypt axis, a gradual return of lamin A expression 
was noted, which became progressively stronger. Expression of Lamin A was 
highly marked in cells lining the upper one third of the crypt and the mucosal lining 
of the colonic lumen (figure 3.6 A). At these sites, lamin A was predominantly seen 
in the nuclei, in a heterogeneous distribution. Small amounts of lamin A were also 
noted in the cytoplasm of these cells. 
The stromal tissue, especially cells making up the basement membrane and 
muscularis mucosae, exhibited lamin A expression in the nuclei in a 
heterogeneous distribution. This expression profile of lamin A appeared similar to 
that seen with lamin A/C expression in the crypt and surrounding mesenchymal 
tissue. 
 
3.2.5 Lamin C expression in the adult human colon crypts 
(Figure 3.7) 
 
The expression profile of lamin C in the crypt was different to that of lamin A. In the 
basal regions, at the putative stem cell niche area, there was no obvious 
expression of lamin C at either the nuclear envelope or in the nucleoplasm (figure 
3.7 B). As the crypt axis was traced upwards and into the proliferative 
compartment, again there was no discernable trace of lamin C expression in the 
cells or their nuclei. 
Approximately two thirds of the way up the crypt axis, there was a progressive 
increase in lamin C expression, being maximal in the cells lining the mucosal 
surface. In this area of the crypt, lamin C expression was predominantly at the 
nuclear area in a heterogeneous distribution pattern (figure 3.7 A). 
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Figure 3.7 
 
Expression profile of lamin C in the intestinal crypts of the colon and 
rectum 
Figure A 
Expression profile of lamin C in cells lining the upper third of the crypt 
(indicated by arrowheads) and corresponding to the differentiated zone 
Scale bar is set at 100µm. (40x) 
Figure B 
No visible expression of lamin C in cells lining the basal region of the 
colonic crypt (indicated by arrow). However, expression of lamin C is seen 
in cells forming the muscularis mucosae 
BM indicates Basement Membrane 
Scale bar set at 100µm. (40x) 
 
Lamin C expression is noted only in cells making up the differentiated 
compartment of the crypt and the muscularis mucosae. There was 
complete absence of lamin C from cells at the base of the crypt or putative 
stem cell niche area. Expression of lamin C in cells making up the 
muscularis mucosae was used as a positive internal control test. In cells 
expressing lamin C, its location was predominantly at the nuclear area. 
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Figure 3.7 (A and B) 
Expression profile of lamin C in the intestinal crypts of the colon and rectum. 
B 
BM 
A 
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Expression of Lamin C was noted in cells of the stromal tissue and smooth muscle 
surrounding the crypts. This was mostly at the nuclei in a heterogeneous 
distribution. The distribution of lamin C expression in this area was similar to that 
seen with lamin A/C expression. 
 
3.2.6 Lamina associated polypeptide 2 alpha (Lap 2 
alpha) expression in the adult human colon crypts 
(Figure 3.8) 
 
Expression of Lap 2 alpha was observed along the whole length of the colonic 
crypt. However, its expression varied at different locations. At the base of the 
crypt, Lap 2 alpha expression was predominantly at the nuclei of the cells but 
cytoplasmic staining was also noted (figure 3.8 B). In this location, a 
heterogeneous distribution of Lap 2 alpha in the cytoplasm was noted. The total 
number of cells expressing this distribution pattern was difficult to quantify in the 
basal region. This was mostly due to the continuing expression of Lap 2 alpha in 
cells of the proliferative compartment. However, interestingly the expression of Lap 
2 alpha showed a tendency towards cytoplasmic expression more than nuclear in 
cells of the proliferative compartment. There was also a decrease in total 
expression of Lap 2 alpha in cells of the proliferative compartment. This decrease 
in expression formed a gradient in the lower two thirds of the crypt axis with a 
gradual return of Lap 2 alpha expression towards the upper one third of the crypt, 
in the differentiated compartment. Another observation about the distribution of 
Lap 2 alpha in the differentiated compartment was the granular distribution of Lap2 
alpha in the cytoplasm of these cells, especially in cells forming the mucosal lining 
of the intestine. In these cells, nuclear expression of Lap 2alpha was seen in a 
heterogeneous distribution (figure 3.8 A).  
Lap 2 alpha expression in the stromal tissue surrounding the crypts was very 
patchy and infrequent. However, the majority of mesenchymal cells that did 
express Lap 2 alpha were located towards the apical regions of the crypt although 
occasional cells close to the muscularis mucosae also exhibited expression of LAP  
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Figure 3.8 
Expression profile of LAP2α in the intestinal crypts of the colon and 
rectum. 
 
Fig A 
Expression and distribution of Lap 2α in cells lining the upper half of the 
colonic crypt. Both nuclear and cytoplasmic expression was noted (short 
arrows). 
Scale bar set at 150µm. (40x) 
 
Fig B 
Expression and distribution of Lap 2α in cells lining the lower half of the 
colonic crypts (long arrows). 
Scale bar set at 150µm. (40x) 
The expression of LAP2α was noted in all cells making up the crypt. Due 
to its granular distribution in the cytoplasm and nucleoplasm as well, it was 
difficult to assess and ascertain any definitive pattern of expression. 
However, there appeared to be a generalised increased expression in the 
nuclear area of cells at the base of the crypt with a loss of nuclear area 
expression in cells making up the proliferative compartment. 
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Figure 3.8 (A and B) 
Expression profile of LAP2α in the intestinal crypts of the colon and rectum. 
  
A 
B 
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2 alpha. In these mesenchymal cells, expression of Lap 2 alpha was nuclear with 
a heterogeneous distribution. The muscularis mucosa stood out in its absolute lack 
of Lap 2 alpha expression (figure 3.8 B). 
 
3.2.7 Emerin expression along the adult human colon 
crypt (Figure 3.9) 
 
The expression of Emerin along the crypt axis revealed a distribution pattern 
similar to that seen with Lap 2 alpha expression; however there appeared to be 
some notable exceptions. In the basal areas of the crypt, corresponding to the 
putative stem cell niche area, an up regulation of Emerin expression was noted. It 
was concentrated mostly in the nucleus (figure 3.9 B). However, there was also 
significant expression of emerin in the cytoplasm of these cells, in a 
heterogeneous distribution. Emerin expression was reduced in the region adjacent 
to the basal area, in the proliferative zone. This decreased level of emerin 
expression could be traced upwards to the junction of the upper third and lower 
two thirds of the crypt region, corresponding to the proliferative compartment of the 
crypt. Here only a small degree of expression was noted, mostly in the cytoplasm. 
In the upper third of the crypt, there was significant expression of Emerin, mostly in 
the cytoplasm of cells, but also at the nucleus. The expression of Emerin in the 
cytoplasm appeared heterogeneous (figure 3.9 A). 
The expression of Emerin in the stromal tissues revealed a pattern different to that 
seen with Lap 2 alpha expression. The mesenchymal cells of the lamina propria 
revealed a predominantly cytoplasmic expression of Emerin with no obvious 
nuclear expression. Also, there did not appear to be any specific gradient of 
Emerin expression in this area. However, cells in the muscularis mucosae and 
submucosa expressed Emerin in their nuclei, in a heterogeneous distribution. This 
was in contrast to Lap 2 alpha expression in the muscularis mucosae, where no 
discernable expression was seen in these areas (figure 3.9 A & B). 
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Figure 3.9 
 
Expression profile of Emerin in the intestinal crypts of the colon and 
rectum 
 
Figure A 
Expression of emerin in cells lining the upper half of the colon crypt (short 
arrows). 
Scale bar set at 150 µm. (40x) 
 
Figure B 
Expression of emerin in cells forming the basal regions of the colonic 
crypts (long arrow). Emerin also stains the nuclear envelope of cells in the 
surrounding stromal tissue. 
Scale bar set at 150 µm. (40x) 
 
The expression of emerin is noted in most cells making up the crypt. 
However, there appears to be an up regulation in its expression in cells 
located at the base of the crypt, in the putative stem cell niche area (as 
indicated by the long arrow). In the proliferative compartment of the crypt, 
a change in expression of emerin was noted with cytoplasmic expression 
predominating although some nuclear envelope expression was also 
noted. In the differentiated compartment of the crypt, both heterogeneous 
cytoplasmic (black short arrow) and nuclear envelope expression (blue 
short arrow) were also noted. 
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Figure 3.9 (A and B) 
Expression profile of Emerin in the intestinal crypts of the colon and rectum. 
A 
B 
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3.2.8 Beta catenin expression in adult human colon crypts 
 
The expression profile of total beta catenin and active beta catenin in normal 
colonic and rectal tissue samples was assessed in all patients. The colonic 
samples were from various areas of the colon, including ascending, transverse, 
descending and sigmoid parts of the colon and did not show any obvious 
differences in expression profiles based on location. 
 
3.2.8.1  Total beta catenin expression in adult human colon 
crypts (Figure 3.10) 
 
Total beta catenin was expressed throughout the crypt but a change in expression 
amongst individual cells was also noted as cells moved up along the crypt axis, 
towards the lumen of the intestine. In the basal regions of these crypts, total beta 
catenin was highly expressed in a few cells, corresponding to the putative stem 
cell niche area. Total beta catenin was expressed predominantly at the nuclear 
area of these cells. Cytoplasmic and intra-nuclear expression of total beta catenin 
was also observed in these basal cells. There did not appear to be any significant 
expression at the cellular junctions in these basal cells (figure 3.10 B). 
Above these basal cells in the crypt, total beta catenin expression appeared to 
diminish somewhat but was still recognisable at the nuclear envelope and 
cytoplasm. Intra-nuclear expression of total beta catenin was difficult to assess but 
appeared to diminish to some extent. This pattern of expression in the proliferative 
compartment of the crypt continued up to the upper third of the crypt, where there 
was a further change in the expression profile of total beta catenin. 
In the upper third of the crypt, total beta catenin expression appeared 
predominantly cytoplasmic with a shift towards cellular junctions (figure 3.10 A).  
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Figure 3.10 
 
Expression of total β-catenin in the intestinal crypts of the colon and 
rectum 
 
Figure A 
Expression and distribution profile of total β catenin in cells lining the upper 
half of the colonic crypt (short arrows). 
Scale bars set at 150µm. (40x) 
 
Figure B 
Expression and distribution profile of β catenin in cells at the base of the 
colon crypts (large arrows). 
Scale bars set at 150µm. (40x) 
 
The expression of total β-catenin was observed throughout all cells making 
up the crypt. It was predominantly observed at the nuclear envelope with 
intranuclear expression also being noted in cells residing at the base of the 
crypts, at the putative stem cell niche area. In the proliferative 
compartment, nuclear envelope expression of total β-catenin was also 
observed. However, in the differentiated compartment, total β-catenin 
expression was predominantly in the cytoplasm with increased levels of 
expression being noted at the intercellular junctions.  
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Figure 3.10 (A and B) 
Expression of total β-catenin in the intestinal crypts of the colon and rectum 
A 
B 
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This was more marked in cells at the luminal surface. Some degree of patchy 
nuclear expression could be discerned though. 
The surrounding mesenchymal tissue around each crypt revealed a distinct 
paucity of total beta catenin expression. Similarly, the muscularis mucosa did not 
exhibit any distinct expression of total beta catenin. 
 
3.2.8.2 Active beta catenin expression in adult human colon 
crypts (figure 3.11) 
 
Active beta catenin had a limited expression profile in the crypt and required high 
resolution imaging to accurately identify its location(s) in the cell. In the basal 
regions of the crypts (figure 3.11 B), it was seen at the nuclear periphery 
predominantly. At this site, very little, if any, cytoplasmic expression of active beta 
catenin was noted. 
Above this basal zone, into the proliferative compartment, the expression of active 
beta catenin further decreased. Due to very low expression levels, it was difficult to 
ascertain accurately the exact distribution of beta catenin in the proliferative 
compartment. At this level active beta catenin was mostly concentrated at the 
nuclear area (figure 3.11 B) in a patchy manner. No obvious cytoplasmic 
expression of active beta catenin was observed in cells of the proliferative 
compartment. 
About two thirds of the way up the crypt axis, active beta catenin expression was 
noted at the nuclear area of cells and in the cytoplasm as well. The expression of 
beta catenin became more prominent towards the luminal surface of the crypt. 
Interestingly, active beta catenin accumulated at the nuclear envelope in a rather 
patchy manner, with relatively normal looking portions of nuclear membrane in 
between. Expression of active beta catenin in the cytoplasm appeared granular 
and increased expression was noted at intercellular junctions (figure 3.11 A). 
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Figure 3.11 
 
Expression of active β-catenin in the intestinal crypts of the colon 
and rectum 
 
Figure A 
Expression and distribution profile of active β catenin in cells lining the 
upper half of the colonic crypt. Active β catenin is expressed predominantly 
in the cell cytoplasm in a fairly uniform fashion. However, at the 
intercellular boundaries, this expression is more noticeable (short arrows). 
Scale bar set at 150µm. (40x) 
Figure B 
Expression and distribution profile of active β-catenin in the lower half of 
the intestinal crypts of the colon and rectum (short arrows). 
 Scale bars set at 150µm. (40x) 
 
The expression of active β-catenin in the lower half of the crypts was 
difficult to asses due to very low expression levels. However, patchy 
expression at the nuclear periphery was noted. In the differentiated zone, 
active β-catenin was predominantly expressed in the cytoplasm of cells 
with a concentration of active β-catenin at the intercellular junctions being 
noted. 
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Figure 3.11 (A and B) 
Expression of active β-catenin in the intestinal crypts of the colon and 
rectum 
  
B 
A 
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Figure 3.12 – 3.14 
 
Comparative profiles of various nuclear proteins 
The mesenchymal tissue surrounding each crypt exhibited occasional cells 
showing expression of active beta catenin. In cells that did express active beta 
catenin, it was predominantly located at the nuclear area with no obvious 
cytoplasmic expression being noted. 
Figure 3.12 (A to F) compared, side by side, the expression profiles of Lamin A/C 
(Figure 3.12 A and B), Lamin A (Figure 3.12 C and D) and Lamin C (Figure 3.12 E 
and F) in normal colonic crypts.  
Figure 3.13 (A to D) compared, side by side, the expression profile of Lamin A/C 
(Figure 3.13 A and B) and total beta catenin (Figure 3.13 C and D) in normal 
colonic crypts. 
Figure 3.14 (A to D) compared, side by side, the expression profile of LAP 2α 
(Figure 3.14 A and B) and Emerin (Figure 3.14 C and D) in normal colonic crypts. 
  
126 | P a g e  
 
Figure 3.12 
 
A comparative analysis between lamin A/C, lamin A and lamin C in 
the intestinal crypts of the colon and rectum 
 
Figures A & B 
The expression and distribution profile of A-type lamins in the cells lining 
the colonic crypt. Scale bar set at 100 µm. (40x) 
 
Figures C & D 
The expression and distribution profile of lamin A in cells lining the colonic 
crypt. Scale bar set at 150 µm. (40x) 
 
Figures E & F 
The expression and distribution profile of lamin C in cells lining the colonic 
crypt. Scale bar set at 150 µm. (40x) 
Heavy arrows point towards the putative stem cell niche area in 
micrographs B, D and F respectively. 
Arrow heads in micrographs B, D and F point out the presumed 
proliferative compartment area. 
Arrow heads in micrographs A, C and E point out the luminal cells or the 
presumed differentiated compartment area. 
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Figure 3.12 (A to F) 
A comparative analysis between lamin A/C, lamin A and lamin C in the 
intestinal crypts of the colon and rectum. 
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Figure 3.13 
 
Comparative analyses between Lamin A/C and total β-catenin in the 
intestinal crypts of the colon and rectum 
 
Figures A & B 
Lamin A/C expression in the crypt. Scale bar set at 100 µm. (40x) 
 
Figures C & D 
Total β-catenin expression in the crypt. Scale bar set at 100 µm. (40x) 
 
Long arrows in micrographs B & D point towards the putative stem cell 
niche area. 
 
Short arrows in micrographs B & D point towards the proliferative 
compartment. 
 
Short arrows in micrographs A & C point towards the luminal cells or 
differentiated compartment. 
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Figure 3.13 (A, B, C and D) 
Comparative analyses between Lamin A/C and total β-catenin in the 
intestinal crypts of the colon and rectum 
A C 
B D 
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Figure 3.14 
 
Comparative analyses between expression of lap 2 α and Emerin, in 
the intestinal crypts of the colon and rectum 
 
Figures A & B 
Expression of Lap 2 α in the crypt. Scale bars set at 150 µm. (40x) 
 
Figures C & D 
Expression profile of Emerin in the crypt. 
Scale bar set at 150 µm. (40x) 
 
Large arrows in micrographs B & D point to crypt base, site of the putative 
stem cell niche. 
Small arrows in micrographs A & C point to the luminal surface of the 
crypts where differentiated cells reside. 
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Figure 3.14 (A, B, C and D) 
Comparative analyses between expression of lap 2 α and Emerin in the 
intestinal crypts of the colon and rectum 
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3.2.9 The stem cell niche in the adult human colon 
 
At the basal regions of the intestinal crypts, in the colon and rectum, is the putative 
stem cell niche area, above which the proliferative compartment is located (Brittan 
and Wright, 2004; Potten, 1998). Stem cells are known to divide at a slower but 
more constant rate and give rise to daughter cells that rapidly divide and move up 
along the crypt axis, under the influence of various factors and signalling 
cascades, including Wnt / β-catenin signalling. These rapidly proliferative cells 
occupy the lower two thirds of the crypt, above the basal or putative stem cell 
niche region. Lamin A/C is a well known marker for differentiation (Hutchison, 
2004), corroborated by its strong expression in the differentiated compartment of 
the crypt. Its presence in the putative stem cell niche area of the intestinal crypts 
was confirmed by repeated experiments. To further clarify this observation, 
antibodies against proliferating cells such as Ki-67 and anti PCNA (Proliferating 
Cell Nuclear Antigen) were used to study the expression profile of proliferating 
cells in the crypt. Results obtained with using anti PCNA antibody were more 
consistent and reproducible and hence I opted to use this antibody in preference 
to Ki-67. PCNA or Proliferating Cell Nuclear Antigen, also known as cyclin, is an 
auxiliary protein of DNA polymerase δ that is essential for DNA replication during 
S-phase (Prives and Gottifredi, 2008) where it is present in the nucleoplasm of 
continually dividing cells.  
Serial sections of normal colonic and rectal mucosa were carefully prepared. After 
checking for appropriate orientation using H&E staining, serial sections were 
assessed for lamin A/C expression (figure 3.15 A) alternating with sections 
assessed for PCNA expression (figure 3.15 B). Repeated experiments confirmed 
the observation that all cells expressing PCNA did not express lamin A/C and vice 
versa. Basal cells in the putative stem cell niche area showing expression of lamin 
A/C did not reveal any PCNA expression, indirectly confirming these cells not to be 
proliferating cells (figure 3.15 A & B). 
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Figure 3.15 
 
Serial sections of crypts showing expression of lamin A/C and PCNA 
in the intestinal crypts of the colon and rectum 
 
Figure A 
Expression and distribution of lamin a/c in colonic crypts. Scale bar at 150 
µm. (20x) 
 
Figure B 
Expression and distribution of PCNA in colonic crypts. Scale bar set at 150 
µm. (20x) 
 
There is a reciprocal loss of lamin a/c expression in areas expressing high 
levels of PCNA and vice versa (compare arrows and arrow heads in both 
figures). 
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Figure 3.15 (A and B) 
Serial sections of crypts showing expression of lamin A/C and PCNA in the 
intestinal crypts of the colon and rectum 
A 
B 
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3.2.10 Lamin A/C expression in colorectal cancers 
(Figure 3.16) 
 
To assess the expression of lamin A/C in colorectal cancers, multiple sections 
were taken from tumour specimens of all stages i.e. Dukes A through to Dukes C 
and assessed using Jol2, an antibody directed against lamin A/C. Intriguingly,  
differential expression of lamin A/C was noted in various samples. In some cases 
there was a distinct lack of lamin A/C expression in the epithelial component of the 
cancerous tissue while in other cases a distinct expression of lamin A/C in the 
epithelial component of the cancerous tissue was noted (Figure 3.16). In all cases, 
the lamina propria or mesenchymal tissue expressed lamin A/C. This expression 
of lamin A/C in the lamina propria proved useful as an internal control to assess 
the effectiveness of lamin A/C antibody used. In the cancer tissue expressing 
lamin A/C, this expression was noted to be in the nuclear area predominantly in a 
heterogeneous distribution, but with some increased expression also being noted 
at the nuclear periphery. The surrounding mesenchymal tissue showed expression 
of lamin A/C at the nuclear area predominantly in a heterogeneous distribution. 
This differential expression of lamin A/C in colorectal cancer samples was noted 
across the whole range of Dukes A to C cancers. 
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Figure 3.16 (A and B) 
 
Expression of Lamin A/C in colorectal cancer 
Figure A 
Dukes B colorectal cancer exhibiting expression of lamin A/C in the 
epithelial layer (arrow). (40x) 
Figure B 
Dukes B colorectal cancer exhibiting a distinct lack of lamin A/C 
expression in the epithelial layer. (40x) 
Lamina propria (LP), exhibiting expression of lamin A/C in both samples and 
acting as an internal control. 
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Figure 3.16 (A and B) 
Expression of lamin A/C in a Duke’s B colorectal cancer from two patients 
Figure A – Nuclear envelope expression of lamin A/C is indicated by arrows 
Figure B – No nuclear envelope expression of lamin A/C is observed in cells as 
indicated by the arrow. L – Lamina Propria acts as an internal +ve control. 
A 
B 
L
P 
L
P 
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3.4 DISCUSSION 
 
3.4.1 Normal crypt Architecture 
 
In the large intestine of humans, the smallest functional unit is the intestinal crypt. 
In anatomical terms the crypt is a tubular or flask shaped structure lined by a 
single layer of columnar cells. At the base of a crypt, these cells are in close 
proximity to the muscularis mucosae, a smooth muscle layer. The space in 
between crypts and muscularis mucosae, the lamina propria, is occupied by 
mesenchymal cells, of indeterminate function, and lymphocytes that occasionally 
aggregated to form lymphoid follicles. The actual height of any crypt, in terms of 
number of cells is very difficult to quantify due to the tremendous variation in crypt 
structure with regards to cell numbers (Potten, 1998). The other observation noted 
is the apparent partial division of some crypts into bifid crypts with a common 
opening onto the luminal aspect. This observation may be in keeping with the 
reported observation of crypt fission noted by others previously (Brittan and 
Wright, 2004). 
 
3.4.2 Lamin A/C Expression 
 
There are various studies looking at the expression profiles of lamin A/C in normal 
colonic mucosa and comparing it with cancers arising from the same tissue. 
However, there are no substantial studies available that look at the expression 
profile of Lamin A/C and its binding partners in colonic crypts. By using antibodies 
specific to lamin A/C, it is observed that the expression profile of lamin A/C in the 
crypt is restricted to fairly well demarcated zones. Specifically, in the crypt there 
appear to be two areas in particular that express lamin A/C strongly. In the upper 
third of the crypt, there is obvious expression of lamin A/C at the nuclear envelope 
along with heterogeneous intra-nuclear expression. There is an obvious gradient 
of lamin A/C expression noted as well, with the highest levels of expression at the 
luminal surface of the crypt, in an area where maximal differentiation is to be 
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expected. Lamin A/C is a well documented marker for cell differentiation (Lehner 
et al., 1987; Lourim and Lin, 1992; Rober et al., 1989; Venables et al., 2001). In 
cells of the upper third of the crypt areas, expression of lamin A/C is accompanied 
by a loss / substantial decrease in proliferating cell markers, PCNA, which lends 
further evidence towards these cells being differentiated.  
In addition, there is a change in the expression of total β-catenin noted in cells 
making up the upper third of the crypt. Total β-catenin appears to translocate 
towards the cytoplasm and intercellular junctions with a decrease in its expression 
at the nuclear envelope. It is already known that β-catenin together with APC 
proteins forms part of the canonical Wnt signalling pathway and is responsible for 
driving cells into a proliferative state (Sancho et al., 2004). This signalling cascade, 
as discussed earlier in chapter 1, exerts its maximum influence in the lower two 
thirds of the crypt axis. The total number of cells making up the proliferative 
compartment or indeed the differentiated compartment is variable, however, on 
average, the junction of upper one third and lower two thirds marks this transition 
area. The mesenchymal cells in the lamina propria around each crypt exhibit 
uniform expression of lamin A/C at the nuclear envelope. The significance of this 
finding is yet to be determined. 
The next step was to identify if lamin A or C, or indeed both, were responsible for 
expression of lamin A/C noted in the crypt. By using specific antibodies against 
lamin A and C, the complete lack of lamin C expression in the basal region or 
putative stem cell niche area, is immediately evident. The other discernable 
difference between the expression profiles of lamin A and C, in cells making up the 
differentiated compartment, is the relatively late appearance of lamin C in these 
cells. In addition, there also appears to be an overall decrease in the relative 
amount of lamin C expression in the mesenchymal cells surrounding the crypts. 
Again, the significance of this observation is unclear at present. From previous 
studies by Pugh et al (Pugh et al., 1997), it has been shown that lamin A and C get 
incorporated into the nuclear lamina via different pathways. In case of lamin A, it 
gets incorporated directly into the nuclear lamina while lamin C first forms intra 
nuclear foci before being incorporated into the nuclear lamina. This results in an 
apparent delay observed in the incorporation of lamin C into the nuclear lamina. 
This observation seems difficult to explain given that lamin A and C both arise 
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from the same LMNA gene by differential splicing (Lin and Worman, 1993) and 
also, lamin A differs from lamin C by the presence of a 98 C-terminal amino acid 
residue (Fisher et al., 1986). However, significantly, lamin C lacks the Caax box 
motif which then induces lamin C to form intranuclear aggregates (Schmidt and 
Krohne, 1995). 
 
3.4.3 Lamin A/C expression in relation to its binding 
partners 
 
The nuclear lamina form the structural framework of a nucleus, which in turn 
determines the size, shape and mechanical stability of the nucleus (Moir et al., 
2000). The major components of lamins are the nuclear lamina, which are type V 
intermediate filament proteins, and lamina associated polypeptides (LAPs), which 
are part of the integral membrane proteins of the inner nuclear membrane. Three 
lamina associated polypeptides have been characterised in detail in mammalian 
cells: LAP 1, the LAP 2 family and a protein called the lamin B receptor (LBR) 
(Gerace and Foisner, 1994). LBR and LAP2 preferentially interact with lamin B 
while LAP1 interacts with both lamin A and B types (Foisner and Gerace, 1993). 
LAP2 is a family of six alternatively spliced proteins. Four of these are type II 
membrane proteins: LAP2 β, -δ, -γ and –ε (Berger et al., 1996) and bind lamin B. 
LAP2α is different, both structurally and functionally. It shares only its N-terminus 
with the other isoforms and has a distinct C-terminus. It also lacks an apparent 
transmembrane binding domain (Harris et al., 1995). LAP2α is distributed 
throughout the nucleus rather than the nuclear envelope (Dechat et al., 1998; 
Dechat et al., 2000a; Vlcek et al., 1999) and is a specific binding partner of 
nucleoplasmic A-type lamins (Dechat et al., 2000a). 
Emerin is a inner nuclear membrane protein that binds both lamins A and B 
(Clements et al., 2000; Lee et al., 2001; Sakaki et al., 2001) and is retained at the 
nuclear envelope by lamin A (Sullivan et al., 1999; Vaughan et al., 2001). It 
contains two regions with sequence similarity to LAP2. Emerin along with all LAP2 
isoforms and MAN1, shares a common structural motif called the LEM-domain, 
which comprises an ~ 40 amino acid long structural motif (Cai et al., 2001; Laguri 
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et al., 2001). This domain mediates binding to barrier-to-autointegration factor 
(BAF), an essential and highly conserved DNA-binding protein. BAF is known to 
bind double stranded DNA without sequence specificity (Zheng et al., 2000). 
In studying the expression profile of LAP2α in the crypt axis, cells known to 
express lamin A/C, at the basal regions, also exhibit an increased expression of 
LAP2α, in the region of the nucleus. In contrast, cells in the proliferative 
compartment exhibit a lack of nuclear expression of LAP2α, however, abundant 
cytoplasmic expression is evident and at times this makes it difficult to accurately 
identify LAP2α expression in the nuclear region. This observation indicates that 
LAP2α translocates to the cytoplasm in cells under-going rapid division as seen in 
cells of the proliferative compartment of the crypt. From previous studies (Dechat 
et al., 2004), it has been shown that LAP2α translocates to the cytoplasm during 
metaphase and returns to the nucleus at the exit of metaphase. In cells forming 
the differentiated compartment of the crypt, the presence of LAP2α is mostly inside 
the nucleus. This observation is in keeping with differentiated cells that are not 
dividing as LAP2α is uniformly distributed through the nuclear interior during 
interphase. 
Emerin expression is linked closely to lamin A expression (Vaughan et al., 2001). 
In the intestinal crypts, cells at the basal region or the putative intestinal stem cell 
niche area show expression patterns similar to those of lamin A. However, in the 
proliferative compartment, cytoplasmic expression of emerin is noted and this is 
unusual. It is known that emerin disperses into the cytoplasm during metaphase, in 
the form of membrane bound vesicles also in the absence of lamin A/C 
(Dabauvalle et al., 1999; Vaughan et al., 2001). Cells in the proliferating 
compartment are undergoing rapid proliferation, whether this accounts for the 
cytoplasmic expression of Emerin or not, is not clear at present. In the 
differentiated compartment, expression of Emerin in the nuclear region is to be 
expected as this area also expresses lamin A/C; however, Emerin expression is 
also noted in the cytoplasm. At this stage the significance of this observation is not 
clear.   
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3.4.4 Putative stem cell niche and lamin A/C 
expression 
 
At the base of the crypts, close to the basement membrane, expression of lamin 
A/C at the nuclear envelope is noted in a handful of cells ~ 8cells. This is unusual 
since the basal region of the crypt is an area presumed to harbour the stem cell 
niche (Barker and Clevers, 2007; Potten, 1998). A logical explanation for this 
observation is difficult to come by as up to date lamin A/C has only been 
associated with differentiated cell types. Also, there is an abrupt loss of lamin A/C 
expression noted in cells higher up the crypt, in the presumed proliferative 
compartment. Why should a limited number of cells at the basal regions of the 
crypt express this protein? The answer to this question is not clear. One 
conclusion could be that stem cells in the stem cell niche area are expressing 
lamin A/C (Willis et al., 2008). If so, what role, if any, does lamin A/C have in adult 
stem cell function? At present the answer to this remains unclear and one can only 
hypothesise. However, there has been increasing speculation about the role of 
lamin A/C in regulation of adult stem cell function to account for the multitude of 
tissues and organ systems involved in laminopathies (Gotzmann and Foisner, 
2006). 
 
3.4.5 Wnt / β-catenin signaling in colonic crypts 
 
The role of Wnt signalling in gut homeostasis was established, unknowingly at the 
time, more than 15 years ago when the tumour suppressor gene Adenomatous 
Polyposis Coli (APC) was found mutated in a large number of hereditary and 
sporadic cases of colorectal cancers (Groden et al., 1991; Kinzler et al., 1991a; 
Kinzler et al., 1991b; Nagase and Nakamura, 1993; Nakamura et al., 1991). Since 
then, much work has been carried out in elucidating the role of Wnt signalling in 
gut homeostasis and colorectal cancer development. At present, the Wnt 
signalling cascade has been shown to play a central role in regulating the crypt 
villous axis, at different stages of gut development and cancer (Gregorieff and 
Clevers, 2005; Pinto and Clevers, 2005b; van de Wetering et al., 2002).  In man, 
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19 Wnt genes have been identified, which encode for cysteine-rich glycoproteins. 
These Wnts activate coresponding cells by interacting with a seven-span 
transmembrane protein called Frizzled (Fz) and a single-span transmembrane 
protein LRP (Bhanot et al., 1996; Pinson et al., 2000; Tamai et al., 2000; Wehrli et 
al., 2000). This represents the initial step in the so-called Canonical Wnt signalling 
pathway, which leads to the formation of nuclear Tcf/β-catenin complexes. Β-
catenin has been identified as the key component of the Wnt canonical pathway. 
In the absence of Wnts, the scaffolding proteins APC and Axin/Axin2 sequester β-
catenin, allowing casein kinase I (CKI) to phosphorylate the N-terminus of β-
catenin at Ser S45, a residue often mutated in cancers (Amit et al., 2002; Liu et al., 
2002). Subsequently, glycogen synthase kinase 3β (GSK3β) is recruited to 
phosphorylate additional serine and threonine residues from the N-terminal to S45. 
Phosphorylated β-catenin is then recognised by the F-box containing protein β-
TrCP, which mediates ubiquitination and proteasomal degradation of β-catenin 
(Hart et al., 1999; Kitagawa et al., 1999; Winston et al., 1999). Together these 
proteins make up the β-catenin destruction complex. 
Continued destruction of β-catenin is prevented following Wnt binding to Fz/LRP. 
Release of β-catenin from the destruction complex allows β-catenin to translocate 
into the nucleus. Here it associates with the Tcf family of transcription factors 
(Tcf1, Lef, Tcf3 and Tcf4) (Waterman, 2004). Tcfs function by targeting β-catenin 
to specific DNA elements found in promoters and enhancers of target genes. In 
turn, β-catenin recruites a number of nuclear factors responsible for transactivating 
Tcf target genes. In the absence of β-catenin, Tcfs associate with general 
transcription repressors such as Groucho (Cavallo et al., 1998).  
The downstream target genes for Tcf / β-catenin have been identified. The more 
important ones include: 
 c-MYC, a bHLH transcription factor responsible for proliferation (He et al., 1998; 
van de Wetering et al., 2002); 
Cyclin D1, a cell cycle regulator (Hulit et al., 2004); 
Id2, an inhibitor of bHLH transcription factors (Russell et al., 2004); 
ITF-2, a bHLH transcription factor (Kolligs et al., 2002); 
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Tcfl, involved in Wnt signalling (Roose et al., 1999); 
PPARδ, ligand activated transcription factors (Gupta et al., 2004; Harman et al., 
2004; Reed et al., 2004); 
COX-2 or cyclooxygenase 2, involved in the prostaglandin pathway (Araki et al., 
2003; Zhu et al., 2004); 
HDAC2, histone deactylase (Zhu et al., 2004); 
FGF18 and FGF20, growth factors (Chamorro, 2005 #1861;Shimokawa, 2003 
#1862); 
BAMBI (BMP and activin membrane bound inhibitor), over expression of which 
blocks TGFβ mediated growth inhibition (Sekiya et al., 2004); 
 
The role of Wnt signalling in the intestine has been shown to be of key significance 
in many areas, including maintenance of the stem cell niche, the proliferative 
compartment and in the switch between proliferation and differentiation along the 
crypt axis. The presence of nuclear β-catenin is associated with an active Wnt 
signalling system. My observations, about the expression of β-catenin in the 
colonic crypts, are in keeping with those from other authors. Interestingly, a higher 
nuclear expression level of β-catenin is noted in cells forming the basal areas of 
the colonic crypt, in the putative stem cell niche area. This is significant since 
previous studies by Korinek et.al (Korinek et al., 1998) have shown the importance 
of Tcf4 (a down stream target of β-catenin) in maintaining the stem cell niche in 
the intestine. Similarly, in the proliferative compartment of the crypt, I have 
observed nuclear β-catenin, which indirectly alludes to an active Wnt signalling 
system in this area. Pinto et.al (Pinto et al., 2003) have shown the importance of 
Wnt ligands in driving the proliferative compartment of the crypts. In their studies, 
Pinto et.al (Pinto et al., 2003) observe disrupted intestinal homeostasis upon 
inhibition of the Wnt ligands using Dickkopf1 (Dkk1), a known Wnt inhibitor. They 
conclude that inhibition of β-catenin results in inhibition of c-MYC expression, and 
subsequent up regulation of p21CIP1/WAF1, leading to cell cycle arrest. Loss of 
nuclear β-catenin expression in cells making up the differentiated compartment of 
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the crypt corresponds with loss of the Wnt signalling system. This is reflected by 
expression of lamin A/C in these cells, indicating differentiation. This key event 
whereby Wnt signals no longer affects cells and there is a switch over from 
proliferation to differentiation has always been an area of speculation. Studies by 
Markiewicz et al (Markiewicz et al., 2006) have highlighted the role of Emerin and 
lamin A/C in regulating β-catenin activity. From my observations, there is no 
sudden change in expression noted between the proliferative and differentiated 
compartments, but rather a gradual change taking place over 3 or 4 cells. Work 
done by Batlle et.al (Batlle et al., 2002) has shown that a Wnt signalling gradient 
controls cell positioning along the crypt axis through regulation of EphB2 and 
EphB3 gene expression. 
Regulation of the Wnt signalling system itself has been an area of speculation. 
Different views are held on this with two non-mutually exclusive mechanisms that 
could explain how the stimulatory effects of the Wnt cascade are turned off in the 
intestine. In one scenario, it is proposed that Wnt signals could gradually and 
passively dissipate as progenitor cells moved up along the crypt. In the second 
scenario, it is believed that Wnt signals are actively counteracted by other 
signalling pathways. In support of the second scenario, various studies have 
implicated the TGFβ, BMP and Hedgehog signalling pathways as being negative 
regulators of the Wnt signalling pathway (Haramis et al., 2004; Hardwick et al., 
2004; Howe et al., 2001; Sancho et al., 2004; van den Brink, 2007; van den Brink 
et al., 2004). Further studies will hopefully elucidate the underlying mechanisms of 
Wnt control in the intestine. 
 
3.4.6 Lamin A/C expression in colorectal cancer 
 
Lamin A/C is a well known marker for differentiation. Well differentiated colorectal 
cancers have a better prognosis as compared to poorly differentiated ones. The 
reasons accounting for a better prognosis in well differentiated cancers are many 
and include features such as a better response to chemotherapy and being less 
prone to metastasis as compared to poorly differentiated cancers, although this is 
dependant heavily on stage of the disease. To this effect it is assumed that 
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colorectal cancers of a higher grade and stage are more likely to express less 
lamin A/C and vice versa. It is surprising to note that there is a mix of lamin A/C 
expressing and non-expressing colorectal tumours for every stage of colorectal 
cancer. Using standard histological and pathological methods to assess these 
tumours for grade, stage, lympho-vascular invasion, perineural invasion, etc, it is 
noted that at any stage of this cancer i.e. Dukes A or B or C, there are tumours 
exhibiting either clear evidence of lamin A/C expression or no expression at all or 
impaired expression of lamin A/C. The significance of this finding is further 
explored in a separate study (Willis et al., 2008), who discovered lamin A/C to be 
an adverse prognostic indicator for patients with colorectal cancer. Lamin A/C 
proves to be an independent factor in their study on colorectal cancer cell lines 
and patients with colorectal cancer. To try and identify the underlying reason for 
this, a few hypotheses are put forward: 
Firstly, colorectal cancers expressing lamin A/C have a more motile phenotype, 
based on in vitro cell mobility assays. This could explain why colorectal cancers 
expressing lamin A/C could, in theory, be more motile and metastasise early and 
thereby impart a poorer prognosis. 
Secondly, colorectal cancers expressing lamin A/C may be more stem cell like, 
based on the observations that lamin A/C is expressed in the putative stem cell 
niche area. The implications for this observation are highly significant as colorectal 
cancers expressing lamin A/C may in fact be cancer stem cells with properties of 
stem cells and thus be immortal and capable of self regeneration indefinitely. 
No definitive answer to explain this variation in lamin A/C expression in colorectal 
cancers can be found. There may be other explanations, in addition to the ones 
described earlier, to account for these observations and further work is needed to 
elucidate a definitive answer. 
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Chapter 4 
Microarray Analysis of Various Stages Seen In 
Colorectal Cancer 
 
4.1 Introduction 
 
Developmentally, the human colon and rectum are derived from all three germ 
layers. Endoderm forms the epithelial lining of the lumen, mesoderm forms the 
smooth muscle and sub mucosal layers and ectoderm forms the enteric nervous 
system. Together, these germ layers give rise to a highly specialised organ with a 
very high cell turnover rate from the epithelial lining of the lumen. The histological 
structure of the colon, especially the epithelial lining of the lumen, lends itself 
admirably to a hierarchical system in which stem cells play a major role. The stem 
cell niche occupies the basal regions of the crypt villus axis followed by a 
proliferative compartment occupying the lower two thirds of the crypt villus axis 
and finally a differentiated zone in the upper one third that merges into the inter 
cryptal table. Control and regulation of the crypt villus axis is very complex indeed 
and is a site prone to undergoing neoplastic transformation. Multiple signalling 
cascades, alongside local and regional factors play a crucial role in maintaining a 
fine balance between optimum function and development of neoplasia. 
 
4.1.1 Stem cell signaling pathways in the human and 
their significance in maintaining homeostasis, especially 
in the colon. 
 
4.1.1.1 Canonical Wnt signaling 
 
The canonical Wnt signalling pathway is considered to be the most significant 
regulator of normal crypt homeostasis and colorectal cancer development (Pinto 
and Clevers, 2005b; van de Wetering et al., 2002). A detailed discussion on Wnt 
signalling can be found in chapter one of this thesis. In the absence of a Wnt 
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signal, members of the T-cell factor / lymphoid enhancing factor (TCF/LEF) family 
of transcription factors are bound to the transcriptional repressor Groucho (Cavallo 
et al., 1998). Active beta catenin directly associates with TCF/LEF factors and 
overcomes this repression imposed by Groucho, thereby transactivating the 
transcription of downstream targets (van de Wetering et al., 1997). TCF-4 is a 
member of the TCF/LEF family and is highly expressed in cells forming the 
epithelial layer of the colon. It forms functionally active complexes with beta 
catenin (Korinek et al., 1997) which in turn are the principal governors of cell 
dynamics at the crypt villus junction, preserving a stem cell and proliferating 
progenitor population in the lower crypt region. This is essential for ensuring an 
orderly turnover of differentiated cells at the luminal surface (van de Wetering et 
al., 2002). By inhibiting the β-catenin/TCF-4 complex with inducible expression of 
dominant negative TCF-4 (dnTCF-4), Van de Wetering et al. (2002) were able to 
demonstrate: Firstly – a concomitant G1 arrest. Secondly – a down-regulation of 
intestinal markers of proliferation such as c-MYC, EPHB2, c-MYB, BMP4, ENC1, 
CD44 and CLDN1, known to be expressed in the proliferative compartment of 
normal crypts, and thirdly – an up-regulation of differentiation markers such as 
FABP1 (fatty acid binding protein 1), CA2 (carbonic anhydrase II) and importantly 
p21CIP1/WAF1. c-MYC, a well known oncogene which is responsible for pushing cells 
from G0 to S-phase of the cell cycle, appears to be one of the most important 
down-stream targets of the β-catenin/TCF-4 complex (He et al., 1998; Oster et al., 
2002). Expression of c-MYC at endogenous levels in dn TCF-4 cells caused re-
entry into the cell cycle with a concomitant reduction in p21CIP1/WAF1 expression. In 
essence then, β-catenin/TCF-4 complexes appear to maintain a progenitor / stem 
cell phenotype in intestinal crypts through c-MYC mediated repression of the cell 
cycle inhibitor p21CIP1/WAF1. Wnt signals are absent in the differentiated 
compartment of the crypt, this results in β-catenin being exported from the nucleus 
by APC and sequestered for removal by the degradation complex. There is 
activation of c-MYC in this zone; therefore p21CIP1/WAF1 expression is induced 
which facilitates cell cycle arrest and differentiation (van de Wetering et al., 2002).  
Previous studies have shown accumulation of β-catenin in the nuclei of crypt 
progenitor cells and aberrant crypt foci (ACF), benign precursors of colorectal 
cancer (van de Wetering et al., 2002), indicating re-initiation of Wnt signalling in 
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colon tumour cells. Up to 85% of colorectal cancers are sporadic, the result of 
mutations in the APC gene (Kinzler and Vogelstein, 1996) which constitutively 
activates β-catenin/TCF signalling (Korinek et al., 1997; Morin et al., 1997). 
Activation of the β-catenin/TCF complex may therefore be the dominant switch 
responsible in the malignant transformation of colon epithelial cells by imposing a 
proliferative phenotype at an early stage. This would imply that colorectal cancer is 
a process of dedifferentiation and increased proliferation as well (van de Wetering 
et al., 2002). 
 
4.1.1.2 Hedgehog Signaling 
 
The Hedgehog (Hh) signalling pathway was originally described in the 
development of Drosophila melanogaster as a segment polarity gene required for 
embryonic patterning (Nusslein-Volhard and Wieschaus, 1980). Hh signalling 
plays a key role in various processes including, embryogenesis, adult tissue repair 
during chronic inflammation, adult tissue homeostasis and carcinogenesis (Hooper 
and Scott, 2005; Lum and Beachy, 2004; Pasca di Magliano and Hebrok, 2003). 
The genes involved in Drosophila are Hedgehog (Hh), Smoothened (Smo), 
Patched (Ptc), Hedgehog – interacting protein (HIP1), Costal – 2 (Cos-2), Fused 
(Fu), Suppressor of Fused [Su(Fu)] and cubitus interruptus (Ci). Components of 
this pathway are highly conserved between species. In vertebrates there are three 
homologues of Hh (Echelard et al., 1993): Sonic hedgehog (Shh) named after a 
popular Sega computer character, desert hedgehog (Dhh) and Indian hedgehog 
(Ihh). Their biological properties are remarkably similar, differing only in their 
potency (Shh>Ihh>Dhh). They demonstrate different, but frequently overlapping 
expression profiles (Pathi et al., 2001). There are two homologues for patched, 
patched – 1 (Ptc-1) and patched – 2 (Ptc-2). Both exhibit similar affinity for Hh. 
Ptc-1 is expressed on target cells and is up regulated by Hh signalling (Carpenter 
et al., 1998). There are three homologues for Ci, Gli-1, Gli-2 and Gli-3. These play 
a major role in Hh signalling (Lees et al., 2005) (Fig 4.1). 
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Hh itself is a 45-kilodalton precursor protein that undergoes autoproteolysis (Lum, 
2004 #1611;Lee, 1994 #1612). This yields a ~ 19 kDa, active, NH2-terminal 
signalling domain (N-Hh), to which a  cholesterol molecule is added (N-Hhp), and 
a ~26 kDa, COOH-terminal fragment, responsible for catalysing the cleavage of 
the precursor Hh protein and also acting as a cholesterol transferase (Bumcrot et 
al., 1995; Porter et al., 1996). Addition of cholesterol to the N-terminal domain 
renders it hydrophobic. This allows it to bind with cell membranes and mediate its 
local actions (Fig 4.1). 
In the absence of Hh protein, Ptc inhibits signalling by Smo. Ptc is a transcriptional 
target for Hh signalling and its expression is up-regulated by Hh activity. Whilst 
simultaneously initiating signalling it also acts in a negative-feedback loop to 
restrict the range of Hedgehog signalling in a tissue by sequestering Hh protein. 
HIP-1 is another cell surface protein that binds to and sequesters Hh (Chuang et 
al., 2003; Chuang and McMahon, 1999). HIP-1 is up-regulated by activation of the 
Hh signalling pathway and serves to down-regulate Hh activity. 
The central role of Wnt signalling in the intestinal epithelium has been discussed 
earlier (section 4.1.1.1). Ihh signalling is activated in the differentiated zone of the 
intestinal epithelium where it induces differentiation (van den Brink, 2004 #1617). 
Hh signalling acts to restrict expression of wnt targets to the base of the crypt in 
vivo (van den Brink et al., 2004). In the absence of Hh signalling, full length Gli 1 is 
phosphorylated by protein kinase A (PKA), casein kinase I (CKI) and glycogen 
synthase kinase 3β (GSK 3β). The resultant truncated form of Gli 1 is incapable of 
activating transcription of Hh target genes. However, binding of Hh to its receptor 
patched (Ptc) results in activation of the Hh signalling receptor smoothened (Smo). 
Smo in conjunction with Cos 2 and fused kinase (Fu) inhibits the proteolytic 
processing of Gli 1 leading to its stabilisation and expression of Hh target genes. 
In vitro studies by Akiyoshi et.al (2006) confirm the inhibitory effect of Hh signalling 
on Wnt signalling. Their studies have implicated Gli 1 as being the main mediator 
of this inhibition by Hh signalling by interacting with β-catenin at a level below β-
catenin phosphorylation (Akiyoshi et al., 2006). At this stage it is not clear whether 
this antagonism of Wnt is mediated directly by Gli 1 protein or is the result of up or 
down regulation of a transcriptional target(s) of Hh signalling (van den Brink and 
Hardwick, 2006).  
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The inhibitory effect of Hh signalling on Wnt signalling may be indicative of the 
anti- oncogenic effects of Hh signalling (van den Brink and Hardwick, 2006), a 
similar view point is also suggested by Berman and colleagues (Berman et al., 
2003). Interestingly, Ihh expression is lost very early in the process of colorectal 
carcinogenesis. Loss or mutations affecting the APC gene results in uncontrolled 
activity of the Wnt signalling pathway, with accumulation of clonal precursor cells 
(Gregorieff and Clevers, 2005). The vast majority of colorectal cancers are 
sporadic, approximately 90% harbour APC mutations or other mutations that 
constitutively activate the Wnt signalling pathway (Gregorieff and Clevers, 2005). 
Loss of Ihh is noted in cases with FAP and in the flat lesions that precede polyp 
formation in the colon, indicating that loss of Ihh expression may be associated 
with the earliest stages of colorectal carcinogenesis, probably a direct 
consequence of overactive wnt stimulation (van den Brink, 2007). There are still 
many questions unanswered as regards the role of Hedgehog signalling in colonic 
epithelium and its role in carcinogenesis. Further work needs to be done to clarify 
its exact role. 
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Figure 4.1 
 
Hh signalling in mammalian cells 
In the absence of Hh protein (Somech et al.), the 12-transmembrane domain 
receptor Ptc exerts an inhibitory effect on Smo, a 7-pass transmembrane protein 
with homology to G-protein–coupled receptors. Smo, in complex with Cos-2, 
prevents nuclear availability of the full Gli product. This occurs by a combination of 
microtubule binding of the complex and proteolysis to a truncated Gli (GliTR). 
Furthermore, when Ptc is unoccupied by Hh, it is suggested that caspase-3 (casp-
3) cleavage of its intra-cellular portion exposes a receptor region that transduces 
an apoptotic signal via Gli-3. In the presence of Hh ligand-binding (B), the 
inhibitory action of Ptc on Smo is released. The full Gli product is now stabilized 
and transferred to the nucleus. This process is likely mediated in part by 
conformational change in the Cos-2/Gli/Fu complex and also by interaction of Gli 
with a phosphorylated Su (Fu). Once in the nucleus, the full Gli product binds to 
and up-regulates transcriptional targets, including Ptc and another Hh-binding 
protein, HIP. In this manner, excess Hh is sequestered, and control is exerted on 
the pathway.                   Adapted from (Lees et al., 2005) 
4.1.1.3 Notch signaling 
 
Notch is a transmembrane receptor that coordinates a signalling system known as 
the Notch pathway. Notch itself was identified more than a hundred years ago by a 
mutant fly with ‘notches’ in its wings (Morgan 1917), which indicated its 
requirement for wing outgrowth. To date, Notch signalling is considered one of the 
key pathways constituting the stem cell network and is responsible for self renewal 
of stem cells, cell fate determination of progenitor cells and terminal differentiation 
of proliferating cells (Androutsellis-Theotokis et al., 2006; Artavanis-Tsakonas et 
al., 1999; Lai, 2004). Core components of the Notch signalling pathway consist of 
a Delta-type ligand, a Notch-type receptor and a transcription factor of the 
CBF1/Su(H)/LAG1(CSL) family. In mammals, Delta-like 1 (DLL1), Delta-like 2 
(DLL2), Delta-like 3 (DLL3), Jagged 1 (JAG1) and Jagged 2 (JAG2) with DSL 
domain constitute typical Notch ligands, whereas F3/Contactin, DNER and NB-3 
153 | P a g e  
 
without a DSL domain constitute atypical Notch ligands. Notch1, Notch2, Notch3 
and Notch4 constitute Notch receptors (Katoh, 2007a; Lai, 2004). 
Notch receptors are cleaved at the S1 site by a Furin like convertase to generate a 
mature heterodimeric receptor. Upon ligand binding to this receptor, further 
cleavage takes place at the S2 and S3 sites by metalloprotease tumour necrosis 
factor-α converting enzyme and by γ-secratase complex, respectively. This gives 
rise to Notch intra cellular domain (NCID) (Katoh, 2007a). Notch signals are 
transduced to either the canonical pathway or the non-canonical pathway, 
depending on the expression profile of Notch ligands, Notch receptors and Notch 
signalling modifiers. 
Canonical Notch signalling. Upon binding of appropriate ligand to its Notch 
receptor, NICD is released and subsequently translocates to the nucleus where it 
associates with CSL (RBPSUH) transcription factor (Androutsellis-Theotokis et al., 
2006). This complex of CSL-NICD is then activated by the Mastermind family of 
co-activators (MAML1, MAML2 and MAML3) which results in transcriptional 
activation of HEY1, HEY2, HEYL, HES1, HES5 and HES7 genes, which encode 
for bHLH/orange domain transcriptional repressors (Iso et al., 2003; Katoh, 2004; 
Li and Harris, 2005). The net effect of Notch signalling to the CSL-NICD-
Mastermind complex is the repression of transcription and inhibition of 
differentiation in stem cells and transit amplifying cells. 
Non-canonical Notch signalling. NICD is also known to interact with p-50 or c-Rel 
in the nucleus. This enhances NF-κB activity (Shin et al., 2006) and forms a 
complex with NICD which results in transcriptional activation of NF-κB target genes 
such as IFN-γ. Binding of atypical Notch ligands on their own to Notch receptors 
results in a CSL-NCID-Deltex complex (Cui et al., 2004; Eiraku et al., 2002; Hu et 
al., 2003). Deltex affects the binding of CSL to DNA which results in transcription 
of unique target genes, such as MAG. MAG is a tissue specific transcription factor 
responsible for induction of terminal differentiation. Thus atypical Notch signalling 
to the CSL-NCID-Deltex complex results in differentiation of progenitor cells 
(Katoh, 2007a) (Fig 4.2). 
Notch signalling plays a key role in the stem cell signalling pathways (Wnt, 
Hedgehog, FGF and BMP) in regulating the balance of proliferation, self renewal 
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and differentiation among stem cells and progenitor cells in their respective niches 
(Katoh, 2005a; Katoh, 2005b; Katoh, 2006a; Katoh and Katoh, 2005; Katoh and 
Katoh, 2006a; Radtke et al., 2006; van den Brink et al., 2004). Notch signalling 
interacts with other stem cell signalling pathways. For example, , the gene JAG1 is 
considered an evolutionary conserved target  in the canonical Wnt signalling 
pathway (Katoh, 2006b). JAG1 expressed on progenitor cells activates the 
canonical Notch signalling pathway in adjacent progenitor or stem cells. This 
activation acts synergistically with the Wnt signalling pathway in maintaining 
homeostasis in stem and progenitor cells. 
In the colon, JAG1, JAG2 and Notch1 are expressed in the lower half of colonic 
crypts (Sander and Powell, 2004). Stem cells reside at the basal regions of these 
crypts. Activation of canonical Notch signalling in this area of the crypt leads to 
Hes1 up-regulation and down-regulation of Atoh1/Hath1/Math1 (Leow et al., 
2004). The net result is inhibition of differentiation and maintenance of stem and 
progenitor cells.  In colorectal cancer, Notch signalling is considered to be 
oncogenic. It has been observed that NOTCH1, NOTCH2 and NOTCH3 are up-
regulated in colon cancer while ATOH1 expression is down-regulated (Leow et al., 
2004). Notch signalling inhibits terminal differentiation of goblet cells and is 
considered oncogenic (Katoh, 2007a). 
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Figure 4.2 
Notch signalling pathway 
Notch signals are transduced to the canonical pathway (CSL-NICD-Mastermind signalling 
cascade) or the non-canonical pathway (NF-κB-NICD and CSL-NICD-Deltex signalling 
cascades) based on the expression profile of Notch ligands, Notch receptors, and Notch 
signalling modifiers. (Left), Binding of DLL1, DLL3, DLL4, JAG1 and JAG2 with DSL 
domain (open circle) to Notch receptor leads to the release of Notch intracellular domain 
(NICD) for transcriptional activation of Notch target genes, such as HES1, through the 
CSL-NICD-Mastermind complex (Middle), Notch signalling activation also leads to 
transcriptional activation of NF-κB target genes, such as IFN-Á through direct association 
between NICD and NF-κB.(Right), Binding of DNER, F3/Contactin and NB-3 without DSL 
domain to Notch receptor leads to transcriptional activation of differentiation-associated 
genes, such as MAG, through the CSL-NICD-Deltex complex.                     
Adapted from Katoh 2007 
4.1.1.4 BMP Signaling 
 
Bon morphogenetic proteins (BMPs) are members of the transforming growth 
factor-β superfamily (TGFβ) which are known to regulate cell differentiation, 
proliferation and apoptosis. They are capable of inducing ectopic bone formation 
from mesenchymal tissue (Urist et al., 1983). Approximately twenty BMPs have 
been identified up to date. BMP 1 does not actually belong to the TGF-β family of 
proteins; it is a Metalloproteinase. BMP ligands bind to serine-threonine kinase 
receptors, type IA (BMPRIA), type IB (BMPRIB) and type II (BMPRII) for 
transducing their signals intracellularly (Gilboa et al., 2000; Koenig et al., 1994; ten 
Dijke et al., 1994). BMP ligands bind to either preformed complexes or initially to 
BMPRI receptors which then recruits BMPRII (Kirsch et al., 2000). Binding of 
ligand results in phosphorylation of BMPRI by BMPRII, which in turn 
phosphorylates intracellular SMAD1, 5 or 8 at their COOH terminus (Kretzschmar 
et al., 1997). Phosphorylated SMADs then associate with SMAD4 to form a 
multimeric complex which translocates to the nucleus and activates transcription 
through interaction with DNA binding proteins or through direct DNA binding to 
SMAD binding elements (SBE). The net effect is regulation of gene expression of 
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various genes associated with cell differentiation, cell proliferation and apoptosis 
(Balemans and Van Hul, 2002).e 
The interaction between BMP and Wnt signalling has been studied by Nishanian 
et al. (2004). Using BMP-treated embryonal carcinoma cells, Nishanian et al. 
examined the gene expression profile of these cells and discovered genes 
implicated in Wnt signalling. Although most of the identified genes (Axin2, 
Cerberus/DAN-related inhibitor of Wnts and BMPs, Wnt5a, Wnt5b and Dapper) 
were antagonists of Wnt signalling, a few genes, such as Lef1 and Wnt2b, were 
positive regulators of Wnt signalling. Previous reports have shown that Lef1 is 
induced by BMP4 in other cell types (Kratochwil et al., 1996). Further tests by 
Nishanian et al.’s team to assess whether BMP4 could regulate Wnt signalling in 
this embryonal carcinoma cells revealed that BMP did in fact activate a Wnt 
reporter gene by four fold after 72 hours (Nishanian et al., 2004). 
In the human colon, it has been shown that BMP2, BMPRIA, BMPRIB, BMPRII, 
pSMAD1 and SMAD4 are expressed in mature colonocytes at the luminal surface 
of the colon (Hardwick et al., 2004). Hardwick et al. (2004) have also shown that 
BMP2 inhibits normal growth of colonic epithelial cells by inhibiting proliferation 
and promoting differentiation and apoptosis. In colon cancer, inactivation of the 
TGF-β signalling pathway appears to play an important role as inactivation of TGF-
β signalling occurs in ~80% of colon cancers (Grady et al., 1998). ACVR2, a TGF-
β superfamily receptor, undergoes mutation in the majority of colon cancers 
exhibiting microsatellite instability (Hempen et al., 2003; Jung et al., 2004). 
 
4.1.1.5 FGF Signaling 
 
Fibroblast growth factors (FGFs) belong to a large family of polypeptide growth 
factors. A variety of multicellular organisms, both vertebrates and invertebrates, 
harbour these FGFs. FGFs are involved in diverse cellular processes including cell 
growth, wound healing, differentiation, cell migration, chemotaxis, apoptosis and 
cell survival (Bottcher and Niehrs, 2005; Powers et al., 2000). FGF signalling 
pathways interact with other signalling pathways such as Wnt Signalling and NFAT 
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signalling pathways (Katoh, 2007c). FGFs have been implicated in the 
development and progression of tumours, for example colorectal cancer 
(Chamorro et al., 2005). 
The family of FGFs in humans consists of 22 members that share certain common 
features. Members of the FGF family have a high affinity for heparin and heparin-
like glycosaminoglycans (HLGAGs) of the extra cellular matrix (ECM) as well as a 
high sequence homology within a central core domain of 120 amino acids (Ornitz 
and Itoh, 2001). This central core folds into twelve anti-parallel β-strands and is 
flanked by more variable amino- and carboxy-terminal regions (Ago et al., 1991; 
Zhang et al., 1991). FGFs have been arranged into sub-groups depending on their 
biological properties, structure and expression profiles. FGFs appear diffusible and 
act in a dose dependant manner (Christen and Slack, 1999; Kengaku and 
Okamoto, 1995).  
FGF receptors (FGFRs) belong to a sub-family of cell surface receptor tyrosine 
kinases (RTKs), encoded by four closely related genes, Fgfr1-4 (Johnson and 
Williams, 1993). These genes code for single spanning transmembrane proteins 
with an intracellular domain harbouring tyrosine kinase activity and an extracellular 
domain containing the ligand binding domain. Many different isoforms of FGFR 
exist, due to alternative splicing of Fgfr transcripts (Johnson and Williams, 1993), 
each isoform displaying distinct FGF-binding specificities (Ornitz et al., 1996). 
Binding of FGFs to FGFRs leads to receptor dimerisation and triggers tyrosine 
kinase activation with autophosphorylation of the intracellular domain (McKeehan 
et al., 1998). Tyrosine autophosphorylation not only serves to control protein 
tyrosine kinase activity of the receptor but also to recruit and assemble various 
signalling complexes (Schlessinger, 2000). Further FGF signal transduction can 
proceed via three pathways of which the RAS / MAPK pathway is most commonly 
used by FGFs and involves the lipid-anchored docking protein FRS2 that binds to 
FGFR1 (Kouhara et al., 1997). After activating FGFR1, tyrosine phosphorylated 
FRS2 acts as a site for the assembly of a multi-protein complex which activates 
and controls the Ras-MAPK and phosphatidylinositol 3 (PI3)-kinase / Akt signalling 
cascades. This cascade then leads to phosphorylation of target transcription 
factors such as c-myc, members of the Ets family of transcription factors and AP1. 
The other two pathways used for signal transduction by FGFs are the 
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Phospholipase C γ (PLCγ) / Ca2+ pathway and the Phosphatidylinositol 3 (PI3)-
kinase / Akt pathway, as mentioned earlier. 
FGF signalling often takes place across epithelial – mesenchymal boundaries and 
plays a major role in developmental processes such as mesoderm formation, 
gastrulation movements, neural induction, AP patterning and endoderm formation. 
FGF has also been implicated in various pathological conditions such as breast 
cancer (Dickson et al., 2000), urological cancers (Cronauer et al., 2003), 
haematological disorders (Moroni et al., 2002) and colorectal cancer (Chamorro, 
2005 #1685).  
The various signalling pathways discussed are all linked to the stem cell signalling 
pathways. In addition, there are multiple other pathways, all equally important in 
maintaining homeostasis in the human body. It is obvious that most of these 
pathways are intricately linked to one another and dysfunction or mutations in one 
pathway could lead to a knock-on effect in other pathways. The result is 
destabilisation of finely tuned homeostatic mechanisms governing and controlling 
cells, especially stem cells, with resultant pathological manifestations, especially 
cancer, developing in the affected tissues. Much work still needs to be done to 
elucidate further interactions with the hope of developing targeted therapeutic 
interventions to reverse or halt various pathological conditions that result from 
dysfunction in these pathways. 
 
4.1.2 Sequence of genetic alterations leading to 
colorectal carcinogenesis 
 
The classic or traditional pathway leading to colorectal cancer was first described 
by Vogelstein et al. in 1988. They described key molecular events that take place 
in progressive pathological stages, from adenoma to cancer in the colon, and were 
able to generate the adenoma-carcinoma model (Fearon and Vogelstein, 1990) 
that has withstood the test of time. This traditional pathway, also known as 
chromosomal instability pathway (CIN) or the suppressor pathway,  accounts for 
nearly 70% - 85% of observed colorectal cancers (Grady, 2004). Well defined 
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mutations account for the traditional pathway, such as mutations in APC or loss of 
5q (APC gene), mutation of K-ras, loss of 18q (with loss of SMAD2, SMAD4 and 
DCC) and deletion of 17p, which harbours the tumour suppressor gene p53 
(Grady, 2004). It is important to note that very few colorectal cancers posses the 
full complement of these molecular events. It is probable that some colorectal 
cancers bypass certain steps of the traditional pathway by other genetic events 
(Smith et al., 2002) but manage to achieve the same biological consequences, i.e. 
colorectal cancer. One such pathway is the microsatellite instability (MSI) pathway 
or the mutator pathway. Approximately 20% of colorectal cancers exhibit this 
mutator phenotype. In the MSI pathway, there is dysfunction of the mismatch 
repair (MMR) system, responsible for correcting replication errors in short repeat 
sequences (microsatellites). Several microsatellites are present in genes 
implicated in colorectal carcinogenesis such as, Bax, Caspase 5, MSH3, MSH6, β-
catenin, APC, TGFβRII, E2F4 and IGF-II (Bresalier, 2002). To aid research and 
clinicopathological practice, the MSI pathway is sub-divided into MSI-High (MSI-
H), MSI-Low (MSI-L) and Microsatellite stable (MSS), based on a standardised 
panel of microsatellites (Boland et al., 1998). MSI-H tumours occur in two settings: 
Firstly, as part of an inherited syndrome called Lynch syndrome or Hereditary Non 
Polyposis Colorectal Cancer (HNPCC), in which there is a germline mutation in the 
MMR genes hMLH1 and hMSH2. Secondly, as sporadic cases of colorectal 
cancer due to epigenetic silencing of the hMLH1 gene (Deng et al., 1999). Another 
pathway, termed the “methylator pathway” has also been described (Worthley et 
al., 2007). DNA methylation is an epigenetic means of regulating gene 
transcription. This occurs at cytosine bases when cytosine and guanine occur in a 
dinucleotide pair i.e. CpG. In carcinogenesis, CpG island methylation results in 
epigenetic silencing of gene transcription, which is the equivalent of acquiring an 
inactivating mutation. Hence, methylation of tumour suppressor genes could have 
adverse effects by suppressing their normal functions. Type C genes (MLH1, p16) 
are associated with CpG methylation in colorectal cancers whereas Type A genes 
(MINT6, MINT24, MINT32, ER) are predominantly methylated in normal colonic 
mucosa and only occasionally in cancer (Rashid and Issa, 2004; Toyota et al., 
1999). Despite all the available research into colorectal cancer, there still remain 
many unanswered questions regarding colorectal carcinogenesis. Further 
research, especially in epigenetic mechanisms driving DNA methylation and the 
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CIN pathway, is needed. Also, further research into the molecular events 
underpinning normal colonic mucosa could reveal new insights into other 
pathways leading to loss of homeostasis in the colonic mucosa.  
 
4.1.3 Expression of lamin A/C in cancerous cells and 
tissue 
 
The role of lamins in cancer has been studied in a variety of different cancers such 
as basal skin cell cancer (Venables et al., 2001) acute lymhoblastic leukaemia, 
non-Hodgkin’s lymphoma (Stadelmann et al., 1990),  human small cell lung cancer 
and non-small lung cell cancer (Broers et al., 1993), colorectal cancer (Cance et 
al., 1992; Moss et al., 1999) and metastatic leiomyosarcoma, rhabdomyosarcoma 
and chondrosarcoma (Cance et al., 1992).  
In some cancers studied, there are conflicting reports about the expression of 
lamins, for example, in colorectal cancer, Moss et al., (1999) describes a decrease 
in nuclear staining for A-type lamins and lamin B1in colon adenomas and 
adenocarcinomas when compared to normal colonic mucosa,  whereas Cance et 
al., (1992) previously reports heterogeneous expression of A-type lamins in two 
colon adenocarcinomas. Interestingly, Venables et al., (2001) demonstrates a 
down regulation of lamin A in basal cell skin cancers exhibiting a high proliferative 
index and a loss of lamin C in slower growing tumours. When assessing for lamin 
A/C expression in colorectal cancers, we have to take into consideration previous 
conflicting reports about lamin A/C expression patterns in different patient groups 
with this cancer.  
 
4.1.4  Microarray analysis 
 
The term ‘microarray’ was first used by Schena et al. in 1995 (Schena, 1995 
#1704). In its original context microarrays were used to describe methods for 
sequencing and gene expression monitoring in the field of biology. Since then, 
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there has been a substantial amount of work done in this field with a huge 
selection of microarray based technologies now available commercially. 
Microarray based experiments are finding more and more uses in every field of 
biological research. Initially, researchers designed microarrays by hand or using 
simple spotting robots to deposit cDNA clone inserts onto a glass slide. Each 
clone was usually hundreds of base pairs long. Nowadays, commercial 
oligonucleotide – based microarrays are available. These are less prone to 
variations, are relatively affordable and offer greater feature densities (Ahmed, 
2006). Interpretation of data from microarray based experiments has always been 
an area fraught with contentious issues. In the early days of microarray 
technology, researchers often published articles using fold change as the single 
parameter to indicate a change in gene expression (Carninci et al., 2005; Rihn et 
al., 2000). This approach often leads to unacceptably high false positive values 
being observed, especially in cases where transcripts have a high natural variation 
leading to high fold change values. Over time, the main emphasis has now moved 
towards developing tools that will enable researchers to use a standard method of 
analysing microarray results. To this end, in 2001, the Minimum Information About 
a Microarray Experiment (MIAME) was introduced by the Microarray and Gene 
Expression Data (MGED) Society (Brazma et al., 2001). These standards are now 
being used frequently by researchers involved in microarray studies. 
 
4.1.4.1 Microarray data analysis 
 
The main processes involved in data analysis of microarray experiments are, the 
extraction of spot signal intensities, filtering of data, normalisation of data and 
assessment of differential expression. Various commercial enterprises such as 
Affymetrix, offer this level of data analysis as part of their gene chip array software. 
The resultant lists of data generated then needs further analysis using specialised 
software. In its simplest form, up and down regulation of genes is relatively straight 
forward to assess. Further analysis is done using various methods, including 
cluster analysis. Cluster analysis looks for changes in expression of genes closely 
related to each other. A large amount of data is generated from a microarray 
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experiment. Clustering enables subdivision of all this gene expression data into 
smaller groups based on similarity. There are various methods of performing a 
cluster analysis. Unsupervised clustering is used for exploratory analysis while 
supervised clustering is often used to create a diagnostic tool based on previously 
established gene expression signatures (Meyer and Ginsburg, 2002; Wiese et al., 
2007). Data mining of microarray analysis usually gives rise to a long list of 
differentially expressed genes or clusters of genes. Further analysis of these 
genes is then needed and there are various methods available to achieve this. 
From a biological point of view, identification of metabolic pathways is an important 
part of gene expression profiling, which allows for a mechanistic understanding of 
the disease under study. Various biological annotations are available for this 
purpose, such as Gene Ontology (GO) terms, Swissport key words and the Koyoto 
Encyclopaedia of Genes and Genomes (KEGG) pathways (Ashburner et al., 2000; 
Kanehisa et al., 2004). KEGG offers the most comprehensive graphical 
representation of known biochemical pathways (Ogata et al., 1999). The 
relationship of genes to other biological pathways and processes is another 
important area to assess during microarray analysis. To this effect, the Gene 
Ontology (GO) Consortium has developed a vocabulary to describe genes and 
gene product attributes for biological processes, molecular functions and cellular 
components(Ashburner et al., 2000). There are commercially available software 
packages that allow for comprehensive visualisation of gene expression levels in 
different pathways, such as GeneSpring (Agilent Technologies, USA), alongside 
other freely available software packages such as GenMAPP (Dahlquist et al., 
2002) and Pathway Assist. A number of online access tools are also available 
which can calculate over-representation statistics for all GO terms with respect to 
a given data set; so called gene class testing (GCT) (Allison et al., 2006), for 
example, EASE(Dennis et al., 2003), MAPPfinder(Doniger et al., 2003) and until 
recently the NetAffx analysis centre by Affymetrix. 
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4.1.4.2 Validation of Array data 
 
With current microarray technology and data analysis tools, the chances of errors 
and/or artefacts occurring in a microarray experiment are very small, but 
nevertheless there is always a possibility for this to occur. It is in this regards that 
validation of microarray data is always important. Once a number of target genes 
have been identified in a microarray experiment, it is always prudent to confirm 
RNA expression levels by an alternate method. The most commonly employed 
method is Quantitative RT-PCR (Rajeevan et al., 2001a; Rajeevan et al., 2001b) 
due to its speed and relative cost effectiveness. Alternatively, Northern blot 
analysis has also been shown to be as effective at validating microarray data 
(Taniguchi et al., 2001). 
In my studies, I opted to use a microarray based method to further assess the 
implications of variable lamin A/C expression in colorectal tumours exhibiting 
similar clinical properties and of a similar histological grade. Variable expression of 
lamin A/C in colorectal cancer in different patients with a similar stage of disease 
has been noted previously and has been shown to have a direct bearing on 
prognosis in these patients, despite standard treatment for their colorectal cancer 
(Willis et al., 2008). Colorectal carcinogenesis is a very complex process involving 
many signalling pathways and altered gene expression in a number of key genes. 
The vast amount of data generated from these microarray experiments has to be 
interpreted with caution and hence, I have analysed this data by two methods: 
a) A simple analysis to identify genes with significant up or down regulation. b) A 
cluster analysis (unsupervised) to identify groups of genes involved in key cell 
signalling pathways and to assess their differential expression.  
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4.2 Results 
 
4.2.1 Collection of tissue samples for 
immunohistochemical analysis of lamin A/C expression  
 
A pilot study to assess the expression of lamin A/C in colorectal cancers at various 
stages of disease progression was undertaken. This was a prospective pilot study 
between the period of January 2005 and August 2006. After due approval by the 
ethics committee at the James Cook University hospital in Middlesbrough and 
appropriate consent by the patient, a total of 42 patients with colorectal cancer and 
1 patient with a tubulo-villous adenoma (Table 1), were enrolled for this pilot study. 
Under supervision by a consultant histopathologist, appropriate tumour and normal 
mucosal samples were taken from the resected colon / rectum specimen from all 
patients. One set of tumour samples was snap frozen in liquid nitrogen and 
another set of samples placed in formalin solution and subsequent fixation prior to 
being processed and embedded in paraffin. Corresponding normal colonic mucosa 
samples were also processed in a similar fashion. To reduce the chances of RNA 
degradation, the whole process of specimen collection and sampling was done 
within 25 minutes of removal of tumour from the patient. Similarly, all specimens 
were washed in 0.9% Sodium Chloride solution to remove any contaminating 
faecal residue. Paraffin embedded and formalin fixed samples were then 
sectioned at 4µm thickness prior to being assessed for lamin A/C expression using 
standard immunohistochemical methods, as described in chapter 2. Mouse 
Monoclonal antibodies against lamin A/C were used throughout for 
immunohistochemical analyses. Snap frozen tissue samples were weighed and 
placed in an appropriate volume of Trizol® reagent (using 1ml of reagent for every 
100mg of tissue) and homogenised as per manufacturer’s protocol, using a glass 
Teflon homogeniser. Subsequent steps in total RNA extraction were as outlined in 
chapter 2, Materials and Methods. 
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4.2.2 Lamin A/C expression profile at various stages 
of colorectal cancer as observed in different regions of 
the colon and rectum 
 
A total of 43 patients participated in this study. Of these patients, 42 had a 
histological diagnosis of colorectal cancer while 1 patient had a tubulo-villous 
adenoma. The distribution of colorectal cancer according to Dukes’ stage was as 
follows: Dukes’ A – 5 patients (11.91%); Dukes’ B – 22 patients (52.38%); Dukes’ 
C1 – 13 patients (30.95%); Dukes’ C2 – 2 patients (4.76%). In each Duke’s stage, 
the presence, absence or depletion of nuclear lamin A/C expression was also 
assessed. Amongst the Dukes’ A group of patients, 2 patient samples had strong 
lamin A/C expression, 2 patient samples did not exhibit any lamin A/C expression 
and 1 patient sample had weak nuclear lamin A/C expression. In the Dukes’ B 
group of patients, 9 patient samples had strong nuclear expression of lamin A/C, 7 
patient samples had no nuclear expression of lamin A/C and 6 patient samples 
had weak nuclear expression of lamin A/C. In the Dukes’ C1 group of patients, 4 
patient samples had strong nuclear expression of lamin A/C, 3 patient samples 
had no nuclear expression of lamin A/C and 6 patient samples had weak nuclear 
expression of lamin A/C. In the Dukes’ C2 group only two patients were identified, 
1 patient sample had strong nuclear expression of lamin A/C and 1 patient sample 
had weak nuclear expression of lamin A/C in their colorectal cancer respectively 
(Table 4.2 A). The incidence of colorectal cancer affecting various areas in the 
colon and rectum was studied and an attempt to correlate this with Dukes’ staging 
and lamin A/C expression was made using a Chi square cross tabulation analysis 
(Table 4.2 B). This did not reveal any significant relation   (p = 0.85). 
A total of 9 patients with ascending colon cancer were identified: 6 patients had 
Dukes’ B stage tumours; 1 patient with Dukes’ A stage tumour and 2 patients with 
Dukes’ C1stage tumours. No lamin A/C expression was noted in tumours from 8 
patients and only 1 patient with a Duke’s C1 cancer had weak nuclear expression 
of lamin A/C. 
A total of 3 patients with cancer at the hepatic flexure were identified: 2 patients 
had a Dukes’ C1 tumour and 1 patient had a Dukes’ B tumour. Strong nuclear 
expression of Lamin A/C was noted in all patients with cancer at the hepatic 
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flexure. None of the patients participating in this pilot study had cancer of the 
transverse colon. 
A total of 2 patients were noted to have cancer at the splenic flexure: 1 patient had 
a Dukes’ A tumour, showing no expression of nuclear lamin A/C, and the other 
patient with a Dukes’ B tumour, had strong nuclear lamin A/C expression. 
 A total of 12 patients were noted to have cancer in the sigmoid colon: 6 patients 
had a Dukes’ B stage tumour, of which two tumours revealed high expression 
levels of nuclear lamin A/C and four tumours expressed low levels of nuclear lamin 
A/C; 4 patients had a Dukes’ C1 stage tumour, of which two tumours had no 
detectable nuclear expression of lamin A/C while two other tumours exhibited low 
nuclear lamin A/C expression; 2 patients had a Dukes’ C2 stage tumours at this 
site, of which one tumour expressed strong nuclear lamin A/C and the other 
tumour expressed only low levels of nuclear lamin A/C. 
At the recto-sigmoid junction area, 4 patients are noted to have cancer: 2 patients 
have Duke’s stage A cancer with one tumour expressing strong nuclear lamin A/C 
levels while the other tumour has low expression levels of nuclear lamin A/C; 1 
patient has a Duke’s stage B tumour, expressing high levels of nuclear lamin A/C; 
1 patient has a Duke’s stage C1 tumour also expressing high nuclear lamin A/C 
levels. 
In the rectum, 12 patients were noted to have cancer: 1 patient had a Dukes’ stage 
A tumour, exhibiting strong nuclear expression of lamin A/C; 7 patients had a 
Dukes’ B stage tumour, in which 4 tumours expressed strong nuclear lamin A/C,  2 
tumours had no detectable expression of nuclear lamin A/C and 1 tumour 
expressed low levels of nuclear lamin A/C expression; 4 patients had a Dukes’ 
stage C1 tumour, in which, 1 tumour expressed strong nuclear lamin A/C levels 
and 3 tumours expressed low levels of nuclear lamin A/C expression (Table 4.3). 
4.2.3 Extraction of total RNA and its qualitative and 
quantitative assessment 
 
Initial attempts at extraction of total RNA were not adequate due to extensive 
contamination resulting in degradation of total RNA. After various attempts at 
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optimisation, it was found that use of a decontaminated flow hood, snap freezing 
tissue samples, smaller sample size to aid in homogenisation and cleaning of the 
initial tissue sample with sterile 0.9% sodium Chloride solution, greatly aided in the 
extraction of total RNA of sufficient purity to allow further experimental work to 
proceed.  
Using a Beckman DU – 600 Analyser, the concentration of total RNA in each 
sample was determined. Samples with an A260/A280 ratio of 1.7 and above were 
then further assessed on an Agarose Formaldehyde Gel with 50µl wells. An 80mV 
current was used in all tests. Using an appropriate RNA marker, 28S (4712 bp) 
and 18S (1950 bp) ribosomal bands were analysed in each sample. Four tumour 
samples exhibiting the best quality RNA were then selected for microarray studies 
(Figure 4.2). The tumour samples selected were as follows: 
1) Patient sample number 29 Tubulo-villous adenoma – lamin negative 
tumour. 
2) Patient sample number 33  Duke’s C1 – lamin negative tumour. 
3) Patient sample number 37  Duke’s B – lamin positive tumour. 
4) Patient sample number 38  Duke’s B – lamin negative tumour.  
The quality of RNA extracted from the remaining tumour samples was not deemed 
of sufficient purity to enable an accurate microarray analysis to be carried out. 
Similarly, the quality of RNA extracted from normal colonic samples was of a poor 
quality and would interfere with interpretation of the microarray results. The 
decision regarding quality of extracted RNA was taken by Dr P Heiko, an 
independent observer, highly experienced in RNA / microarray work at the Centre 
for Life in Newcastle upon Tyne. The four samples selected contained the best 
quality RNA and were selected for microarray analysis. 
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RNA Concentration Ratios in Tissue Samples  
A260/280 ratios of samples used for microarray analysis 
 
Patient 
Sample 
 No 
Absorbance 
at  
260.0 nm 
Absorbance 
at  
280.0 nm 
Background 
absorbance at 
320.0 nm 
260.0 nm 
280.0 nm 
280.0 
nm 
260.0 
nm 
29 2.1953 1.1976 0.0167 1.8449 0.5420 
33 1.1576 0.6535 0.0078 1.7807 0.5616 
37 0.4249 0.2409 0.0073 1.7874 0.5595 
38 0.4621 0.2587 0.0121 1.8246 0.5481 
 
 
Interestingly, by substituting DEPC treated dH2O for TRIS during analyses, there 
was a substantial difference in the A260 nm / A280 nm ratio. For example, in 
sample 29 the original ratio noted using DEPC treated dH2O was 1.8449 whereas 
this ratio was 2.128 if TRIS were used instead. This effect was well known and the 
difference in the A260/A280 ratio was related to a decrease in absorbance at 280 
nm when the ionic strength and/or pH of the solution increased (Wilfinger, 1997 
#1706). The concentration of RNA in each case was determined using the 
following formula: 
X (A260 nm reading) x 40 µg/ml x Dilution factor (50) = Y µg/ml (RNA 
concentration) 
The concentration values of RNA in each sample were as follows: 
Sample 29  2.1953 x 40 x 50 = 4390.6 µg/ml OR 4.39 µg/µl 
Sample 33  1.1576 x 40 x 50 = 2315.2 µg/ml OR 2.32 µg/µl 
Sample 37  0.4249 x 40 x 50 = 849.8 µg/ml OR 0.85 µg/µl 
Sample 38  0.4621 x 40 x 50 = 924.2 µg/ml OR 0.92 µg/µl 
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4.2.4 Microarray analysis using The Human Genome 
U133A Plus 2.0 Array® by Affymetrix® 
 
A qualitative Genome-wide DNA microarray pair-wise screening was carried out 
on four separate tissue samples, corresponding to advancing stages of colorectal 
neoplasia from the adenoma stage up to Dukes’ C stage. In addition, a 
comparative analysis of a Dukes’ B tumour expressing lamin A/C with a Dukes’ B 
tumour not expressing lamin A/C was also undertaken. This study was carried out 
using the Human Genome U133A Plus 2.0 Array® Genechip by Affymetrix® 
(Affymetrix, Santa Clara, CA, USA). This array offered a comprehensive analysis 
of genome-wide expression on a single array. Analyses of the relative expression 
levels of more than 47,000 transcripts and variants’, including more than 38,500 
well characterised genes and UniGenes (Figure 4.3) was done. Further detailed 
analysis of the results, including extraction of spot signal intensity, filtering and 
normalisation of data was carried out in accordance with the associated 
Affymetrix® guidelines for the GH-U133A using the GeneChip® Operating Software 
by Affymetrix®. A preliminary gene list was generated by means of a series of 
relevance thresholds for signal detection level, signal detection p-value 
significance, expression change in p-value significance, and Signal Log Ratio 
(SLR), for each analysis. After generating appropriate data lists, these were then 
imported into Microsoft Excel® for further analysis, including fold change analysis. 
Genes of interest were identified and a difference in their expression profile 
between different tissue samples was analysed. 
 
4.2.4.1 Comparative gene analysis of a Tubulo-Villous (TV) 
adenoma of the colon with Dukes’ B stage and Dukes’ C 
stage colorectal tumours (Table 4.4) 
 
Assessment of the microarray data from the TV adenoma tissue sample revealed 
no signal detection in 31163 transcripts, positive signal detection in 22664 
transcripts, and only a moderate signal detected in the remaining 848 transcripts. 
Similarly, analysis of the microarray data from the lamin A/C negative Dukes’ B 
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stage colorectal tumour sample revealed no signal detection in 28598 transcripts, 
positive signal detection in 25235 transcripts and only a moderate signal in the 
remaining 842 transcripts. Analysis of the array data from the lamin A/C positive 
Dukes’ B stage colorectal tumour sample revealed no signal detection in 27656 
transcripts, positive signal detection in 26250 transcripts and only a moderate 
signal in 769 transcripts. Finally, analysis of the microarray data from the Duke’s C 
stage colorectal tumour sample showed no detectable signal from 28907 
transcripts, positive signal detection in 24976 transcripts and only a moderate 
signal in 792 transcripts. In all four tissue microarray experiments, transcripts 
exhibiting a positive signal had a detection p-value of p < 0.05 (Table 4.4). 
The next stage of this analysis focused on simple fold changes observed in these 
four different tissue samples. For comparative purposes a baseline set of data was 
needed against which to compare and calculate the relevant fold changes. To this 
end data obtained from the tissue sample consisting of a tubulo-villous adenoma 
was used as a comparative base line against which microarray data from the other 
three tissue samples was compared. Since I was not performing a cluster analysis, 
it was safe to assign a cut off value for assessing the fold change. Arbitrarily, a fold 
change value of 2 was assigned and appropriate comparative expression analysis 
of the microarray data done. 
 
4.2.4.1.1 A comparative microarray analysis of changes in functional 
genes between a Dukes’ B adenocarcinoma (nuclear lamin A/C 
negative) tumour sample and a Tubulo-Villous adenoma (nuclear 
lamin A/C negative) tumour sample (Table 4.5) 
 
Comparative expression analysis between both tissue samples revealed a total of 
527 transcripts exhibiting a fold change of 2 or more in the Dukes’ B sample 
devoid of lamin A/C expression. 190 transcripts were noted to be down-regulated 
while 337 transcripts were up-regulated. This indicated a significant increase of 
63.94% in the number of up-regulated transcripts in the Dukes’ B tissue sample. 
Given the large number of transcripts exhibiting a fold change of 2 or more, an 
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initial assessment was made only of the 20 most up and down regulated 
transcripts. Refer to table 5 for a full list and description of these transcripts. 
The highest fold change observed amongst the up-regulated transcripts was 
+388.02 (p=0.00002). This highly up-regulated transcript was encoding for a gene 
called insulin-like growth factor 2 (Somatomedin A or IGF2). The, maximum fold 
change noted amongst the down-regulated transcripts was     -59.71, 
corresponding to the gene encoding for Gremlin 1(GREM1). 
 
4.2.4.1.2 A comparative microarray analysis of changes in functional 
genes between a Dukes’ C adenocarcinoma (nuclear lamin A/C 
negative) tumour sample and a Tubulo-Villous adenoma (nuclear 
lamin A/C negative) tumour sample (Table 4.6) 
 
Comparative expression analysis between both tissue samples revealed a total of 
1080 transcripts exhibiting a fold change of 2 or more in the Dukes’ C sample. Of 
these transcripts, 216 were down-regulated while 864 transcripts were up-
regulated. This indicated a highly significant increase of up to 80% in the number 
of transcripts that were up-regulated in the Dukes’ C tissue sample. Assessment of 
1080 transcripts individually would prove to be prohibitive and very time 
consuming, instead an assessment of 20 transcripts that were highly up-regulated 
and a further 20 transcripts that were highly down regulated was undertaken. 
Refer to Table 4.6 for a full list and description of these transcripts. 
The maximum fold change observed amongst the up-regulated transcripts was 
+78.79 (p=0.00002), corresponding to the gene encoding for homosapiens 
carbonic anhydrase 1(CA1). Similarly the maximum fold change observed 
amongst the down-regulated transcripts was -84.45 (p=0.99998), corresponding to 
the gene encoding for homo sapiens regulator of G protein signalling (RGS13). 
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4.2.4.1.3 A comparative microarray analysis of changes in functional 
genes between a Dukes’ C adenocarcinoma (nuclear lamin A/C 
negative) tumour sample and a Dukes’ B adenocarcinoma 
(nuclear lamin A/C negative) tumour sample (Table 4.7). 
 
Comparative expression analysis between both tissue samples revealed a total of 
2591 transcripts exhibiting a fold change of 2 or more in the Dukes’ C tissue 
sample. Of these transcripts, 572 were down-regulated while 2019 transcripts 
were up-regulated. This indicated a highly significant increase of up to 77.92% in 
the number of transcripts that were up-regulated amongst the Dukes’ C tissue 
sample. Given the large volume of transcripts identified, further assessment of 
these individually would prove to be very time consuming, instead an assessment 
of 20 transcripts that were highly up-regulated and a further 20 transcripts that 
were highly down regulated was undertaken. Refer to table 4.7 for a full list and 
description of these transcripts. 
The maximum fold change observed in the up-regulated transcripts was +97.01. 
This corresponded to the gene encoding for homo-sapiens carbonic anhydrase 
1(CA1). The maximum fold change observed in the down-regulated transcripts 
was -128.00 and corresponded to the gene encoding for insulin like growth factor 
II (Somatomedin A or IGF2). 
 
4.2.4.1.4 A comparative microarray analysis of changes in functional 
genes between a Dukes’ B adenocarcinoma (nuclear lamin A/C 
positive) tumour sample and a Dukes’ B adenocarcinoma 
(nuclear lamin A/C negative) tumour sample (Table 4.8) 
 
A comparative microarray analysis of two tissue samples belonging to the same 
stage and grade of colorectal cancer i.e. Dukes’ B stage and moderately well 
differentiated cancer, was undertaken. The only difference between both tissue 
samples was the complete lack of nuclear lamin A/C expression in one sample 
and a strong nuclear expression of lamin A/C in the other. Data obtained after 
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analysis of the tissue sample lacking nuclear lamin A/C expression was used as a 
baseline against which a comparative expression analysis was done using data 
obtained from analysis of the tissue sample expressing nuclear lamin A/C. 
Initial comparative analyses revealed a very large number of transcripts amounting 
to more than 50,000 that were identified as showing a fold change. This data was 
narrowed down by adding a filter in the form of a fold change cut off at +/- 2. This 
substantially narrowed down the analysed data to a total of 4487 transcripts. Of 
these transcripts, 557 were noted to be up-regulated while 3930 transcripts were 
down-regulated, in the Dukes’ B, lamin A/C expressing tumour sample. These 
results indicated a very significant overall down-regulation of genes (87.58%) in 
the tumour sample expressing nuclear lamin A/C. A detailed analysis of each and 
every transcript was beyond the scope of this chapter, instead, by limiting the 
transcripts to just 20 each from the most up-regulated and down-regulated 
transcripts, a list of appropriate genes was created and analysed further. Refer to 
Table 4.8 for a detailed list of these transcripts. 
The maximum fold change observed in the down-regulated transcripts was   -
97.01. This corresponded to the gene SPP1 (Secreted Phosphoprotein 1) 
encoding for human nephropontin (also known as Osteopontin or Bone 
Sialoprotein or Early T Lymphocyte activation 1). The maximum fold change 
observed in the up-regulated transcripts was +84.45 and corresponded to the 
genes encoding for human creatine kinase brain (CKB) and 3-hydroxy-3-
methylglutaryl-Coenzyme A synthase (HMGCS2), respectively. 
 
4.2.4.2 Comparative microarray analysis of functional gene 
groups involved in intestinal homeostasis and 
carcinogenesis 
 
A targeted analysis of the microarray data was undertaken. This involved 
compiling a list of relevant genes and arranging them into functional groups 
associated with intestinal epithelial morphogenesis, maintenance of the 
proliferative and differentiated compartments of mature crypts, adult stem cells, 
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tumour suppressor genes, oncogenes and other key genes affected in colorectal 
neoplasia. A number of nucleoskeletal and cytoskeletal genes were also 
assessed. This list of genes was compiled in collaboration with key researchers in 
the laboratory, after a thorough literature search. A total of 164 genes that made 
up 16 functional groups, were used in the analysis. Fold change values were not 
assigned any specific cut off level as the main focus here was to assess these 
genes as a functional group and by assigning fold change cut off values, many 
genes that exhibited no fold change, would be omitted. Expression batch queries 
were carried out on all genes identified, using data mining tools available freely 
from the Affymetrix web site. This expression batch analysis focused on the 
following areas: 
 Gene ontology biological process classifications 
 Gene ontology molecular function classifications 
 Gene ontology cellular component classifications 
 Ortholog targets 
 GenMAPP pathway details 
 Entrez Annotations and grades 
 SwissProt and InterPro descriptions 
 OMIM, Ensembl, UniGene and RefSeq entries 
 Chromosomal locations 
 Gene bank descriptions 
 Affymetrix unique Id codes 
Emphasis was focused on two key areas of interest: Wnt signalling and stem cells. 
Twenty two (22) genes were included in the Wnt signalling group with the omission 
of c-myc and APC, as both these genes were recognised oncogenes and hence 
they were classified accordingly to their relevant functional group. Thirty (30) 
genes were identified and classified under the stem cell differentiation group. The 
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remaining genes were allocated to their representative groups. Microarray data 
was then analysed focusing on the areas specified above and relevant information 
was organised appropriately using Microsoft Excel® (tables 4.9 – 4.14). 
 
4.2.4.2.1 A comparative microarray analysis of changes in functional gene 
groups between a Dukes’ B adenocarcinoma (nuclear lamin A/C 
negative) tumour sample and a Tubulo-villous adenoma (nuclear 
lamin A/C negative) tumour sample (Table 4.9) 
 
The signal log ratio (SLR) profiles of various genes expressed in the tubulo-villous 
adenoma sample were used as a reference level from which fold change (FC) 
values were calculated for genes expressed in the Dukes’ B (nuclear lamin A/C 
negative) tumour sample. A higher than 9 FC value was assigned to identify key 
genes of interest. The following genes were identified as being significantly up 
regulated in the Dukes’ B (nuclear lamin A/C negative) tumour sample: 
1) IGF2 – FC value of +388.02  Insulin like growth factor 2 (Somatomedin 
A). 
2) FN – FC value of +64  Fibronectin. 
3) FN1 – FC value of +18.38  Cellular fibronectin. 
4) TCF1 – FC value +11.31  Transcription factor 1, hepatic 
5) SCF – FC value of +10.56  Stem cell factor. 
6) MACF1 – FC value of +9.85  Microtubule-actin crosslinking factor 1. 
Similarly, the following genes were identified as being significantly down regulated: 
1) MAPT – FC value of -18.38  Microtubule-associated protein tau. 
2) PICK3CG – FC value of -10.56  Phosphoinositide-3-kinase, catalytic, 
gamma polypeptide. 
3) PRG3 – FC value of -10.56  p53 responsive gene. 
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Key genes had been clustered into various functional groups and their expression 
profiles had been assessed. This had revealed certain interesting findings: 
 A general down regulation of key genes involved in regulating apoptosis. 
 A subtle down regulation noted in key genes involved with protein 
translation, processing, transport and degradation. 
 A down regulation of key genes involved with Tumour suppression. 
 Amongst the genes studied in the Wnt functional group, there was a mixed 
picture but overall an increase in the expression profile of genes had been 
noted. 
 In the stem cell functional group, no conclusive evidence was available to 
decide between either an overall up or down regulation of gene expression. 
 In the remaining functional groups, no significant overall up or down 
regulation in gene expression was noted. 
 
4.2.4.2.2 A comparative microarray analysis of changes in functional gene 
groups between a Tubulo-villous adenoma (nuclear lamin A/C 
negative) tumour sample and a Dukes’ B adenocarcinoma 
(nuclear lamin A/C positive) tumour sample (Table 4.10) 
 
The signal log ratio (SLR) profiles of various genes expressed in the Dukes’ B 
(nuclear lamin A/C positive) tumour sample were used as a reference level from 
which fold change (FC) values were calculated for genes expressed in the tubulo-
villous adenoma sample. A higher than 9 FC value had been assigned to identify 
key genes of interest. The following genes were identified as being significantly up 
regulated in the tubulo-villous (nuclear lamin A/C negative) adenoma sample: 
1) FN – FC value of +103.97  Fibronectin. 
2) FN1 – FC value of +32  Cellular fibronectin 
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3)  SPP1 – FC value of +24.25  Secreted Phosphoprotein 1(Osteopontin). 
4) EPHB1 – FC value of +19.7  Epherin receptor B1. 
5) CSPG2 – FC value of +13  Chondroitin sulphate proteoglycan 2 
(versican). 
6) COL1A2 – FC value of +10.56  Collagen type 1, alpha 2. 
7) MACF1 – FC value of +9.85  Microtubule-actin crosslinking factor 1. 
Similarly, the following genes were identified as being significantly down regulated: 
1) FABP1 – FC value of -1097.5  Fatty acid binding protein 1, hepatic. 
2) CKB – FC value of -84.45  Creatine kinase brain. 
3) BMP4 – FC value of -45.25  Bone morphogenetic protein 4. 
4) ASCL2 – FC value of -32  Achaete-scute complex-like 2. 
5) PLP – FC value of -24.25  Proteolipid protein. 
6) TDGF1 – FC value of -18.38  Teratocarcinoma derived growth factor 1. 
7) CCNA1 – FC value of -17.15  Cyclin A1. 
8) EGF – FC value of -13.93  Epidermal growth factor. 
9) MLH1 – FC value of -13.93  MutL homolog , colon cancer, non-polyposis 
type 2. 
10) SLC16A1 – FC value of -13.93  Solute carrier family 16, member 1. 
11) PRG3 – FC value of -12.13  p53 responsive gene. 
12) PLS3 – FC value of -9.19  Plastin 3 (T isoform) 
Key genes had been clustered into various functional groups and their expression 
profiles had been assessed. These revealed: 
 Down regulation of key genes involved in regulating apoptosis. 
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 Down regulation of all key genes studied, apart from one gene, involved in 
cell cycle progression, proliferation and growth. 
 Down regulation of key genes involved in DNA replication and repair. 
 Down regulation of key oncogenes 
 Down regulation of key genes involved in protein translation, processing, 
transport and degradation. 
 An overall down regulation of key genes involved in stem cell differentiation. 
 Down regulation of key tumour suppressor genes studied apart from one 
gene i.e EPHB1. 
  The remaining functional groups studied had not revealed any significant 
differences. 
 
4.2.4.2.3 A comparative microarray analysis of changes in functional gene 
groups between a Dukes’ C adenocarcinoma (nuclear lamin A/C 
negative) tumour sample and a Tubulo-villous adenoma (nuclear 
lamin A/C negative) tumour sample  (Table 4.11) 
 
The signal log ratio (SLR) profiles of various genes expressed in the tubulo-villous 
adenoma sample were used as a reference level from which fold change (FC) 
values were calculated for genes expressed in the Dukes’ C (nuclear lamin A/C 
negative) tumour sample. A higher than 9 FC value had been assigned to identify 
key genes of interest. The following genes were identified as being significantly up 
regulated: 
1) FN – FC value of +294.07  Fibronectin. 
2) FN1 – FC value of +84.45  Cellular fibronectin. 
3) TF – FC value of +9.85  Transferrin. 
4) ITGB1 – Fc value of +9.19  Integrin beta 1. 
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Similarly, the following genes were identified as being significantly down regulated: 
1) EGF – FC value of -24.25  Epidermal growth factor. 
Key genes had been clustered into various functional groups and their expression 
profiles had been assessed. These revealed: 
 Down regulation of key genes involved in regulating apoptosis. 
 Up regulation of key genes involved in gene transcription. 
 The remaining functional groups studied had not revealed any significant 
differences. 
 
4.2.4.2.4 A comparative microarray analysis of changes in functional gene 
groups between a Dukes’ B adenocarcinoma (nuclear lamin A/C 
positive) tumour sample and a Dukes’ B adenocarcinoma 
(nuclear lamin A/C negative) tumour sample (Table 4.12) 
 
The signal log ratio (SLR) profiles of various genes expressed in the Dukes’ B 
(nuclear lamin A/C negative) tumour sample were used as a reference level from 
which fold change (FC) values were calculated for genes expressed in the Dukes’ 
B (nuclear lamin A/C positive) tumour sample. A higher than 9 FC value had been 
assigned to identify key genes of interest. The following genes were identified as 
being significantly up regulated: 
1) IGF2 – FC value of +1024  Insulin-like growth factor 2 (Somatomedin A). 
2) FABP1 – FC value of +776.05  Fatty acid binding protein 1, liver. 
3) CKB – FC value of +84.45  Creatine kinase brain. 
4) BMP4 – FC value of +21.11  Bone morphogenetic protein 4. 
5) NEFL – FC value of +9.19  Neurofilament light polypeptide. 
6) PLS3 – FC value of +9.19  Plastin 3 (T isoform) 
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Similarly, the following genes were identified as being significantly down regulated: 
1) SPP1 – FC value of -97.01  Secreted phosphoprotein 1 (Osteopontin). 
2) PTGS2 – FC value of -19.7  Prostaglandin-endoperoxide synthase 2 
(cyclooxygenase) 
3) CD14 – FC value of -18.38  CD14 antigen. 
4) MAPT – FC value of -16  Microtubule associated protein tau. 
5) LCP1 – FC value of -9.19  Lymphocyte cytosolic protein 1 (L-Plastin). 
6) CDH1 – FC value of -1.32  Cadherin 1, type1, E-cadherin (epithelial) 
Key genes had been clustered into various functional groups and their expression 
profiles had been assessed. These revealed: 
 An overall down regulation of key genes studied involved in regulation of 
the cytoskeleton and nucleoskeleton. 
 Slight down regulation of key genes studied involved in regulation of gene 
expression / transcription. 
 Down regulation of key genes studied involved in signal transduction. 
 Down regulation of key genes studied involved in tumour suppression. 
 The remaining functional groups studied had not revealed any significant 
differences. 
 
4.2.4.2.5 A comparative microarray analysis of changes in functional gene 
groups between a Dukes’ B adenocarcinoma (nuclear lamin A/C 
positive) tumour sample and a Dukes’ C adenocarcinoma 
(nuclear lamin A/C negative) tumour sample (Table 4.13) 
 
The signal log ratio (SLR) profiles of various genes expressed in the Dukes’ C 
(nuclear lamin A/C negative) tumour sample were used as a reference level from 
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which fold change (FC) values were calculated for genes expressed in the Dukes’ 
B (nuclear lamin A/C positive) tumour sample. A higher than 9 FC value had been 
assigned to identify key genes of interest. The following genes were identified as 
being significantly up regulated: 
1) FABP1 – FC value of +724.08  Fatty acid binding protein 1, liver. 
2) MMP3 – FC value of +107  Matrix metalloproteinase 3 (Stromelysin 1, 
gelatinase). 
3) PLP – FC value of +51.98  Proteolipid protein. 
4) CKB – FC value of +29.86  Creatine kinase brain. 
5) PRG3 – FC value of +29.86  p53-responsive gene. 
6) ASCL2 – FC value of +22.63  Achaete-scute complex-like 2. 
7) TDGF1 – FC value of +12.13  Teratocarcinoma-derived growth factor 1. 
8) FGF5 – FC value of +11.31  Fibrobalst growth factor 5. 
9) PLS3 – FC value of +9.66  Plastin 3 (T isoform) 
Similarly, the following genes were identified as being significantly down regulated: 
1) SPP1 – FC value of -48.5  secreted phosphoprotein 1 (osteopontin). 
2) PTGS2 – FC value of -45.25  prostaglandin-endoperoxide synthase 2 
(cyclooxygenase). 
3) CD14 – FC value of -11.31  CD 14 antigen. 
4) SOD 2 – FC value of -9.19  superoxide dismutase 2, mitochondrial. 
Key genes had been clustered into various functional groups and their expression 
profiles had been assessed. These revealed: 
 An overall increase in gene expression related to protein translation, 
processing, transport and degradation 
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 A comparative increase in the expression of genes associated with stem 
cell differentiation 
 The remaining functional groups studied had not revealed any significant 
differences, apart from the Wnt group, where a gene was significantly up 
regulated i.e FABP1. 
 
4.2.4.2.6 A comparative microarray analysis of changes in functional gene 
groups between a Dukes’ C adenocarcinoma (nuclear lamin A/C 
negative) tumour sample and a Dukes’ B adenocarcinoma 
(nuclear lamin A/C negative) tumour sample (Table 4.14) 
 
The signal log ratio (SLR) profiles of various genes expressed in the Dukes’ B 
(nuclear lamin A/C negative) tumour sample were used as a reference level from 
which fold change (FC) values were calculated for genes expressed in the Dukes’ 
C (nuclear lamin A/C negative) tumour sample. A higher than 9 FC value had been 
assigned to identify key genes of interest. The following genes were identified as 
being significantly up regulated: 
1) MAPT – FC value of +21.11  Microtubule-associated protein tau. 
2) BGN – FC value of +10.56  Biglycan. 
3) FGF5 – FC value of +9.85  Fibroblast growth factor 5. 
4) PLP – FC value of +9.85  Proteolipid protein. 
Similarly, the following genes were identified as being significantly down regulated: 
1) IGF2 – FC value of -724.08  Insulin-like growth factor 2 (somatomedin A). 
2) EGF – FC value of -9.85  Epidermal growth factor. 
Key genes had been clustered into various functional groups and their expression 
profiles had been assessed. These revealed: 
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 An overall increase in the expression of key, selected genes involved in 
extracellular matrix: components, processing, cellular attachment, 
proteases and protease inhibitors. 
 Up-regulation of key selected genes involved in signal transduction. 
 An overall increase in the expression of key, selected genes involved in 
stem cell differentiation. 
 Up regulation of key, selected genes involved in tumour suppression. 
 The remaining functional groups displayed equivocal expression levels. 
 
All results of up and down regulated genes in the functional groups had been 
closely studied and a detailed literature search carried out. Interest was focused 
on CKB (creatine kinase brain), T-Plastin and E-Cadherin. The reason for this 
interest was due to previous studies showing a significant role these genes played 
in colorectal cancer. Further confirmation of the presence of the aforementioned 
genes and lamin A/C status in each experimental sample, was done by RT-PCR. 
 
4.2.5 RT-PCR studies to confirm lamin A/C status and 
gene expression in various tumour samples 
 
4.2.5.1 RT-PCR to assess expression of lamin A and C in a 
tubulo-villous adenoma sample (Figure 4.4) 
 
Using immunohistochemical techniques, no discernable nuclear expression of 
lamin A/C was noted in the tubulo-villous adenoma sample. However, to confirm 
this, semi quantitative RT – PCR was carried out on equal concentrations of total 
RNA (verified by a β-actin RT – PCR – Figure 4.4). No obvious expression of 
lamin A/C was observed. This observation was in keeping with the microarray 
results. 
184 | P a g e  
 
 
4.2.5.2 RT-PCR to assess expression of lamin A and C in a 
Dukes’ C tumour sample (Figure 4.5) 
 
Immunohistochemical analyses of the Dukes’ C tumour sample did not show any 
expression of lamin A/C. To confirm this observation a semi quantitative RT-PCR 
was carried out on equal concentrations of total RNA (verified by a β-actin RT-
PCR, figure 4.5). The RT-PCR did not show any evidence of lamin A/C expression 
in this tumour sample. Similarly, the microarray data also suggested no significant 
change of lamin A/C expression to be found in this specific tumour sample. 
 
4.2.5.3 RT-PCR to assess expression of lamin A and C in a 
Dukes’ B tumour sample known to express lamin A/C 
and its comparison with a similar Dukes’ B tumour 
sample deficient in lamin A/C expression (Figure 4.6) 
 
Immunohistochemical analyses of two Dukes’ B tumour samples revealed strong 
nuclear envelope expression of lamin A/C in one tumour sample and complete 
absence of lamin A/C expression in the other tumour sample. To confirm these 
observations a semi quantitative RT-PCR was carried out on equal concentrations 
of total RNA from both tumour samples (verified by a β-actin RT-PCR, figure 4.6). 
The results of the RT-PCR supported the aforementioned observations of strong 
lamin A/C expression in one tumour sample and no expression of lamin A/C in the 
other tumour sample, respectively. The microarray data also confirmed these 
observations. 
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4.2.5.4 RT-PCR to assess the expression of creatine kinase 
brain (CKB) in a tubulo-villous adenoma (devoid of 
nuclear lamin A/C expression), a Dukes’ B tumour 
sample (expressing strong nuclear lamin A/C), a Dukes’ 
B tumour sample (devoid of nuclear lamin A/C) and a 
Dukes’ C tumour sample (devoid of nuclear lamin A/C 
expression) (Figure 4.7) 
 
Comparative microarray analysis of all tumour samples revealed a significant up 
regulation of creatine kinase brain (CKB) in the Dukes’ B tumour sample 
expressing lamin A/C. To confirm this observation, a semi quantitative RT-PCR 
was carried on equal concentrations of total RNA from all tumour samples (verified 
by a β-actin RT-PCR, figure 4.8) as illustrated in figure 4.7. The results supported 
the microarray observation of increased expression of CKB in the Dukes’ B tumour 
sample expressing lamin A/C.  
 
4.2.5.5 RT-PCR to assess expression of T-Plastin and E-
cadherin between two Dukes’ B tumour samples, one 
expressing nuclear lamin A/C and the other devoid of 
nuclear lamin A/C expression (Figure 4.9) 
 
A comparative microarray analysis between two Duke’s B tumour samples, one 
expressing strong nuclear lamin A/C and the other devoid of nuclear lamin A/C 
expression, revealed an up regulation in the levels of T-plastin with a concomitant 
low expression of E-cadherin in the Dukes’ B tumour sample expressing lamin 
A/C. On the other hand, significantly decreased expression levels of T-plastin with 
increased expression levels of E-cadherin were noted in the Dukes’ B tumour 
sample exhibiting no lamin A/C expression. These observations were confirmed by 
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a semi quantitative RT-PCR using equal volumes of total RNA (verified by a β-
actin RT-PCR, figure 4.9). 
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4.3  Tables and Figures   
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Table 4.1 
 
Table 4.1 is a list of all patients with colorectal cancer participating in this study. A 
total of 43 patients participated in this study. Tumour site, Dukes’ staging and 
lamin A/C expression profiles (positive, depleted or negative), in each case are 
listed. 
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Table 4.1 
 
Table of all patients participating in the study, showing site of tumour, Dukes’ 
stage and lamin A/C profile 
Number Site Dukes Stage Lamin A/C expression (Nuclear) 
1 Rectum A Positive 
2 Sigmoid B Lamin depleted 
3 Recto-sigmoid junction A Lamin depleted 
4 Ascending colon C1 Lamin depleted 
5 Sigmoid B Lamin depleted 
6 Ascending colon B Negative 
7 Ascending colon B Lamin depleted 
8 Rectum B Negative 
9 Rectum C1 Positive 
10 Hepatic Flexure C1 Positive 
11 Recto-sigmoid junction B Positive 
12 Sigmoid C1 Negative 
13 Rectum B Lamin depleted 
14 Hepatic Flexure C1 Positive 
15 Hepatic Flexure B Positive 
16 Ascending colon B Negative 
17 Rectum B Positive 
18 Recto-sigmoid junction C1 Positive 
19 Ascending colon C1 Negative 
20 Rectum B Positive 
21 Sigmoid B Lamin depleted 
22 Sigmoid C2 Positive 
23 Rectum C1 Lamin depleted 
24 Sigmoid C1 Lamin depleted 
25 Sigmoid B Positive 
26 Sigmoid C2 Lamin depleted 
27 Ascending colon B Negative 
28 Rectum C1 Lamin depleted 
29 Rectum TV - Adenoma Negative 
30 Sigmoid C1 Lamin depleted 
31 Sigmoid B Positive 
32 Recto-sigmoid junction A Positive 
33 Rectum C1 Lamin depleted 
34 Rectum B Positive 
35 Sigmoid C1 Negative 
36 Rectum B Negative 
37 Splenic flexure B Positive 
38 Sigmoid B Lamin depleted 
39 Ascending colon A Negative 
40 Splenic flexure A Negative 
41 Ascending colon B Negative 
42 Ascending colon B Negative 
43 Rectum B Positive 
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Table 4.2 (A and B) 
 
Table 4.2 illustrates the relationship between various Dukes’ stages and lamin A/C 
expression in tumour samples taken from all patients participating in this study. 
Due to low numbers, it is difficult to establish any statistical significance. 
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Table 4.2 A 
Distribution of various Duke’s stages and associated expression profiles of 
lamin A/C at each stage. 
Duke’s Stage % Frequency Lamin +ve Lamin -ve Lamin 
Depleted 
A 11.91% 
(05 patients) 
2 (40%) 2 (40%) 1 (20%) 
B 52.38% 
(22 patients) 
9 (40.91%) 7 (31.82%) 6 (27.27%) 
C1 30.95% 
(13 patients) 
4 (30.77%) 3 (23.08%) 6 (46.15%) 
C2 04.76% 
(02 patients) 
1 (50%) 0 (0%) 1 (50%) 
 
Table 4.2 B 
Chi square cross tabulation between Duke’s stage and lamin A/C 
expression. 
Observed 
Values 
Lamin +ve Lamin –ve Lamin 
Depleted 
Total 
Duke’s A 2 2 1 5 
Duke’s B 9 7 6 22 
Duke’s C1 4 3 6 13 
Duke’s C2 1 0 1 2 
Total 16 12 14 42 
     
Expected 
values 
Lamin +ve Lamin –ve Lamin 
Depleted 
Total 
Duke’s A 1.9 1.4 1.7 5 
Duke’s B 8.4 6.3 7.3 22 
Duke’s C1 5.0 3.7 4.3 13 
Duke’s C2 0.8 0.6 0.7 2 
Total 16 12 14 42 
     
   p = 0.85 
 
Simple chi-square cross-tabulation of Duke’s stage against lamin status shows no 
significant correlation (p=0.85) although the size of the population (n=42) 
significantly limits the power of such statistical analysis. 
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Table 4.3 
 
A comparative analysis of colorectal cancer according to Dukes’ stage, 
lamin A/C expression and anatomical location 
Site Duke’s A Duke’s B Duke’s 
C1 
Duke’s     
C2 
Total 
Ascending colon 
Lamin A/C +ve 
Lamin A/C –ve 
Lamin A/C 
depleted 
1 
0 
1 
0 
6 
0 
6 
0 
2 
0 
1 
1 
0 
0 
0 
0 
9 (21.42%) 
0 
8 
1 
Hepatic flexure 
Lamin A/C +ve 
Lamin A/C –ve 
Lamin A/C 
depleted 
0 
0 
0 
0 
1 
1 
0 
0 
2 
2 
0 
0 
0 
0 
0 
0 
3 (7.14%) 
3 
0 
0 
Transverse colon 0 0 0 0 0 
Splenic flexure 
Lamin A/C +ve 
Lamin A/C –ve 
Lamin A/C 
depleted 
1 
0 
1 
0 
1 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
2 (4.76%) 
1 
1 
0 
Descending colon 0 0 0 0 0 
Sigmoid colon 
Lamin A/C +ve 
Lamin A/C –ve 
Lamin A/C 
depleted 
0 
0 
0 
0 
6 
2 
0 
4 
4 
0 
2 
2 
2 
1 
0 
1 
12 (28.57%) 
3 
2 
7 
Recto-sigmoid 
junction 
Lamin A/C +ve 
Lamin A/C –ve 
Lamin A/C 
depleted 
2 
 
1 
0 
1 
1 
 
1 
0 
0 
1 
 
1 
0 
0 
0 
 
0 
0 
0 
4 (9.52%) 
 
3 
0 
1 
Rectum 
Lamin A/C +ve 
Lamin A/C –ve 
Lamin A/C 
depleted 
1 
1 
0 
0 
7 
4 
2 
1 
4 
1 
0 
3 
0 
0 
0 
0 
12 (28.57%) 
6 
2 
4 
Total 5 22 13 2 42 
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Table 4.4 
 
List of total transcripts analysed by microarray with their corresponding 
signal detection values, from each tissue sample analysed 
 
Sample Total No of 
Transcripts  
+ve Signal 
detection 
-ve Signal 
detection 
Moderate 
Signal 
detection 
Detection  
p-value 
TV Adenoma 54,675 22,664 31,163 848 ≤0.05 
Duke’s B 
 lamin A/C –ve 
54,675 25,235 28,598 842 ≤0.05 
Duke’ B 
Lamin A/C +ve 
54,675 26,250 27,656 769 ≤0.05 
Duke’s C 
Lamin A/C –ve 
54,675 24,976 28,907 792 ≤0.05 
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Table 4.5 
A comparative microarray analysis of changes in functional genes between 
a Dukes’ B adenocarcinoma (nuclear lamin A/C negative) tumour sample and 
a Tubulo-Villous adenoma (nuclear lamin A/C negative) tumour sample 
 
Using microarray data obtained from the tubulo-villous (nuclear lamin A/C 
negative) adenoma sample as a baseline, a comparative microarray expression 
analysis was made to assess the twenty most up (red) and down (green) regulated 
genes in the Dukes’ B (nuclear lamin A/C negative) adenocarcinoma sample. Fold 
change values have been shown as well as a brief description of the involved 
genes in the Dukes’ B (nuclear lamin A/C negative) adenocarcinoma sample. 
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Table 4.6 
 
A comparative microarray analysis of changes in functional genes between 
a Dukes’ C adenocarcinoma (nuclear lamin A/C negative) tumour sample and 
a Tubulo-Villous adenoma (nuclear lamin A/C negative) tumour sample  
 
Using microarray data obtained from the tubulo-villous (nuclear lamin A/C 
negative) adenoma sample as a baseline, a comparative microarray expression 
analysis was made to assess the twenty most up (red) and down (green) regulated 
genes in the Dukes’ C (nuclear lamin A/C negative) adenocarcinoma sample. Fold 
change values have been shown as well as a brief description of the involved 
genes in the Dukes’ C (nuclear lamin A/C negative) adenocarcinoma sample. 
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Table 4.7 
 
A comparative microarray analysis of changes in functional genes between 
a Dukes’ C adenocarcinoma (nuclear lamin A/C negative) tumour sample and 
a Dukes’ B (nuclear lamin A/C negative) tumour sample 
 
Using microarray data obtained from the Dukes’ B (nuclear lamin A/C negative) 
adenocarcinoma sample as a baseline, a comparative microarray expression 
analysis was made to assess the twenty most up (red) and down (green) regulated 
genes in the Dukes’ C (nuclear lamin A/C negative) adenocarcinoma sample. Fold 
change values have been shown as well as a brief description of the involved 
genes in the Dukes’ C (nuclear lamin A/C negative) adenocarcinoma sample. 
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Table 4.8 
 
A comparative microarray analysis of changes in functional genes between 
a Dukes’ B (nuclear lamin A/C positive) tumour sample and a Dukes’ B 
adenocarcinoma (nuclear lamin A/C negative) tumour sample 
 
Using microarray data obtained from the Dukes’ B (nuclear lamin A/C negative) 
adenocarcinoma sample as a baseline, a comparative microarray expression 
analysis was made to assess the twenty most up (red) and down (green) regulated 
genes in the Dukes’ B (nuclear lamin A/C positive) adenocarcinoma sample. Fold 
change values have been shown as well as a brief description of the involved 
genes in the Dukes’ B (nuclear lamin A/C positive) adenocarcinoma sample. 
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Table 4.9 
 
A comparative microarray analysis of changes in functional gene groups 
between a Dukes’ B (nuclear lamin A/C negative) tumour sample and a 
Tubulo-villous adenoma (nuclear lamin A/C negative) tumour sample 
 
Using microarray data obtained from the tubulo-villous (nuclear lamin A/C 
negative) adenoma sample as a baseline, a comparative microarray expression 
analysis was made to assess changes in sixteen functional gene groups, 
containing 164 genes in total, in the Dukes’ B (nuclear lamin A/C negative) 
adenocarcinoma sample. Affymetrix Id numbers, unique Gene codes, fold change 
(FC) values, using an arbitrary cut off level set at +/- 9, and a brief description of 
the genes were also included amongst other criteria, as mentioned in section 
4.2.4.3. Genes of interest were appropriately highlighted to indicate either an up 
(highlighted in red) or down (highlighted in green) regulation. Some genes not 
exhibiting a significant FC values were also highlighted (in blue) as this information 
was deemed important in analysis of the functional gene group as a whole. 
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Table 4.10 
 
A comparative microarray analysis of changes in functional gene groups 
between a Dukes’ B (nuclear lamin A/C positive) tumour sample and a 
Tubulo-villous adenoma (nuclear lamin A/C negative) tumour sample 
 
Using microarray data obtained from the tubulo-villous (nuclear lamin A/C 
negative) adenoma sample as a baseline, a comparative microarray expression 
analysis was made to assess changes in sixteen functional gene groups, 
containing 164 genes in total, in the Dukes’ B (nuclear lamin A/C positive) 
adenocarcinoma sample. Affymetrix Id numbers, unique Gene codes, fold change 
(FC) values, using an arbitrary cut off level set at +/- 9, and a brief description of 
the genes were also included amongst other criteria, as mentioned in section 
4.2.4.3. Genes of interest were appropriately highlighted to indicate either an up 
(highlighted in red) or down (highlighted in green) regulation. Some genes not 
exhibiting a significant FC values were also highlighted (in blue) as this information 
was deemed important in analysis of the functional gene group as a whole. 
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Table 4.11 
 
A comparative microarray analysis of changes in functional gene groups 
between a Dukes’ C (nuclear lamin A/C negative) tumour sample and a 
Tubulo-villous adenoma (nuclear lamin A/C negative) tumour sample  
 
Using microarray data obtained from the tubulo-villous (nuclear lamin A/C 
negative) adenoma sample as a baseline, a comparative microarray expression 
analysis was made to assess changes in sixteen functional gene groups, 
containing 164 genes in total, in the Dukes’ C (nuclear lamin A/C negative) 
adenocarcinoma sample. Affymetrix Id numbers, unique Gene codes, fold change 
(FC) values, using an arbitrary cut off level set at +/- 9, and a brief description of 
the genes were also included amongst other criteria, as mentioned in section 
4.2.4.3. Genes of interest were appropriately highlighted to indicate either an up 
(highlighted in red) or down (highlighted in green) regulation. Some genes not 
exhibiting a significant FC values were also highlighted (in blue) as this information 
was deemed important in analysis of the functional gene group as a whole. 
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Table 4.12 
 
A comparative microarray analysis of changes in functional gene groups 
between a Dukes’ B (nuclear lamin A/C positive) tumour sample and a 
Dukes’ B (nuclear lamin A/C negative) tumour sample 
 
Using microarray data obtained from the Dukes’ B (nuclear lamin A/C negative) 
adenocarcinoma sample as a baseline, a comparative microarray expression 
analysis was made to assess changes in sixteen functional gene groups, 
containing 164 genes in total, in the Dukes’ B (nuclear lamin A/C positive) 
adenocarcinoma sample. Affymetrix Id numbers, unique Gene codes, fold change 
(FC) values, using an arbitrary cut off level set at +/- 9, and a brief description of 
the genes were also included amongst other criteria, as mentioned in section 
4.2.4.3. Genes of interest were appropriately highlighted to indicate either an up 
(highlighted in red) or down (highlighted in green) regulation. Some genes not 
exhibiting a significant FC values were also highlighted (in blue) as this information 
was deemed important in analysis of the functional gene group as a whole. 
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Table 4.13 
 
A comparative microarray analysis of changes in functional gene groups 
between a Dukes’ B (nuclear lamin A/C positive) tumour sample and a 
Dukes’ C (nuclear lamin A/C negative) tumour sample 
 
Using microarray data obtained from the Dukes’ C (nuclear lamin A/C negative) 
adenocarcinoma sample as a baseline, a comparative microarray expression 
analysis was made to assess changes in sixteen functional gene groups, 
containing 164 genes in total, in the Dukes’ B (nuclear lamin A/C negative) 
adenocarcinoma sample. Affymetrix Id numbers, unique Gene codes, fold change 
(FC) values, using an arbitrary cut off level set at +/- 9, and a brief description of 
the genes were also included amongst other criteria, as mentioned in section 
4.2.4.3. Genes of interest were appropriately highlighted to indicate either an up 
(highlighted in red) or down (highlighted in green) regulation. Some genes not 
exhibiting a significant FC values were also highlighted (in blue) as this information 
was deemed important in analysis of the functional gene group as a whole. 
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Table 4.14 
 
A comparative microarray analysis of changes in functional gene groups 
between a Dukes’ B (nuclear lamin A/C negative) tumour sample and a 
Dukes’ C (nuclear lamin A/C negative) tumour sample 
 
Using microarray data obtained from the Dukes’ C (nuclear lamin A/C negative) 
adenocarcinoma sample as a baseline, a comparative microarray expression 
analysis was made to assess changes in sixteen functional gene groups, 
containing 164 genes in total, in the Dukes’ B (nuclear lamin A/C negative) 
adenocarcinoma sample. Affymetrix Id numbers, unique Gene codes, fold change 
(FC) values, using an arbitrary cut off level set at +/- 9, and a brief description of 
the genes were also included amongst other criteria, as mentioned in section 
4.2.4.3. Genes of interest were appropriately highlighted to indicate either an up 
(highlighted in red) or down (highlighted in green) regulation. Some genes not 
exhibiting a significant FC values were also highlighted (in blue) as this information 
was deemed important in analysis of the functional gene group as a whole. 
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Figure 4.2 
 
Quality and purity of total RNA used in microarray experiments. 
 
Total RNA was extracted from four different samples using Trizol® reagent, 
as per manufacturer’s recommendations: 
 Sample 29 – Tubulo-villous adenoma (nuclear lamin A/C negative) 
Sample 33 – Duke’s C cancer sample (nuclear lamin A/C negative) 
Sample 37 – Duke’s B cancer sample (nuclear lamin A/C positive) 
Sample 38 – Duke’s B cancer sample (nuclear lamin A/C negative) 
Quality was verified by gel electrophoresis. 28S and 18S ribosomal bands 
were visualised in all cases. In lane 1 some RNA degradation was noted, 
however no obvious DNA contamination was noted. RNA purity was 
determined by measuring the ratio of absorbance in DEPC treated dH2O at 
260 nm and 280 nm (A260/280). An A260/280 value greater than1.8 indicates 
very pure RNA. M indicate RNA size markers in base pairs (bp). 
 
 
  
Patient 
Sample 
 No 
Absorbance 
at  
260.0 nm 
Absorbance 
at  
280.0 nm 
Background 
absorbance at 
320.0 nm 
260.0 nm 
280.0 nm 
280.0 
nm 
260.0 
nm 
29 2.1953 1.1976 0.0167 1.8449 0.5420 
33 1.1576 0.6535 0.0078 1.7807 0.5616 
37 0.4249 0.2409 0.0073 1.7874 0.5595 
38 0.4621 0.2587 0.0121 1.8246 0.5481 
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Figure 4.3 
 
GeneChip HG-U133 Plus 2.0 array® by Affymetrix used in microarray 
analysis of tissue samples. Each array utilised probe sets with 11µm 
features to provide multiple, independent measurements for each 
transcript. The GeneChip array was scanned using a GeneArray® 2500 
scanner to generate a GeneChip® Human Genome U133 Plus 2.0 .dat file 
with appropriate .CEL files exhibiting cell intensities. More than 54000 
probe sets were used to analyse the expression level of more than 47000 
transcripts and variants, including approximately 38500 well characterised 
human genes. All four samples subjected for microarray analysis were 
analysed using this specific array. 
A) GeneChip® Human Genome U133 Plus 2.0 .CEL file illustrating probe sets 
exhibiting varying expression levels for each transcript. Black squares 
indicate no discernable expression whereas red squares indicate highly 
significant expression levels. 
B) Expanded view to illustrate individual probe sets. 
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Figure 4.3 
GeneChip® Human Genome U133 Plus 2.0 .CEL file 
 
A) 
 
 
B) 
Magnified view of each 11µm probe set in the chip 
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Figure 4.4 
 
RT-PCR to assess expression of lamin A and C in Tubulo-villous 
adenoma sample. 
 
Immunohistological analysis revealed no discernable expression of lamin 
A and C in the tissue sample. This was confirmed on semi-quantitative RT-
PCR. Primers were designed to amplify lamin A and C in the sample. 
Equal loading of starting material was verified by monitoring the 
transcriptional activity of β-actin, seen as an 834 bp product. Lane M was 
used a marker lane, lane 1 was used for β-actin, lane 2 was used for lamin 
A and lane 3 was used for lamin C. Three separate gels were run to 
examine any variation between each experiment. The results were 
analysed by densitometric analysis and standard deviation measured. 
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Figure 4.4 
Graph showing densitometric analysis of three separate RT-PCR samples 
assessing the expression of lamin A and C in a tubulo-villous adenoma sample. 
Standard Deviation was measured. 
AU – Arbitrary Units   
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Figure 4.5 
 
RT-PCR to assess expression of lamin A and C in a Dukes’ C tumour 
sample. 
 
Immunohistological analysis revealed no discernable expression of lamin 
A and C in the tissue sample. This was confirmed on semi-quantitative RT-
PCR. Primers were designed to amplify lamin A and C in the sample. 
Equal loading of starting material was verified by monitoring the 
transcriptional activity of β-actin, seen as an 834 bp product. Lane M was 
used a marker lane, lane 1 was used for β-actin, lane 2 was used for lamin 
A and lane 3 was used for lamin C. Three separate gels were run to 
examine any variation between each experiment. The results were 
analysed by densitometric analysis and standard deviation measured. 
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Figure 4.5 
Graph showing densitometric analysis of three separate RT-PCR samples 
assessing the expression of lamin A and C in a Dukes’ C tumour sample. 
Standard Deviation was measured. 
AU – Arbitrary Units   
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Figure 4.6 
 
RT-PCR to assess expression of lamin A and C in a Dukes’ B tumour 
sample (sample 37) known to express lamin A/C and its comparison 
with a similar Dukes’ B tumour sample (sample 38) deficient in lamin 
A/C expression. 
 
 Immunohistological analysis revealed no discernable expression of lamin 
A and C in the tissue sample number 38, known to be a Dukes’ stage B 
tumour. This was confirmed on semi-quantitative RT-PCR. Similarly, tissue 
sample number 37, a Dukes’ B stage tumour, was known to express lamin 
A/C and this was confirmed on semi-quantitative RT-PCR. Primers were 
designed to amplify lamin A and C in both samples. Equal loading of 
starting material was verified by monitoring the transcriptional activity of β-
actin, seen as an 834 bp product. Lane M was used a marker lane, lanes 1 
and 4 were used for β-actin, lanes 2 and 5 were used for lamin A and 
lanes 3 and 6 were used for lamin C. Lamin A expression was noted by 
observing a band at 1137 bp while lamin C expression was noted by 
observing a band at 993 bp. Three separate gels were run to examine any 
variation between each experiment. The results were analysed by 
densitometric analysis and standard deviation measured. 
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Figure 4.6 
Graph showing densitometric analysis of three separate RT-PCR samples 
assessing the expression of lamin A and C in two Dukes’ B tumour samples 
(sample 37 and 38 respectively). 
Standard Deviation was measured. 
AU – Arbitrary Units 
 
Sample 37 Sample 38 
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Figure 4.7 
 
RT-PCR to assess for expression of creatine kinase brain (CKB) in a 
tubulo villous adenoma (lamin A/C negative), Dukes’ B (lamin A/C 
positive), Dukes’ B (lamin A/C negative) and Dukes’ C tumour 
samples (lamin A/C negative). 
 
All tumour samples were assessed for the expression of creatine kinase 
brain. Lane 1 contained a sample from a tubulo villous adenoma; lane 2 
contained a sample from a Dukes’ B (lamin A/C positive) tumour; lane 3 
contained a sample from a Dukes’ B (lamin A/C negative) tumour and lane 
4 contained a sample from a Dukes’ C (lamin A/C negative) tumour 
sample. Lane M was used a marker lane. Three separate gels were run to 
examine any variation between each experiment. The results were 
analysed by densitometric analysis and standard deviation measured. 
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Figure 4.7 
Graph showing densitometric analysis of three separate RT-PCR samples 
assessing the expression of CKB in all tumour samples. 
Standard Deviation was measured. 
AU – Arbitrary Units 
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Figure 4.8 
 
RT-PCR showing expression of Beta-actin in all tumour samples used 
for assessing expression levels of creatine kinase brain. 
 
This figure shows the expression of beta-actin in all tumour samples used 
for the assessment of creatine kinase brain, as shown in figure 4.6. Beta 
actin is expressed uniformly in all samples. Lane 1 corresponds to a 
tubulo-villous (lamin A/C negative) sample; lane 2 corresponds to a Dukes’ 
B (lamin A/C negative) sample; lane 3 corresponds to a Dukes’ B (lamin 
A/C positive) sample and lane 4 corresponds to a Dukes’ C (lamin A/C 
negative) tumour sample. 
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Figure 4.9 
 
Expression of T-plastin and E-cadherin in two Dukes’ B tumour 
samples, one expressing lamin A/C and the other devoid of any lamin 
A/C expression. 
 
Semi quantitative RT-PCR to assess for levels of T-plastin and E-cadherin 
in Dukes’ B (lamin A/C) and Dukes’ B (lamin A/C negative) tumour 
samples revealed high expression of T-plastin in the tumour sample 
expressing lamin A/C (lane 3) whereas low levels were detected in the 
tumour sample lacking nuclear expression of lamin A/C (lane 4). On the 
other hand, low levels of E-cadherin were detected in the tumour sample 
expressing lamin A/C (lane 5) as compared to the tumour sample lacking 
nuclear expression of lamin A/C (lane 6). M indicates a DNA marker lane. 
Lane 1 exhibits beta-actin from a Dukes’ B (lamin A/C) tumour sample 
while lane 2 exhibits beta-actin from a Dukes’ B (lamin A/C negative) 
tumour sample. 
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Figure 4.9 
 
Graph illustrating densitometric analysis of three separate RT-PCR samples 
assessing the expression of T-plastin and E-cadherin in two Dukes’ B tumour 
samples, one expressing lamin A/C and the other devoid of lamin A/C expression, 
respectively. Β-actin was also measured. 
Standard error was measured. 
AU – Arbitrary units
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Figure 4.9 
 
Relative RNA Expression 
Lamin A/C +ve 
Lamin A/C -ve 
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4.4 Discussion 
 
Work done previously by Cox, Willis (Willis et al., 2008) has shown differential 
expression of lamin A/C in colorectal cancers of the same stage and grade. 
Hence, to confirm their findings and explore the underlying mechanism(s) leading 
to their observations, a prospective study involving 42 patients with bowel cancer, 
undergoing elective surgery, were recruited (n=42) from a local hospital after due 
approval by the ethics committee. Initial efforts were focused on assessing the 
expression of lamin A/C using  jol2, monoclonal antibodies (Dyer et al., 1997) in 
cancer tissue samples from these patients. Looking at the cohort as a whole, the 
incidence of bowel cancer according to Dukes’ staging reveals no significant 
difference in the Dukes’ A group when compared with UK national values (cancer 
research UK 2002). However, in the Dukes’ B group the observed incidence of 
52% is higher than expected from the UK national value of 35%. Similarly in the 
Dukes’ C group the observed incidence value of 36% is higher than the UK 
national average of 26%. The main reason for these differences in observation is 
due to the exclusion of Dukes’ D patients from the cohort studied. Dukes’ D 
patients are not deemed suitable candidates for definitive treatment and receive 
palliative care only, hence their exclusion from the study. To assess whether or not 
lamin A/C expression influences the stage of colorectal cancer, a simple chi-
square cross-tabulation of Dukes’ stage against lamin status was carried out. This 
shows no significant correlation (p=0.85) although the size of the population 
(n=42) puts significant limits on the power of such a statistical analysis. Comparing 
the incidence of colorectal cancer according to site involved in the colon and 
rectum, the observed values are more or less in keeping with those observed 
nationally in the UK (cancer research UK 2002). 
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4.4.1 Comparative microarray analysis of Dukes’ B and C 
(nuclear lamin A/C negative) tumour samples with a 
tubulo-villous adenoma (nuclear lamin A/C negative) 
sample 
 
The genetic alterations involved in the progression of a colorectal adenoma 
towards a fully developed colorectal cancer and its metastatic spread, have been 
elucidated excellently by previous studies and have given rise to the well known 
adenoma – carcinoma sequence (Fearon and Vogelstein, 1990). However, 
knowledge about lamin A/C imparting a less favourable outcome in patients with 
colorectal cancer (Willis et al., 2008) has recently been brought to light. In order to 
get a clearer picture of the various genetic alterations involved in colorectal 
carcinogenesis, a microarray experiment has been designed using three different 
tissue samples, each from a different patient; a tubulo-villous adenoma, a Dukes’ 
B cancer and a Dukes’ C cancer, respectively. Intentionally, all samples selected 
are lacking in nuclear lamin A/C expression in order to achieve minimal bias in the 
results. Using microarray data obtained from analysis of the tubulo-villous 
adenoma sample as a base line, comparative arrays are carried out on the other 
two samples and the results analysed. In the Dukes’ B group, the gene encoding 
for insulin-like growth factor 2 (somatomedin A) exhibits the highest level of up 
regulation, while the gene encoding for Gremlin 1 (part of the cysteine knot 
superfamily) is down regulated the most. In the Dukes’ C group, the gene 
encoding for carbonic anhydrase 1 is up regulated the most while the gene 
encoding for regulator of G protein signalling is down regulated the most. By using 
the microarray data from the Dukes’ B tumour sample as a base line, a 
comparative array study of the Dukes’ C sample reveals maximal up regulation in 
the gene encoding for carbonic anhydrase 1 and maximal down regulation in the 
gene encoding for insulin-like growth factor 2 (Somatomedin A). From this data it 
appears that the gene encoding for insulin-like growth factor 2 (Somatomedin A) is 
uniquely up regulated in the Dukes’ B tumour sample only and has no bearing on 
increasing stage of colorectal cancer, if anything, it is greatly suppressed. 
Similarly, the gene encoding for carbonic anhydrase 1 is uniquely up regulated in 
the Dukes’ C tumour sample only.  
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By clustering key genes into functional groups it is observed that genes involved 
with apoptosis are universally down regulated in both Dukes’ B and Dukes’ C 
tumour samples. This finding is not unusual as loss of these apoptotic inhibitors is 
usually seen in cancer cells. 
Examination of key genes involved in tumour suppression also reveal an overall 
down regulation in the Dukes’ B sample but no significant change is seen in the 
Dukes’ C sample. No specific reason can be found to explain this observation in 
the Dukes’ C group. 
A general up regulation of key genes involved in stem cell differentiation is noted 
in the Dukes’ C sample. This observation is difficult to explain as there are no 
plausible explanations found in the literature. However, various studies have 
suggested that colorectal cancer may be a consequence of adult stem cell 
dysfunction. Also, many cancers are known to exhibit certain characteristics that 
are typical of stem cells, for example, immortality, self renewal, monoclonality, etc. 
To this end, it appears that colorectal cancers, through some unknown 
mechanism(s), might be acquiring stem cell like attributes. At what stage does this 
change occur is open to debate. Some authors are firm proponents of colorectal 
cancer being a stem cell problem right from the beginning (Preston, 2003), while 
others believe in the top down morphogenesis of colorectal cancer in which a 
colorectal cancer invades downwards into the crypt and eventually encroaches 
upon the stem cell niche and manages to acquire stem cell like properties (Shih et 
al., 2001), thus priming the stage for possible metastatic spread. From the 
microarray data it appears that acquisition of stem cell properties may be a late 
event and is observed in later stages of colorectal cancer, however definitive proof 
is lacking and further studies are needed to clarify this. 
The Wnt signalling pathway in the colon is well known for driving the proliferative 
compartment of the crypt and aberrations in this pathway, especially mutations in 
the APC (Adenomatous Polyposis Coli) gene are known to lead towards polyp 
formation and constitute part of the adenoma carcinoma pathway (Fearon and 
Vogelstein, 1990). No significant changes in either APC or downstream mediators 
of Wnt signalling, such as c-MYC, are noted. This result is expected as all three 
tumour samples will already harbour changes in the APC gene and its associated 
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pathways i.e. the Wnt signalling pathway and hence no significant change 
between each sample is expected. An exception here is the observation that 
epherin receptor B1 (EPHB1) is up regulated in all samples compared. At present 
no explanation is forthcoming for this observation. 
 
4.4.2 Comparative microarray analysis of a Dukes’ B 
(nuclear lamin A/C positive) tumour sample with a tubulo-
villous adenoma (nuclear lamin A/C negative), Dukes’ B 
(nuclear lamin A/C negative) and Dukes’ C (nuclear lamin 
A/C negative) tumour samples 
 
Patients with Dukes’ B colorectal cancer pose a unique challenge to clinicians as 
regards optimum treatment. The reasons for this dilemma lie in the results of 
various trials that have not shown a conclusive benefit of adjuvant therapy in 
improving long term survival figures (IMPACT B2 trials - 1999). In this context, 
assessment of two Dukes’ B tumour samples from different patients with identical 
stage and grades but different expression of nuclear lamin A/C, reveal very 
interesting features. The following genes are greatly up regulated in the Dukes’ B 
(lamin A/C positive) tumour sample: Insulin-like growth factor 2 (Somatomedin A); 
Fatty acid binding protein 1, liver; T plastin; creatine kinase brain and bone 
morphogenetic protein 4. On the other hand, key genes that are down regulated in 
the Dukes’ B (lamin A/C positive) tumour sample included: Secreted 
Phosphoprotein 1 (Osteopontin), E-cadherin and cyclooxygenase (COX2) 
amongst other down regulated genes. 
Comparative analysis between the tubulo-villous adenoma sample and Dukes’ B 
(lamin A/C positive) sample show a general up regulation in key genes involved 
with apoptotic inhibitors, cell cycle progression / proliferation and growth, 
oncogenes, stem cell differentiation and Wnt signalling, with the notable exception 
of epherin receptor B1 which is down regulated.  When compared with the other 
Dukes’ B sample (nuclear lamin A/C negative), no clear cut change can be 
observed in any functional gene group as a whole, although certain genes are 
significantly up regulated in the Dukes’ B (lamin A/C positive) group when 
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compared with the Dukes’ C (lamin A/C negative) sample. These key genes are: 
Matrix metalloproteinase 3 (progelatinase); fatty acid binding protein 1, liver; bone 
morphogenetic protein 4; creatine kinase brain; proteolipid protein and T-plastin. 
On the other hand, key genes that are down regulated in the Dukes’ B (lamin A/C 
positive) tumour sample include: Secreted Phosphoprotein 1 (Osteopontin), E-
cadherin and cyclooxygenase (COX2) amongst other down regulated genes.  
 
4.4.3 Key genes of interest identified from the 
microarray experiment and their role in colorectal cancer 
 
A brief description of key genes of interest identified through the microarray 
studies and their possible role in colorectal cancer is further explored and reveals 
the following: 
Creatine kinase brain (CKB) is an enzyme known to act as a catalyst in the 
conversion of creatine to phosphocreatine and adenosine diphosphate. 
Phosphocreatine acts as an energy reservoir and plays an important role in the 
rapid buffering and regeneration of adenosine triphosphate in tissues, via the 
phosphocreatine shuttle (Wallimann et al., 1992). In human cells, creatine kinase 
consists of two subunits (B-Brain; M-Muscle) and three isoforms (BB, MM and 
MB). The genes encoding for the B subunit are on chromosome 14q32. The 
increased levels of creatine kinase brain subunit, observed in the Dukes’ B, lamin 
A/C positive tumours is intriguing. Proteomic studies done by Friedman et.al 
(Friedman et al., 2004) describe low levels of creatine kinase observed in 
colorectal cancers. Their observations are supported by other studies as well 
(Joseph et al., 1997). However, Balasubramani et.al (Balasubramani et al., 2006) 
observes high levels of creatine kinase in the nuclear matrix but low levels in the 
cytoplasm of cells taken from colorectal cancer tissue samples. No definite 
explanation for this observation is available, however, it is postulated that due to 
post-translational modification(s), creatine kinase preferentially translocates to the 
nuclear matrix with a resultant low level observed in the cytoplasm. In other 
studies, high creatine kinase levels are observed in cancers of the lung and breast 
(Arenas et al., 1989; Joseph et al., 1997; Zarghami et al., 1996). Also, serum 
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levels of creatine kinase are known to be elevated in cancers of the lung, colon, 
ovary and prostate. Joseph et.al speculates that increased levels of creatine 
kinase observed in the serum of patients with colorectal and lung cancer are 
probably due to enhanced enzyme release due to necrosis of tumour cells (Joseph 
et al., 1997). Creatine kinase would thus seem to be more of a generic marker 
rather than a specific marker for colorectal cancer (Arenas et al., 1989; Mercer and 
Talamo, 1985). The key interest in this enzyme from my point of view is the 
observation that it is closely associated with the nuclear matrix, of which lamins 
A/C are an integral part. This raises the possibility that lamins A/C can potentially 
play a part in nuclear energy metabolic pathways, which could be a unique finding 
if proven true. Also, the prospect of assessing a patient’s serum for CKB levels 
and using this information, in conjunction with nuclear lamin A/C status in the 
colorectal tumour sample, to impart an accurate prognosis can prove a very useful 
tool. Obviously, further studies are needed to confirm this. 
 
T-plastin is a member of the actin bundling protein group and includes L-plastin 
and I-plastin. All three isoforms share between a 70% and 78% homology with 
each other (Delanote et al., 2005). T-plastin is found in epithelial and 
mesenchymal tissue. Neoplastic transformation in these tissues also results in 
synthesis of T-plastin and L-plastin. The actin based cytoskeleton is known to be 
involved in a multitude of functions such as cell interaction, cytokinesis and cell 
migration. Work done by Willis et.al (Willis et al., 2008) reveals an increase in T-
plastin levels with a concomitant decrease in E-cadherin levels, in SW480 cell 
lines transfected with lamin A/C. SW480 cell lines are known to be deficient in 
lamin A/C expression (Willis et al., 2008). Their results show an increase in cell 
motility and invasiveness associated with increased expression of T-plastin and 
decreased expression of E-cadherin in SW480 cells transfected with lamin A/C. E-
cadherin is a well known regulator of adhesive properties in epithelial cells 
(Masciari et al., 2007) and is  a known  downstream target for the BMP signalling 
cascade. E-cadherin has been implicated in many solid tumours such as breast 
and pancreatic cancers (von der Hardt et al., 2007; Zeisberg et al., 2005). 
Significant expression of T-plastin with a decrease in E-cadherin expression in the 
Dukes’ B lamin A/C positive tumour might suggest an adverse prognosis in this 
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group of cancers as the tumour cells may be less adhesive and more invasive with 
a higher likelihood of metastatic spread. Further studies will, of course, be required 
to prove this. 
 
Bone morphogenetic protein 4 (BMP4) is a member of the Transforming Growth 
Factor – Beta (TGF-β) superfamily with more than 20 different BMP isoforms 
having been identified in mammals and Drosophila. In addition to regulating bone 
and cartilage formation, BMPs are also involved in development, morphogenesis, 
chemotaxis, cell proliferation and apoptosis (Leivonen and Kahari, 2007), in a 
diverse range of cells and tissues. BMPs exert their biological effects by binding to 
heteromeric type I / type II receptor complexes, containing serine / threonine 
kinase domains (Chen et al., 2004). Upon BMP binding, the heteromeric complex 
between type I and type II receptors initiate intracellular signalling by 
phosphorylation of Smad1, Smad 5 and Smad 8 (Kretzschmar et al., 1997). These 
phosphorylated Smads in turn associate with Smad 4 and translocate to the 
nucleus where they modulate the transcription of target genes involved in cell 
proliferation, cell differentiation and apoptosis (Balemans and Van Hul, 2002). 
Three different type I BMP receptors have been identified: activin receptor-like 
kinase-2 (ALK- 2), BMP type IA receptor (BMPR-IA)/ALK-3 and BMPR-IB/ALK-6 
(Koenig et al., 1994; Liu et al., 1995; ten Dijke et al., 1994). Three different BMP 
type II receptors have been isolated: BMPR-II, activin type II receptor (ActR-II) and 
ActR-IIB (Liu et al., 1995; Rosenzweig et al., 1995). BMP2 and BMP4 appear to 
only bind to BMPR-IA and BMPR-II receptors. 
Dysregulation of BMP signalling has been linked to various cancers. Involvement 
of the BMP signalling pathway in colorectal cancer was first detected in patients 
with juvenile Polyposis syndrome, in whom a BMPR-IA mutation was noted (Howe 
et al., 2001). Further studies by Hardwick et.al (Hardwick et al., 2004) reveal that 
BMP 2 has an inhibitory effect on normal colonic epithelial growth by promoting 
differentiation and apoptosis and inhibiting cell proliferation. It is not surprising to 
find that inactivation of the TGF-β signalling mechanisms is noted in approximately 
80% of all colorectal cancers (Grady et al., 1998). Interestingly, the expression of 
BMP 4 is elevated in early colorectal cancers but then declines in colorectal 
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cancers that metastasise to lymph nodes or distant organs (Deng et al., 2007). No 
obvious explanation is found for this observation but the implications are that BMP 
4 may help initiate metastasis of colorectal cancer but then has a lesser role in 
maintaining these metastasis. Over expression of BMP 4 has also been shown to 
promote a more invasive phenotype in HCT116 colorectal cancer cell lines. The 
exact mechanisms for this are not clear but it is observed that over expression of 
BMP 4 in HCT116 colorectal cancer cells induces the expression of urokinase 
plasminogen activator (uPA) mRNA and secretion of uPA protein, which is an 
extracellular matrix degrading proteinase. BMP 4 signalling can thus be involved in 
the regulation of uPA activity which may enhance the malignant potential of cancer 
cells by increasing their invasive potential. It has also been observed that BMP 4 
over expression can protect colon cancer cells from apoptotic death under 
stressful conditions (Deng et al., 2007). What interactions do lamin A/C expressing 
colorectal cancer cells have with BMP 4 signalling that confers a poorer prognosis 
in this sub-group, is open to debate. Several intriguing possibilities are noted, as 
mentioned above, but no conclusive evidence is available to establish a definite 
link between BMP 4 signalling and lamin A/C status in colorectal cancer. Further 
work will be needed to explore these observations. 
 
Osteopontin (OPN) is a phosphoglycoprotein, found in the extra-cellular matrix 
and secreted by a number of cells. OPN is known to bind with CD44 and integrin 
receptors (Ding et al., 2002) and is believed to be involved in a number of 
pathological / physiological processes (Sodek et al., 2000). It has been shown to 
play a major role in tumourigenesis, tumour invasion and metastasis in lung, 
breast, prostate and colon cancer (Agrawal et al., 2002; Chambers et al., 1996; 
Thalmann et al., 1999; Tuck et al., 1997). OPN levels are notably elevated in 
tumour samples with high metastatic potential (Craig et al., 1990; Oates et al., 
1996). In addition OPN has also been shown to play a role in cellular processes 
such as adhesion, motility, invasion and angiogenesis, in a diverse range of 
tissues (Hirama et al., 2003; Liaw et al., 1995; Tuck et al., 2003). The increased 
expression of OPN in a variety of cancers, including bowel cancer, has been 
associated with a poorer prognosis (Irby et al., 2004; Rohde et al., 2007). It has 
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been proposed previously that OPN may contribute towards tumour invasion and 
metastasis via an integrin mediated signalling pathway (Irby et al., 2004). 
Rohde et.al (Rohde et al., 2007) has linked OPN over-expression to aberrant Wnt 
signalling in colorectal cancers and has observed a very strong and independent 
association of OPN over-expression with increasing tumour stage, especially liver 
metastasis, and poor survival in patients with colorectal cancer. The molecular 
mechanisms linking OPN to Wnt signalling are not very clear but the observation 
that mitogenic DNA fragments are able to induce OPN expression via TCF4/LEF 
(TCF T-cell factor; Lymphoid enhancer factor) in a breast cancer model, suggest 
that OPN may be a target of the Wnt signalling pathway. The role of OPN in 
colorectal cancer has been studied by other groups and there appears to be a 
common association between increased levels of OPN and advanced tumour 
stage with a subsequent poorer prognosis. 
The reduced expression levels of OPN observed in the Dukes’ B (lamin A/C 
positive) group appear to suggest an early stage tumour since elevated levels of 
OPN are typically associated with higher stage / metastatic tumours. Whether any 
other mechanism(s) exists to explain this decrease in OPN levels in the nuclear 
lamin A/C expressing Dukes’ B tumour sample, is unknown. Further work is 
needed in this direction since OPN appears to be an important marker for 
colorectal cancer progression. 
 
Insulin-like growth factor 2 (Somatomedin A) and insulin-like growth factor 1, 
are known to be important regulators of cell differentiation and growth (Chao and 
D'Amore, 2008) and are structurally similar to insulin. In adult humans, insulin-like 
growth factor 2 (IGF2) is the predominant insulin-like growth factor (IGF) (LeRoith 
and Roberts, 2003) and its altered expression is implicated in many pathological 
conditions (Docquier et al., 2005), including colon cancer (Kaneda and Feinberg, 
2005). In adult humans, IGF2 is found to be the major gene expressed amongst 
the IGFs (LeRoith and Roberts, 2003). The regulation and expression of Igf2 is 
very complex. The gene encoding for IGF2 is found to be imprinted, or expressed 
monoallelically, and active only on the paternally inherited gene (DeChiara et al., 
1991). Loss of imprinting, with resultant over expression of Igf2, is shown to be a 
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fairly common observation in many cancers [reviewed in (Feinberg et al., 2006)], 
including colorectal cancer (Kaneda and Feinberg, 2005). The exact underlying 
mechanisms involved are still not clear but it has been shown that Sonic 
Hedgehog (shh) can transcriptionally activate Igf2 (Ingram et al., 2002). Activation 
of Gli is the last stage involved in shh signalling cascade, resulting in activation of 
key target genes. In mouse models, it is shown that Igf2 is up-regulated in 
mesenchymal cells transfected with Gli1and also points towards a putative binding 
site for Gli1 on the Igf2 promoter (Ingram et al., 2002). Another important 
association is also noted between IGF2 and its ability to up-regulate VEGF, partly 
by indirectly up-regulating HIF (Kim et al., 1998). These associations serve only to 
highlight the importance of IGF2 in tumour development. The striking features 
observed in my experiments are the observation that IGF2 levels are greatly up-
regulated only in the Dukes’ B stage but not the Dukes’ C stage. This is unusual 
as one can expect a continually rising level of IGF2 in advancing tumours. The 
only difference in Dukes’ stage B and C tumours is the spread of tumour to 
surrounding lymph nodes. Upon a literature search I cannot find any studies 
comparing IGF2 levels to increasing tumour stage in colorectal cancer. If IGF2 
levels are genuinely increased only in Dukes’ B tumours then the implications of 
this may have significant bearing on our understanding of colorectal cancer 
pathogenesis. It might imply a defining moment in the tumours capacity to spread 
or metastasize to other areas. Obviously, further work is needed to confirm this 
and to clarify any other possible explanation(s) for this observation. 
 
Fatty acid binding protein 1 (liver) belongs to a group of low molecular weight 
proteins mostly involved in transport of fatty acids and other lipophilic substances 
between extracellular and intracellular membranes. Its gene location is mapped 
out on chromosome 2. These proteins are known to play a key role in the 
intracellular compartmentalisation of long chain fatty acids, thereby enhancing 
their cellular uptake and further processing (Storch and Thumser, 2000). Fatty acid 
binding proteins are known to play an active role in fatty acid mediated signal 
transduction pathways and regulation of gene expression (Hertzel and Bernlohr, 
1998) and consequently their active role in modulating cell division (Sorof, 1994), 
cell growth and differentiation (Schroeder et al., 2001). Given their diverse role(s) 
297 | P a g e  
 
in various physiological functions and their altered expression in various cancers, it 
is proposed that fatty acid binding proteins might play a role in tumourigenesis 
(Jing et al., 2000). The role of fatty acid binding protein 1, found in the liver, is 
further explored by Lawrie et.al (Lawrie et al., 2004). Their team conclude that fatty 
acid binding protein 1 is greatly decreased in colorectal cancers, especially at the 
adenoma stage of tumour development. My own observations from the microarray 
experiments do not coincide with their observations. However, the level of fatty 
acid binding protein 1 is greatly up-regulated in the Dukes’ B, lamin A/C positive 
group and this can be interpreted in different ways. Lamin A/C is a known marker 
for differentiation and is expressed predominantly in the differentiated 
compartment of the colonic crypts; the same area of expression is also noted for 
fatty acid binding protein 1. It might be feasible to propose then that the presence 
of lamin A/C in colorectal tumours imposes a more differentiated phenotype thus 
preserving the expression of fatty acid binding protein 1 in these tissues. After a 
literature search, no definite explanation can be found for this observation though 
and further experimental work would be needed to clarify this. 
4.5 Summary 
 
This comparative microarray study has shown clearly the differences existing 
between two tumours that were classed as Dukes’ B with similar grading. Both 
patients from whom these samples were obtained would have had the same 
treatment and follow up. The patient expressing lamin A/C in his / her tumour 
would have had a higher likelihood of mortality as compared with the patient not 
expressing lamin A/C (Willis et al., 2008). The explanation for this observed 
increase in mortality associated with lamin A/C expression is difficult to explain, 
but in vitro work done by Dr Willis et al (2008) reveals a possible mechanism of 
action to explain the poor outcome associated with lamin A/C expression. Firstly, 
cells expressing lamin A/C are more motile / less adherent and so can spread with 
ease. Secondly, cells expressing lamin A/C have potentially a more stem cell like 
phenotype. My own observations support those made by Dr Willis et.al. 
Furthermore, I have identified genes and certain pathways that might explain why 
lamin A/C expressing tumours are more motile and thereby impart an adverse 
prognosis. Obviously further experimental work is needed to find the missing links 
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and map out in detail various signalling pathways through which lamin A/C 
expressing colorectal cancers may act to impart a poorer prognosis and potentially 
identify therapeutic targets and / or further prognostic markers. 
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CHAPTER 5 
General Discussion 
 
5.1 Background to this project 
 
The role of non-functional A-type lamins and their binding partners in tissue 
specific diseases is well established and observed in tissue-specific familial 
disorders such as autosomal inherited Emery-Dreifuss  Muscular Dystrophy, 
Dilated Cardiomyopathy type-1A, Dunnigan type—Familial Partial Lipodystrophy, 
Mandibulosacral Dysplasia, Hutchinson-Gilford progeria and Charcot-Marie-Tooth 
type-2B1 (De Sandre-Giovannoli, 2003 #1783;Bonne, 1999 #268;Fatkin, 1999 
#1577;Hegele, 2000 #583;Hegele, 2000 #582;Raffaele Di Barletta, 2000 #956;De 
Sandre-Giovannoli, 2002 #1582;Novelli, 2002 #897). Mutations in the lamin A 
binding region of Emerin also gives rise to an X-linked form of Emery-Dreifuss 
Muscular Dystrophy (Bione et al., 1994; Lee et al., 2001). Altered expression and 
distribution of A-type lamins has also been reported in a growing number of 
neoplasms affecting epithelial, mesenchymal and lymphoid lineages. These 
observations highlight the importance of A-type lamins and their binding partners 
in the regulation of growth pathways and their possible link(s) with tumour 
progression. In the UK, colorectal cancer is the second most common cause of 
death after lung cancer. In this thesis an attempt has been made to explore the 
role of A-type lamins and their binding partners in normal colonic mucosa and at 
various stages of colorectal cancer. 
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5.2 Expression of A-type lamins and their binding 
partners in normal colonic mucosa 
 
5.2.1 Expression of A-Type Lamins in normal colonic 
/ rectal mucosa 
 
The expression and distribution profile of A-type lamins (lamins A and C), and their 
binding partners LAP2α and Emerin, in the colon and rectum is assessed using 
standard immunohistochemical techniques, with emphasis being placed on the 
orientation of tissue samples, in order to maximise complete crypt profile studies. 
The observed distribution of A-type lamins is, as expected, in the differentiated 
compartment of the crypt, specifically in the upper third. Here A-type lamins are 
predominantly expressed at the nuclear periphery with some heterogeneous 
intranuclear distribution of A-type lamins also being noted. The expression of A-
type lamins is noted to follow a gradient with increasing expression towards the 
luminal surface. This is in keeping with increasing differentiation of these cells as 
confirmed by decreasing / absence of PCNA, a marker for proliferating cells in 
these areas. In the lower two thirds of the crypt, except the basal zone, lamin A/C 
expression is virtually absent with concomitant high expression of PCNA, 
indicating active proliferation of cells in this region.  
The switch from proliferation to differentiation is a complex area with many factors 
involved in its regulation, many of which are unknown. However, Wnt signalling 
pathways are known to play a key role in maintaining this proliferative zone. After 
asymmetric division of stem cells at the base of the crypt, the daughter cells, under 
the influence of Wnt signals arising from mesenchymal cells, enter into a phase of 
rapid proliferation. These Wnt factors are known to activate β-catenin and lead to 
activation of Tcf/Lef transcription factors, namely Tcf-4 in the colon. These in turn 
result in transactivation of downstream target genes such as c-MYC, CCND1, 
MMP7, CD44, PLAUR and PPARD (Jo and Chung, 2005). These downstream 
targets are typically associated with initiating and driving cellular proliferation, for 
example c-MYC which represses the cell cycle inhibitor p21 CIP1/WAF1 and allows 
cells to leave G1 and enter S phase of the cell cycle. It would thus seem that β-
catenin/Tcf-4 driven gene transcription is the major regulator driving the 
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proliferating progenitor population in the lower two thirds of the crypt and is 
responsible for maintaining the crypt villus axis and replenishing the continual 
turnover of differentiated cells at the crypt lumen (van de Wetering et al., 1997; 
van de Wetering et al., 2002). Since Wnt signalling appears to be switched off 
higher up the crypt, in the differentiated zone, it appears to play a key role in the 
proliferation/differentiation switch associated with crypt regeneration. The study of 
Eph-receptors and epherins in the intestine has shed further light into the actual 
mechanisms involved in separating proliferating cells from differentiated cells and 
in cell positioning along the crypt axis. The Eph family of receptors are known to 
represent the largest known subfamily of receptor tyrosine kinases (Tuzi and 
Gullick, 1994). Based on their ligand binding specificity, Eph receptors are divided 
into two groups, EphA receptors, binding A-type epherins, and EphB receptors 
binding B-type epherins (Frisen et al., 1999). The Eph – epherin interactions are 
known to be important in development, especially in cell to cell interactions, which 
frequently results in repulsion forces between cells. The role of Eph-receptors and 
epherins in determining cell position along the crypt axis is highlighted in 
experiments done by Batlle et al 2002 (Batlle et al., 2002). These studies reveal 
the inverse relationship associated with β-catenin/TCF signalling and 
EphB/Epherin B in cell positioning in the intestine. They also show a reciprocal 
gradient of epherin B to that of β-catenin/TCF signalling i.e. the concentration of 
epherin B is maximal at the mucosal surface and decreases further down the 
crypt. These studies also demonstrate loss of cell positioning along the crypt axis 
and intermingling of differentiated cells with proliferating cells in the crypts of mice 
with mutations involving EphB receptors. Work done by Holmberg et.al (Holmberg 
et al., 2006) has focused on intestinal stem cells and they were able to identify 
EphB receptors as major regulators of proliferation in the intestinal stem cell niche. 
In addition Holmberg et.al demonstrated EphB kinase-dependant signalling in the 
intestine promoting cell-cycle re-entry and extending the proliferative domain in 
crypts. However, a complete picture as to the exact underlying mechanisms 
involved in this switch from proliferation to differentiation, is still not clear. The role 
of A-type lamins in this setting and whether it has any bearing on influencing this 
switch from proliferation to differentiation is still obscure, and at best, hypothetical. 
However, with cell cycle arrest, indicating a halt to proliferation and differentiation 
setting in, it is no surprise to find A-type lamins being expressed in this setting. 
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There is however an unusual expression of lamin A, but not lamin C, at the base of 
the crypts in the colon / rectum mucosa, in an area known to harbour the stem cell 
niche. An explanation for this observation is not available as there are no previous 
studies done in this area with which I can compare my findings. Can lamin A be 
expressed in adult stem cells of the colon crypt? From my observations, this 
appears to be very plausible based on: 
 Firstly, the anatomical location and cell numbers exhibiting expression of 
lamin A in the basal regions of the crypts corresponds with studies that 
identify stem cells in these locations. 
 Secondly, adult stem cells are not, in the strictest sense, fully 
undifferentiated cells as is the case with embryonic stem cells, and so one 
can argue that these cells have taken the first step(s) towards 
differentiation and in the process of doing so they can potentially exhibit 
markers of differentiation, such as lamin A. 
Also, it is well known that A-type lamins are completely disassembled during cell 
division and reassembled afterwards in the new daughter cells. In case of the 
proliferating compartment of the crypts in colonic mucosa, the Wnt signalling 
pathway has always been assumed to follow a concentration gradient with 
maximum concentration at the basal regions of the crypts with progressively 
decreasing expression levels further up the crypt until the concentration of Wnt 
signals gets so weak that it can no longer exert its proliferative effects on crypt 
cells. At this stage then, cells are known to undergo cell cycle arrest and terminally 
differentiate prior to undergoing apoptosis at the luminal surface and being shed. 
The current explanation for the role of Wnt signalling in preventing differentiation, 
and subsequently expression of A-type lamins in proliferating cells of crypt, are 
well known and relate to the transactivation of  downstream target genes which 
result in cellular proliferation by different mechanisms, including inhibition of cell 
cycle inhibitors, as mentioned earlier. Why then is lamin A being expressed in a 
handful of cells at the basal regions of the crypts, in the putative stem cell niche 
area, where the expression of Wnt signals is supposed to be at its maximum? 
What is protecting these cells from the influence of Wnt signals? Can the presence 
of lamin A in these cells confer a protective effect from Wnt signals? If so what are 
the underlying molecular mechanisms for this? Can A-type lamins in conjunction 
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with Emerin be responsible for this effect by inhibiting the entry of β-catenin into 
these putative stem cells and thereby blocking the proliferative effects of Wnt 
signalling? These questions and many more are difficult to answer at this stage. It 
is felt however that A-type lamins in some way have an important role to play in 
preserving the ‘Stemness’ of these putative stem cells in the basal regions of the 
intestinal crypts. Future studies into this area will hopefully clarify this picture and 
probably highlight in greater detail the role of A-type lamins in adult stem cells of 
the colon. 
 
5.2.2 Expression of Emerin in normal colonic / rectal 
mucosa 
 
The expression of Emerin in crypts of the colonic / rectal mucosa reveal an 
expression pattern similar to that of A-type lamins, but with a few notable 
differences. In the basal regions of the crypts, at the putative stem cell niche area, 
Emerin is strongly expressed in the nuclear area; however, heterogeneous intra-
cytoplasmic expression is also noted which is in contrast to A-type lamin 
expression in this area. In the proliferative zone of the crypts, Emerin expression is 
greatly reduced and only small traces of this protein are noted in the cytoplasm. 
This expression profile changes higher up the crypt axis, in the differentiated zone, 
where Emerin expression once again becomes evident in the nuclear area in 
addition to heterogeneous intra-cytoplasmic expression. Significant expression of 
Emerin in the nuclear area is also observed in cells making up the muscularis 
mucosae however, expression of Emerin in cells making up the surrounding 
mesenchyme is predominantly cytoplasmic with only a few cells expressing 
Emerin in the nucleus. It would appear that Emerin and A-type lamins follow a very 
similar pattern of expression in crypts located in the colon / rectal mucosa and the 
main difference(s) in expression between each is related to greater intra-
cytoplasmic expression of Emerin in corresponding cells. 
Emerin is a type II integral membrane protein of the inner nuclear membrane 
(INM) belonging to the ‘LEM-domain’ family of nuclear proteins. The localisation of 
Emerin at the INM is through its association with A-type lamins, type V 
304 | P a g e  
 
intermediate filament proteins, (Sullivan et al., 1999; Vaughan et al., 2001), which 
form part of the nuclear lamina (Hutchison, 2002). Emerin on its own is 
dispensable for cell survival (Harborth et al., 2001) and normal development 
(Gruenbaum et al., 2002), but has overlapping functions in cell division and 
chromosome segregation with the INM protein MAN1 (Liu et al., 2003), another 
LEM-protein. Other family members of LEM-proteins include otefin, Lem-3 and 
SANE (Cohen et al., 2001; Dechat et al., 2000b; Lin et al., 2000; Raju et al., 2003). 
The LEM-domains of Emerin and LAP2β are known to bind with Barrier-to-
Autointegration Factor (BAF), a highly conserved chromatin protein essential for 
the viability of dividing cells (Zheng et al., 2000). BAF is known to bind DNA, has 
structural roles during nuclear assembly and dictates higher order chromatin 
structure via unknown mechanisms (Segura-Totten et al., 2002; Zheng et al., 
2000). BAF also represses gene expression by inhibiting transcription activators 
(Wang et al., 2002). The central region of Emerin is essential for binding lamin A 
(Lee et al., 2001; Vaughan et al., 2001) and this coupled with distinct binding 
regions for BAF and lamins on LAP2β (Foisner and Gerace, 1993; Shumaker et 
al., 2001), suggest that BAF links chromatin directly to membrane anchored LEM-
proteins and indirectly to lamins. In addition, Emerin is also shown to interact with 
GCL (germ-cell-less) a gene regulatory protein that is known to repress E2F-DP 
regulated genes (Holaska et al., 2003). The binding site for GCL is mapped to two 
regions in Emerin that overlaps proposed binding regions for BAF and lamin A. 
Interestingly, competition assays demonstrate that Emerin forms stable tertiary 
complexes with either lamin A plus BAF, or lamin A plus GCL. However, Emerin 
cannot bind simultaneously to both GCL and BAF and BAF’s estimated 
concentration at the NE (nuclear envelope) can be sufficient to inhibit GCL binding 
(Holaska et al., 2003). Emerin is also known to bind two other proteins implicated 
in gene expression: Btf and YT521-B (Wilkinson et al., 2003). YT521-B is involved 
in selecting sites for alternative mRNA splicing and Emerin influences this splice 
site selection. Btf is a known transcription repressor that induces cell death when 
over-expressed (Kasof et al., 1999). It is speculated that Emerin sequesters Btf 
and, thus, suppresses apoptosis (Tzur et al., 2002). The aforementioned roles of 
Emerin imply strongly that Emerin plays a significant role directly or indirectly in 
transcription regulation. 
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No studies are available to indicate what role Emerin plays in homeostasis of 
crypts from colonic / rectal mucosa. In this regards, my study is unique. Work done 
by Markiewicz et.al (Markiewicz et al., 2006) in human fibroblasts has shed light 
on the interaction between Emerin and β-catenin. Studies by Markiewicz et.al 
(2006) has shown that Emerin interacts with β-catenin through a C-terminal APC-
like domain. They show that over-expression of Emerin inhibits β-catenin signalling 
by preventing its nuclear accumulation. In contrast, expression of a mutant form of 
Emerin that lacks the β-catenin-binding domain dominantly stimulates β-catenin 
accumulation in the nucleus and its signalling potential. The underlying 
mechanism(s) are unclear; however, Emerin appears to act by stimulating the 
export of β-catenin from the nucleus. They also show that correct localisation of 
Emerin at the INM is necessary for its influence on nuclear accumulation of β-
catenin. These findings are of great significance to my work since I have 
demonstrated the presence of Emerin in the nuclear area in differentiated cells 
and its absence in proliferating cells of the crypt. Also, cells at the putative stem 
cell niche area only express lamin A and, from previous studies, it is known that 
Emerin binds preferentially to lamin A (Lee et al., 2001; Vaughan et al., 2001). It is 
plausible that Emerin in conjunction with lamin A and other unknown factors can 
be responsible for maintaining the stem cell niche in crypts of the colon / rectal 
mucosa. This can be achieved by increased shuttling of β-catenin out of the 
nucleus and thereby protecting stem cells from the proliferative effects of β-catenin 
and hence the Wnt signalling cascade. The prospect of Emerin playing a 
significant role in stem cell signalling could add another dimension to the functional 
role(s) of Emerin. 
 
5.2.3 Expression of LAP2α in normal colonic / rectal 
mucosa 
 
LAP2α is expressed in the majority of cells involved in the crypt. However, the 
distribution of LAP2α is not uniform at various sites in the crypt. In the basal 
regions of the crypt, corresponding to the putative stem cell niche area, LAP2α is 
distributed in a heterogeneous manner in the nucleoplasm and cytoplasm. In the 
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proliferative compartment of the crypt, the expression of LAP2α is mostly 
cytoplasmic with a granular appearance. Interestingly, LAP2α exhibits a 
concentration gradient in this zone with gradually increasing levels of expression in 
the cytoplasm being observed higher up along the crypt axis. In the differentiated 
zone of the crypt, the expression of LAP2α is again noted in the nuclear area with 
maximal concentration levels being observed in cells lining the mucosal surfaces 
of the crypts. In addition, LAP2α is also expressed in a heterogeneous distribution 
in the nucleoplasm and cytoplasm of these same cells. A striking difference 
between the expression of LAP2α and Emerin in the crypts is the complete 
absence of LAP2α expression in cells making up the muscularis mucosae. Cells 
making up the mesenchyme surrounding each crypt also exhibit LAP2α 
expression in the nuclear area with heterogeneous nucleoplasmic and cytoplasmic 
expression but this expression is in a patchy distribution. 
Lamina associated polypeptides (LAPs) are known to form part of the integral 
membrane family of proteins at the inner nuclear membrane. In mammalian cells, 
three lamina associated polypeptides have been characterised in detail: LAP 1, 
LAP 2 and a protein called the lamin B receptor (LBR) (Gerace and Foisner, 
1994). LBR and LAP2 are known to preferentially interact with lamin B while LAP1 
interacts with both lamin A and B types (Foisner and Gerace, 1993). The LAP2 
family members are known to comprise six alternatively spliced proteins; four of 
these are type II membrane proteins: LAP2 β, -δ, -γ and –ε (Berger et al., 1996) 
that bind lamin B. LAP2α is different, both structurally and functionally as it shares 
only its N-terminus with the other isoforms and has a distinct C-terminus. It also 
lacks an apparent transmembrane binding domain (Harris et al., 1995). The 
distribution of LAP2α in cells is throughout the nucleus rather than the nuclear 
envelope (Dechat et al., 1998; Dechat et al., 2000a; Vlcek et al., 1999). LAP2α is a 
well known specific binding partner of nucleoplasmic A-type lamins (Dechat et al., 
2000a). At their N-terminus, LAP2 proteins share a LEM (LAP2, Emerin and 
MAN1) domain (Lin et al., 2000), which binds to BAF (barrier-to-autointegration-
factor), an essential, highly conserved DNA-binding protein in eukaryotes (Segura-
Totten and Wilson, 2004). Based on these interactions, LEM domain proteins in 
the nuclear lamina and the nuclear interior have been implicated in chromatin 
organisation (Dechat et al., 2004; Segura-Totten and Wilson, 2004). In addition, 
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LAP2α interacts with chromosomes via its α-specific C-terminal domain in a 
phosphorylation dependant manner (Dechat et al., 2004; Vlcek et al., 1999). Over-
expression of C-terminal fragments of LAP2α are shown to dominantly inhibit 
assembly of endogenous LAP2α, nuclear membranes and A-type lamins in in-vitro 
nuclear assembly assays and to cause-cell cycle arrest at interphase, indicating a 
role for LAP2α in cell cycle progression (Vlcek et al., 2002). 
The retinoblastoma protein (Rb) is known to regulate the activity of E2F 
transcription factors, which in turn are responsible for controlling the expression of 
cell cycle regulatory genes (Classon et al., 2000; Frolov and Dyson, 2004). In non-
cycling cells, Rb is hypophosphorylated and thereby active as a transcriptional 
repressor by binding to and inhibiting E2F transcription factors. A-type lamins and 
LAP2α complexes are known to bind with the C-terminal nuclear anchorage 
domain of Rb and keep it hypophosphorylated, resulting in repression of E2F 
(Dorner et al., 2006; Mancini et al., 1994; Markiewicz et al., 2002; Ozaki et al., 
1994). Rb has been shown to be essential for the differentiation of various tissues, 
including skeletal muscle and adipocytes (Hansen et al., 2004; Huh et al., 2004) 
by maintaining a balance between initiation and differentiation in adult stem cells 
(Classon et al., 2000). Adult stem cells are known not to proliferate; instead, they 
enter the cell cycle upon specific signals to self propagate and maintain a stable 
population of adult stem cells in the tissue. At the same time, they are also known 
to differentiate and regenerate damaged tissue or maintain a basic turnover of 
differentiated cells (Wagers and Weissman, 2004). Lap2α and A-type lamins are 
known to be essential co-factors of RB in maintaining the balance between 
proliferation and differentiation in adult stem cells (Dorner et al., 2006). Given the 
expression profiles of A-type lamins and LAP2α in the crypts of the colon / rectal 
mucosa, it is plausible that LAP2α might play a significant role in the stem cell 
niche and also in differentiation of colonocytes along the crypt axis. In support of 
this view, proliferating cells in the lower third of the crypts do not exhibit any 
significant expression of LAP2α in the nucleoplasm of the cells. The exact 
mechanisms underlying the observed expression profile of LAP2α in the crypts is 
still not clear and probably multiple signalling pathways are involved; however, the 
close link between LAP2α and A-type lamin expression in the nuclei of 
differentiated cells and of the putative stem cells could support the view that, in 
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addition to other well documented pathways involved in crypt homeostasis, LAP2α 
in association with A-type lamins might play a significant role in maintaining the 
crypt profile via the retinoblastoma-E2F pathway. 
 
5.2.4 Expression of β-catenin in normal colonic / 
rectal mucosa 
 
In the crypts of the colon, the expression profile of total β-catenin exhibits certain 
interesting features. At the basal region of the crypt, in the putative stem cell niche 
area, significant expression of total β-catenin is noted in the nuclear area in 
addition to cytoplasmic expression. In the proliferative compartment of the crypt, 
total β-catenin expression is observed in the nuclear area and cytoplasm of cells 
but nucleoplasmic expression has diminished considerably. A further change in 
expression of total β-catenin is then observed in cells making up the differentiated 
compartment of the crypt. In these differentiated cells, total β-catenin is 
predominantly expressed in the cytoplasm with an increased concentration being 
observed at the inter-cellular junctions. 
β-catenin plays a central role in the canonical Wnt signalling pathway, which is 
considered to be the most significant regulator of normal crypt homeostasis and 
colorectal cancer development (Pinto and Clevers, 2005b; van de Wetering et al., 
2002). In the absence of a Wnt signal, members of the T-cell factor / lymphoid 
enhancing factor (TCF/LEF) family of transcription factors are bound to the 
transcriptional repressor Groucho (Cavallo et al., 1998). Active beta catenin is 
known to directly associate with TCF/LEF factors and overcome this repression 
imposed by Groucho, thereby transactivating the transcription of downstream 
targets (van de Wetering et al., 1997). TCF-4 is a member of the TCF/LEF family 
and is highly expressed in cells forming the epithelial layer of the colon. It forms 
functionally active complexes with beta catenin (Korinek et al., 1997) which in turn 
are the principal governors of cell dynamics at the crypt villous junction, preserving 
a stem cell and proliferating progenitor population in the lower crypt region. This is 
essential for ensuring an orderly turnover of differentiated cells at the luminal 
surface (van de Wetering et al., 2002). Inhibition of the β-catenin/TCF-4 complex 
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(van de Wetering et al., 2002) has been shown to result in the following: Firstly – a 
concomitant G1 arrest. Secondly – a down-regulation of intestinal markers of 
proliferation such as c-MYC, EPHB2, c-MYB, BMP4, ENC1, CD44 and CLDN1, 
known to be expressed in the proliferative compartment of normal crypts, and 
thirdly – an up-regulation of differentiation markers such as FABP1 (fatty acid 
binding protein 1), CA2 (carbonic anhydrase II) and importantly p21CIP1/WAF1. c-
MYC, a well known oncogene responsible for pushing cells from G0 to S-phase of 
the cell cycle, appears to be one of the most important down-stream targets of the 
β-catenin/TCF-4 complex (He et al., 1998; Oster et al., 2002). In essence then, β-
catenin/TCF-4 complexes appear to maintain a progenitor / stem cell phenotype in 
intestinal crypts through c-MYC mediated repression of the cell cycle inhibitor 
p21CIP1/WAF1. Wnt signals are absent in the differentiated compartment of the crypt, 
resulting in β-catenin being exported from the nucleus by APC and sequestered 
for removal by the degradation complex. Activation of c-MYC also occurs in this 
zone resulting in p21CIP1/WAF1 being induced which facilitates cell cycle arrest and 
differentiation (van de Wetering et al., 2002). After a literature search, no direct 
role for A-type lamins in the Wnt signalling pathway has been observed, up to 
date. From my observations, the expression profile of Lamin A/C and β-catenin in 
the proliferation and differentiation regions of the crypt appears to be in keeping 
with their known functions. However, at the base of the crypt a very interesting 
picture is emerging. Both A-type lamins and β-catenin are being expressed in the 
nuclear area with β-catenin also being expressed in the cytoplasm of these cells 
located in the stem cell niche area. It appears that stem cells are expressing both 
lamin A/C and total β-catenin and yet are not actively proliferating, as evidenced 
by the lack of PCNA (a well known marker of proliferation), nor are they known to 
be fully differentiated. It is difficult to explain this observation; however, it appears 
that A-type lamins are somehow preventing the effects of β-catenin on the nuclear 
machinery by limiting its movement across the nuclear envelope and hence the 
observations mentioned earlier. Also, it is well known that stem cells are able 
divide asymmetrically and give rise to another stem cell and a daughter cell that 
then undergoes rapid proliferation prior to terminal differentiation in the crypt. In 
addition, stem cells are also known to divide symmetrically and give rise to two 
adult stem cells which can then restore the total numbers of adult stem cells 
making up the niche. The exact factors and signalling pathways controlling both 
310 | P a g e  
 
types of cell division in adult stem cells are not yet known. At this stage I can only 
hypothesise about the role(s) of lamin A/C and β-catenin in stem cells, for 
example; could the presence of lamin A/C in adult stem cells protect them from the 
effects of β-catenin at a nuclear level and help in maintaining an adult stem cell 
phenotype at this location? Are there as yet undiscovered pathways that could link 
lamin A/C with the Wnt signalling pathway directly? The answers to these 
questions and many more require further work in this direction. 
   
5.3 Expression of A-type lamins in colorectal 
cancer 
 
The expression profile of A-type lamins in various stages of colorectal neoplasia 
was studied in a cohort of forty two patients. Tumour samples from all stages of 
colorectal neoplasia, including polyps, were studied using standard 
immunohistochemical techniques. Although the sample size is not large enough to 
make any definite conclusions, certain observations are intriguing: 
 Variable expression of A-type lamins is noted in colorectal cancer 
specimens ranging from very strong nuclear area expression of A-type 
lamins to virtually no expression in the nucleus.  
 This variation is not limited to cancer stage or differentiation status. 
 Irrespective of nuclear area expression, the cells making the mesenchyme 
and lamina propria, exhibit strong expression of A-type lamins in the 
nucleus. 
Given that A-type lamins are well known as markers for differentiation, the natural 
tendency is to assume that cancers expressing A-type lamins are more 
differentiated as compared to other cancers of a similar stage not expressing A-
type lamins. However, this proves not to be case since well differentiated cancers 
(defined by using standard histo-pathological criteria) are found to be lacking 
expression of A-type lamins and vice versa. 
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The expression of nuclear lamins has previously been studied most extensively in 
lung cancer (Broers and Ramaekers, 1994; Broers et al., 1993; Kaufmann et al., 
1991) and keratinocytic tumours of the skin (Oguchi et al., 2002; Venables et al., 
2001), but other studies have also focussed on acute lymphoblastic leukaemia, 
non-Hodgkin’s lymphoma, (Prokocimer et al., 2006; Stadelmann et al., 1990; Wu 
et al., 2009), gastric cancer (Wu et al., 2009) and colorectal cancer (Cance et al., 
1992; Moss et al., 1999; Prokocimer et al., 2006; Willis et al., 2008).  
The transcriptional and post-transcriptional regulation of A-type lamins has also 
been reported previously. Broers et.al (Broers et al., 1993) demonstrate a 
decrease in lamin A and C mRNA levels accompanied down-regulation of protein 
expression in two small cell lung cancer (SCLC) cell lines. Work by Machiels et.al 
(Machiels et al., 1995) demonstrates preferential repression of lamin A protein 
expression relative to lamin C in a human lung adenocarcinoma cell line and 
ascribe this imbalance to a reduction in the amount of lamin A transcript. Equally, 
up-regulation of lamin A/C protein expression can be reflected in mRNA levels. 
Expression of the mutant v-Ha-ras oncogene in a SCLC cell line induces a 10 fold 
increase in lamin A/C protein levels which are accompanied by elevation in the 
corresponding mRNA species (Kaufmann et al., 1991). Post transcriptional 
mechanisms by which lamin A expression might be abrogated but lamin C 
unaffected have been described in a study on the premature ageing disease 
Hutchinson-Gilford progeria syndrome. De novo point mutations in the lamin A-
specific tail domain are thought to prevent complete processing of prelamin A, 
while lamin C is processed as normal (Eriksson et al., 2003). 
A decrease in the expression of A-type lamins has previously been reported in 
colorectal cancer by Moss et.al (Moss et al., 1999), but they do not distinguish 
between individual A-type lamin polypeptides. The first evidence of a differential 
relationship between lamins A and C in tumours is described by Venables et.al 
(Venables et al., 2001). They report a mutually exclusive pattern of lamin A and 
Ki67 expression in basal cell cancers (BCC) of the skin and correlate loss of lamin 
A with rapidly proliferating tumours. However, further studies by Willis et.al (2005), 
using in vitro studies, demonstrate no correlation between lamin A expression and 
growth rate or proliferation and are therefore not consistent with the observations 
made by Venables et.al (Venables et al., 2001). 
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A complex relationship between lamin A/C expression and cellular proliferation / 
differentiation has emerged. A decrease in A-type lamin levels has been correlated 
with proliferation in Swiss 3T3 murine fibroblasts (Pugh et al., 1997). Similarly 
lamin A/C expression has been inversely correlated with proliferation in lung 
tumours (Coates et al., 1996; Rowlands et al., 1994). However, many groups have 
reported a coincident appearance of lamin A/C during tissue and cellular 
differentiation, whereas at least one B-type lamin is always expressed (Lebel et 
al., 1987; Paulin-Levasseur et al., 1989; Rober et al., 1989; Stewart and Burke, 
1987). Further to the work by Venables et.al (Venables et al., 2001) on BCC, 
Oguchi et.al (Oguchi et al., 2002) have examined a range of keratinocytic tumours 
of the skin and report the greatest reduction in lamin A/C in poorly differentiated 
tumours. Tilli et.al (Tilli et al., 2003) also come to the conclusion that A-type lamin 
expression is strongly associated with well-differentiated tumours, but that it does 
not follow that these cells possess no proliferative capacity. They observe 
simultaneous expression of lamin A/C and Ki67 in approximately 50% of the 
proliferating cells in BCC and Squamous cell cancer (SCC) of the skin. 
In general these investigations have reported down regulation of A-type lamins in 
association with increased proliferation and a strong association of A-type lamins 
with increasing differentiation of tumours. These studies have provided significant 
insight into the role(s) A-type lamins might play in the development and 
progression of cancer. However, there is still controversy about the exact role of A-
type lamins in colorectal cancer due to the contradictory findings related to A-type 
lamin expression in colorectal tumours. Attempts to link changes in expression to 
patient prognosis or directly to tumour progression result in conflicting results 
between different groups (Cance et al., 1992; Moss et al., 1999; Willis et al., 
2008). 
Recently, Willis et.al (Willis et al., 2008), have described an adverse outcome in a 
group of patients with colorectal cancer expressing lamin A/C. Their study involves 
656 patients taking part in the Netherlands Cohort Study on Diet and Cancer (van 
den Brandt et al., 1990). Willis et.al (Willis et al., 2008). They are able to 
demonstrate clearly that patients expressing A-type lamins in their colorectal 
tumour are almost twice as likely to die from colorectal cancer related causes as 
compared to clinicopathologically identical patients that do not express A-type 
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lamins in their tumours. Their studies have linked this adverse outcome to 
increased motility and invasiveness in colorectal cancer cells expressing lamin 
A/C. They also propose that colorectal cancers exhibiting A-type lamins in their 
cells might be a reflection of these cells acquiring a more stem cell like phenotype. 
 
5.4 Comparative microarray analysis of various 
stages involved in colorectal cancer 
 
Previous studies, apart from that carried out by Willis et.al (Willis et al., 2008), 
have all hinted towards A-type lamins being associated with increasing 
differentiation in tumours from various regions of the body and thereby implying a 
better prognosis in these patients exhibiting A-type lamins in their tumours. My 
own findings are not in keeping with these previous observations. To try and clarify 
the role of A-type lamins in colorectal cancer, I carried out a comparative 
microarray analysis comparing various stages of colorectal cancer tumours. To 
this end the Affymetrix Gene Chip® was used for the microarray experiment. 
Microarray data obtained in this manner does have its limitations and needs to be 
interpreted with caution. To obtain meaningful results from a microarray 
experiment one has to pay particular attention to the experimental design and the 
statistical methods used for interpreting the results. A good experimental design 
will minimise variance. Variance can arise from multiple areas, including RNA 
handling and isolation, chip to chip variability, hybridization conditions, sample to 
sample differences, etc (Pan et al., 2007). A reduction in variance is achieved by 
using multiple biological replicates and multiple arrays which can then allow for 
appropriate calibration, also known as normalisation (Huber et al., 2002). The ratio 
of these calibrated intensities is also known as the ‘Fold Change’ and is a useful 
way of quantifying transcript abundance. In replicate microarray studies, the 
variance for measured spot intensities increases with their mean and hence the 
need for biological and array replicate studies. Appropriate use of statistical 
methods in microarray data analysis is another crucial area. To validate all 
significant genes thus identified by RT-PCR or Northern Blot analysis is prohibitive 
and impractical and hence some form of multiple testing correction needs to be 
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applied, typically Bonferroni (very stringent) or Benjamani-Hochberg. This will 
control the false discovery rate (FDR). In reality, FDR is not widely used and could 
explain why so many array studies have results that cannot be reproduced (Pan et 
al., 2007). The lack of biological and array replicates in my experiments are areas 
of potential contention with the results I have described. Also, the statistical 
methods used to analyse the data are not stringent enough to allow a very high 
degree of confidence in the results. Subsequently, there is some minor lack of 
correlation between the microarray data and the RT-PCR data used to validate the 
results from the microarray studies. On a plus note, the Affymetrix Genechip® has 
about a hundred so called ‘house keeping’ genes that help keep variance down to 
a minimum and are useful indicators to this effect. Ideally I would have used array 
data from normal tissue samples as a base line against which various comparative 
studies would be carried out, unfortunately, the quality of RNA from the normal 
samples was poor and hence a decision was taken to use only tumour samples for 
the microarray study. Despite these drawbacks to my experiments, it was felt that 
useful information could be obtained from the selected tumour samples. 
From a clinical point of view, there has always been controversy about managing 
patients with a Dukes’ B adenocarcinoma since there are no clear prognostic 
indicators to identify which patients are at high risk of an adverse outcome from 
their cancer and thereby require adjuvant treatment to decrease this risk. The 
mainstay of treatment for Dukes’ A cancers is surgery alone and for Dukes’ C 
patients, either neo-adjuvant or adjuvant treatment in addition to surgery. The 
identification of a genuine prognostic indicator, especially in Dukes’ B 
adenocarcinomas, will greatly aid in the decision making policy for treatment in 
these patients. Initially, a comparative analysis between three tumour samples of 
different stages, and all exhibiting no nuclear lamin A/C expression, was 
assessed. This was then followed by a comparative microarray analysis of two 
Dukes’ B adenocarcinoma samples, one with strong nuclear expression of lamin 
A/C and the other with complete absence of nuclear expression of lamin A/C.  
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5.4.1 Comparative microarray analysis between a 
tubulo-villous adenoma, a Dukes’ B and Dukes’ C 
adenocarcinoma, all lacking nuclear lamin A/C 
expression. 
 
Three tumour samples were selected based on their complete lack of nuclear 
lamin A/C expression. These samples are representative of an increasing stage of 
colorectal neoplasia i.e. from a polyp to a Dukes’ C adenocarcinoma. Given the 
lack of nuclear lamin A/C expression in these samples, it is felt that absence of A-
type lamins will not confound the results of the microarray analysis. Two different 
approaches were undertaken to analyse the data. The first approach looks at the 
highest and lowest up-regulation of genes while the second approach clusters key 
genes into functional groups and then assessments are made to look for any 
unusual activation or suppression overall in the functional group being examined.  
By using the array data obtained from microarray analysis of the Tubulo-villous 
adenoma sample as a base line against which to compare array data obtained 
from the Dukes’ B & C cancer samples, it is observed that the gene encoding for 
insulin like growth factor 2 (Somatomedin A) is maximally up regulated only in the 
Dukes’ B sample while the gene encoding for carbonic anhydrase 1 is maximally 
up regulated in the Dukes’ C sample only. The genes encoding for Gremlin 1 (part 
of the cysteine knot family) and regulator of G protein signalling are down 
regulated significantly in the Dukes’ B and C samples respectively. Interestingly, 
when the array data from the Dukes’ B sample  is used as a baseline and a 
comparison made with the Dukes’ C sample  array data, it shows maximal down 
regulation in the gene encoding for insulin like growth factor 2 (Somatomedin A) 
and maximal up regulation in the gene encoding for carbonic anhydrase 1, in the 
Dukes’ C sample. It is thus immediately apparent that up regulation of the gene 
encoding for insulin like growth factor 2 (Somatomedin A) is uniquely up regulated 
only in the Dukes’ B stage tumour.  
By clustering key genes into functional groups and using the array data obtained 
from the microarray analysis of the tubulo-villous adenoma sample as a base line 
for comparison, it is observed that: 
316 | P a g e  
 
 Key genes involved in apoptosis are down regulated significantly in 
both Dukes’ B and C samples. 
 Key genes involved in tumour suppression are down regulated 
only in the Dukes’ B sample but not in the Dukes’ C sample. 
 Key genes involved in stem cell differentiation are generally up 
regulated in the Dukes’ C sample only. 
 No obvious changes are noted in key genes involved with the Wnt 
signalling pathway or its downstream mediators, such as c-MYC. 
 Other functional groups studied do not reveal any significant 
changes as a group, although instances of individual genes in a 
functional group do reveal significant changes. 
At this stage of the analysis from the microarray data obtained from three different 
stages of colorectal neoplasia, all devoid of nuclear lamin A/C expression, 
significant changes affecting the transition of colorectal cancer from the Dukes’ B 
stage towards the Dukes’ C stage are noted. From a clinical point of view, the 
main difference between these stages is related to the development of lymphatic 
spread in the Dukes’ C cancers. Up to date, various factors involved in this 
transition are still not clear and one can only speculate at best. The observation 
that key genes involved in tumour suppression are down regulated in the Dukes’ B 
cancer probably indicates a defining moment in the cancers ability to develop the 
potential to metastasise. Once metastasis takes place, the role of specific genes 
involved in tumour suppression might not be very significant, as illustrated by no 
significant changes in these genes in the Dukes’ C cancer; however, this is purely 
speculative and no definite evidence to support this viewpoint is found in the 
literature. The other key change noted is the up regulation of known key genes 
involved in stem cell differentiation, in the Dukes’ C cancer only. No definite 
explanation can be offered for this observation. However, stem cells are implicated 
by various authors in the development of colorectal cancer with some groups 
favouring the development of colorectal cancer due to a primary stem cell 
dysfunction (Preston et al., 2003) while other groups are of the opinion that 
colorectal cancers invade the stem cell niche and then take on attributes of stem 
cells (Shih et al., 2001) prior to attaining metastatic potential. From the array 
results, it appears that if any stem cell involvement is contributing to colorectal 
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cancer progression, it will be at a later stage of the cancer. This observation is in 
keeping with that proposed by Vogelstein et.al (Shih et al., 2001). This could also 
explain certain overlapping features of cancers with stem cells as regards 
immortality, self renewal, capacity to develop in different environments, etc. What 
are the individual factors and signalling cascades responsible for this switch in 
expression of key functional genes between a Dukes’ B and a Dukes’ C cancer, 
are still elusive, however, significantly the Wnt signalling cascade does not appear 
to contribute in any significant manner to these changes.  
 
5.4.2 Comparative microarray analysis of a Dukes’ B 
tumour sample expressing nuclear lamin A/C with a 
tubulo-villous adenoma, Dukes’ B and Dukes’ C tumour 
samples, devoid of nuclear lamin A/C expression. 
 
Assessment of two Dukes’ B tumour samples from different patients with identical 
stage and grades but different expression of nuclear lamin A/C, reveal very 
interesting features. The following genes are greatly up regulated in the Dukes’ B 
(lamin A/C positive) tumour sample: Insulin-like growth factor 2 (Somatomedin A); 
Fatty acid binding protein 1, liver; T plastin; creatine kinase brain and bone 
morphogenetic protein 4 (BMP4). On the other hand, key genes that are down 
regulated in the Dukes’ B (nuclear lamin A/C positive) tumour sample include: 
Secreted Phosphoprotein 1 (Osteopontin) and cyclooxygenase (COX2) amongst 
other down regulated genes. In addition, a microarray comparison using the 
Dukes’ B cancer sample expressing nuclear lamin A/C as a base line and 
comparing it with a tubulo-villous adenoma and a Dukes’ C tumour sample, both 
devoid of nuclear lamin A/C expression, reveals up regulation in the following 
additional key genes in the Dukes’ B sample expressing nuclear lamin A/C: Matrix 
metalloproteinase 3 (progelatinase) and proteolipid protein. Microarray analysis to 
assess for key down regulated genes reveals a similar set of genes as to those 
already observed when compared with the Dukes’ B sample devoid of nuclear 
lamin A/C expression.  
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Microarray assessment of key genes making up relevant functional groups reveals 
up regulation of the following functional gene groups in the Dukes’ B sample 
expressing nuclear lamin A/C when compared to the other tumour samples not 
expressing nuclear lamin A/C: 
 Apoptotic inhibitors 
 Cell cycle progression / proliferation and growth 
 Oncogenes 
 Stem cell differentiation 
 Wnt signalling (with the notable exception of epherin receptor B1 
which was down regulated) 
In the Dukes’ B cancer sample expressing lamin A/C, it is interesting to observe an 
up regulation in key genes involved in Wnt signalling, especially fatty acid binding 
protein 1, liver (FABP1). Similarly, in the stem cell functional group, an overall 
increase in the expression of key genes is noted, with the gene encoding for 
BMP4 (bone morphogenetic protein 4) being highly expressed. Amongst the 
functional group of genes involved with the cytoskeleton / nucleoskeleton, T-
plastin (PLS3) is highly expressed. This is accompanied by a modest down 
regulation of E-cadherin. Of interest is the observation that CKB (creatine kinase 
brain) is greatly up regulated.  
Given the microarray data analysis, a very complex picture is emerging as regards 
the role of lamin A/C in colorectal cancer. Many different signalling cascades are 
being implicated in cancers expressing lamin A/C. Work done by Willis et.al (Willis 
et al., 2008) has shown that cells expressing lamin A/C cause a downstream up 
regulation of T-plastin which in turn leads to a down regulation of E-cadherin. T-
plastin has previously been shown to be a member of the actin bundling protein 
group and includes L-plastin and I-plastin. All three isoforms share between a 70% 
and 78% homology with each other (Delanote et al., 2005). T-plastin expression 
has been identified in epithelial and mesenchymal tissues. The actin based 
cytoskeleton is known to be involved in a multitude of functions such as cell 
interaction, cytokinesis and cell migration. Neoplastic transformation in these 
tissues is accompanied by an increase in synthesis of T-plastin and L-plastin. 
Work done by Willis et.al (Willis et al., 2008) shows an increase in T-plastin levels 
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with a concomitant decrease in E-cadherin levels, in SW480 cell lines transfected 
with lamin A/C. SW480 cell lines are known to be deficient in lamin A/C expression 
(Willis et al., 2008). Their results show an increase in cell motility and invasiveness 
associated with increased expression of T-plastin and decreased expression of E-
cadherin. E-cadherin is a well known regulator of adhesive properties in epithelial 
cells (Masciari et al., 2007) and is a known downstream target for the BMP 
signalling cascade. E-cadherin has been implicated in many solid tumours such as 
breast and pancreatic cancers (von der Hardt et al., 2007; Zeisberg et al., 2005). 
Significant expression of T-plastin with a decrease in E-cadherin expression in the 
Dukes’ B sample expressing nuclear lamin A/C may be associated with an 
adverse prognosis in this group of cancers as the tumour cells could be less 
adhesive and potentially more invasive with a higher likelihood of metastatic 
spread. 
BMP4 is a known member of the transforming growth factor-β superfamily (TGFβ), 
members of which are known to play an important role in regulating cell growth, 
differentiation, proliferation and apoptosis via the TGFβ signalling pathway (BMP 
signalling pathway). Both up and down regulation of BMPs and their receptors 
have been reported in association with the progression of a variety of cancers. For 
example, up regulation of BMPR-IA, BMPR-II and BMP 2 mRNA levels has been 
reported in pancreatic cancers with 55% of these cancers exhibiting biallelic loss 
of SMAD4 (Moskaluk et al., 1997; Zhang et al., 1997).  A strong expression of 
BMP 4, 6 and 7 has also been detected in prostatic adenocarcinomas with 
established metastasis, thereby linking the role of BMPs in the development of 
skeletal metastasis in prostate cancers (Autzen et al., 1998; Hamdy et al., 1997; 
Masuda et al., 2003). An up-regulation of BMP 4 and BMP 7 expression has also 
been reported in several melanoma cell lines and increased expression is noted in 
primary and metastatic melanoma compared with naevi (Rothhammer et al., 
2005). In addition, Nishanian et.al (Nishanian et al., 2004) also demonstrate a link 
between Wnt signalling and BMP signalling. The role of BMP signalling pathway in 
colorectal cancer was first reported in patients with juvenile Polyposis syndrome 
(Howe et al., 2001). Further studies by Hardwick et.al (Hardwick et al., 2004) 
reveal that BMP 2 has an inhibitory effect on normal colonic epithelial growth by 
promoting differentiation and apoptosis and inhibiting cell proliferation. In the 
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development of colorectal cancer, uncontrolled and abnormal cellular proliferation 
coupled with aberrant cell death mechanisms, are known to play a very important 
role, amongst other mechanisms. It is not surprising then to find that inactivation of 
the TGF-β signalling mechanisms have been noted in approximately 80% of all 
colorectal cancers (Grady et al., 1998). The implications of these observations are 
that BMP signalling has a suppressive role in the development of colorectal 
cancer. However, the expression of BMP 4 has been detected in several colon 
cancer cell lines and is induced by an APC gene mutation(s) and / or activated β-
catenin, which occurs very frequently in colorectal tumours (Kim et al., 2002). Up-
regulation of BMP 4 in early colorectal cancers as compared to normal colonic 
mucosa has also been observed in a separate study by Nosho et.al (Nosho et al., 
2005). Interestingly, the expression of BMP 4 is noted to be elevated in early 
colorectal cancers but then declines in colorectal cancers that metastasise to 
lymph nodes or distant organs (Deng et al., 2007). No obvious explanation is 
found for this observation but the implications are that BMP 4 may help initiate 
metastasis of colorectal cancer but then plays a lesser role in maintaining these 
metastasis. Over expression of BMP 4 has also been shown to promote a more 
invasive phenotype in HCT116 colorectal cancer cell lines. The exact mechanisms 
for this are not clear but it is noted that over expression of BMP 4 in HCT116 
colorectal cancer cells induces the expression of urokinase plasminogen activator 
(uPA) mRNA and secretion of uPA protein, which is an extracellular matrix 
degrading proteinase. BMP 4 signalling can thus be involved in the regulation of 
uPA activity which can enhance the malignant potential of cancer cells by 
increasing their invasive potential. A further study  observes that BMP 4 over 
expression can protect colon cancer cells from apoptotic death under stressful 
conditions (Deng et al., 2007). What interaction(s) does lamin A/C expressing 
colorectal cancer cells have with BMP 4 signalling that confers a poorer prognosis 
in this sub-group? The answer to this question is not clear at present. Several 
intriguing possibilities are noted but no conclusive evidence is available to 
establish a definite link between BMP 4 signalling and lamin A/C status in 
colorectal cancer. Further work is needed to explore these observations since A-
type lamins might be implicated in BMP / TGFβ signalling pathways and if proved, 
this will be a novel finding, adding a further dimension to the known properties of 
A-type lamins.  
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Another gene found to be uniquely up regulated only in the Dukes’ B cancer 
sample expressing lamin A/C, is creatine kinase brain (CKB). CKB is an enzyme 
known to act as a catalyst in the conversion of creatine to phosphocreatine and 
adenosine diphosphate, via the phosphocreatine shuttle (Wallimann et al., 1992). 
Phosphocreatine is to known to act as an energy reservoir and plays an important 
role in the rapid buffering and regeneration of adenosine triphosphate in tissues. 
Studies done by Balasubramani et.al (Balasubramani et al., 2006) reveal high 
levels of creatine kinase in the nuclear matrix but low levels in the cytoplasm of 
cells taken from colorectal cancer tissue samples. There is no definite explanation 
for their observations; however, they propose post translational modifications as 
being responsible for the preferential translocation of CKB to the nuclear matrix 
with resultant low expression levels in the cytoplasm. In other studies involving 
cancers of the lung and breast (Arenas et al., 1989; Joseph et al., 1997; Zarghami 
et al., 1996), high levels of CKB expression are also noted in tumour samples. 
Another observation about CKB, which is very relevant and of significance to my 
work, is the observation that CKB levels are elevated in the serum of patients with 
cancer of the colon, lungs, ovaries and prostate. These high levels of CKB 
expression in the serum are difficult to explain but one theory put forward by 
Joseph et.al (Joseph et al., 1997) is that necrosis of tumour cells results in the 
high expression levels of serum CKB noted in these patients. Another key interest 
in this enzyme is the observation that it is closely associated with the nuclear 
matrix, of which lamins A/C are an integral part, raising the possibility of A-type 
lamins being involved, in some way, with nuclear energy metabolic pathways. This 
will add a new facet to the already known functions of lamin A/C in the nucleus 
and can explain partially why tumour cells expressing lamin A/C have an adverse 
prognosis. CKB has the potential for being developed as a prognostic tool in 
colorectal cancer, even though it is not very specific for colorectal cancer, its use 
as a serum marker and the fact that it is greatly up regulated only in lamin A/C 
expressing tumours, which are known to have an adverse prognosis, are features 
making it very attractive for use as a prognostic tool. Obviously, further 
experiments and trials will be needed to clarify the exact role of CKB as a 
prognostic tool in conjunction with lamin A/C expression. 
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Insulin-like growth factors (IGFs) are known to play an important role in cell 
growth and differentiation in many species (Chao and D'Amore, 2008). IGF1 and 
IGF2 are two proteins involved in mediating the observed effects of IGFs and are 
structurally similar to insulin. Both IGF1 and IGF2 are known to mediate their 
mitogenic signals through type I IGF receptors (IGF1R), present on most cells. 
Upon binding to IGF1R, the IGFs can activate Ras/Raf/MAPK and PI3-kinase/Akt 
cascades, and depending on the cell type, stimulate proliferation, differentiation or 
both (Baserga et al., 2003). PI3-kinase activation can lead to anti-apoptotic 
signals, and components of this pathway are frequently amplified or mutated in 
cancers (Hennessy et al., 2005).  In humans, IGF2 is the predominant IGF 
(LeRoith and Roberts, 2003) and its altered expression is observed in many 
pathological conditions (Docquier et al., 2005), including colon cancer (Kaneda 
and Feinberg, 2005). The regulation and expression of Igf2 is very complex since 
the gene encoding for IGF2 is found to be imprinted, or expressed monoallelically, 
and active only on the paternally inherited gene (DeChiara et al., 1991). Loss of 
imprinting, with resultant over expression of Igf2, is a fairly common observation in 
many cancers [reviewed in (Feinberg et al., 2006)], including colorectal cancer 
(Kaneda and Feinberg, 2005). Interestingly, transcriptional activation of IGF2 by 
the sonic hedgehog signalling pathway is also demonstrated in other studies 
(Ingram et al., 2002). Sonic hedgehog (Shh) along with Indian hedgehog (Ihh) and 
desert hedgehog (Ihh), make up three homologues of the Hedgehog (Hh) 
signalling pathway, each with remarkably similar biological properties, differing 
only in their potency (Shh>Ihh>Dhh). Hedgehog (Hh) signalling is known to inhibit 
Wnt signalling in the differentiated zone of the colonic crypts and thereby allow 
differentiation of cells to take place (van den Brink, 2007). Hedgehog (Hh) 
signalling is also known to restrict expression of Wnt targets to the base of the 
crypt in vivo (van den Brink et al., 2004), at the putative stem cell niche area, and 
thereby act as an anti-oncogenic factor towards Wnt signalling. The vast majority 
of colorectal cancers are sporadic, with approximately 90% harbouring APC 
mutations or other mutations that constitutively activate the Wnt signalling pathway 
(Gregorieff and Clevers, 2005). Interestingly, Ihh expression is lost very early in 
the process of colorectal carcinogenesis. Also, loss of Ihh has previously been 
noted in cases with FAP and in the flat lesions that precede polyp formation in the 
colon, indicating that loss of Ihh expression can be associated with the earliest 
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stages of colorectal carcinogenesis, probably as a direct consequence of 
overactive Wnt stimulation (van den Brink, 2007). From my microarray data, it is 
evident that IGF2 expression levels are low in the earliest stages of colorectal 
carcinogenesis; these then peak to a maximum in the Dukes’ B tumour expressing 
lamin A/C before dramatically tapering off in the Dukes’ C stage of colorectal 
cancer. It is difficult to explain this finding but it is apparent that significant events 
are taking place in the Dukes’ B tumour involving the expression of lamin A/C and 
potentially linking A-type lamins to IGFs. Can the cancer at this stage be 
undergoing changes that will then prime the stage for metastatic spread? Are 
these changes indicative of lamin A/C imposing a more differentiated phenotype 
on the cancer? Alternatively, is this the stage at which cancer cells are interacting 
with stem cells at the basal regions of the crypt and taking on a more stem cell like 
phenotype prior to attaining the potential for metastatic spread? An obvious 
explanation for these observations is lacking but a significant role for A-type lamins 
in controlling cell growth and differentiation via interacting with IGFs is a distinct 
possibility and merits further studies. 
Fatty acid binding protein 1 (liver) belongs to a group of low molecular weight 
proteins mostly involved in transport of fatty acids and other lipophilic substances 
between extracellular and intracellular membranes. Fatty acid binding proteins are 
known to play an active role in fatty acid mediated signal transduction pathways 
and regulation of gene expression (Hertzel and Bernlohr, 1998) and consequently 
its active role in modulating cell division (Sorof, 1994), cell growth and 
differentiation (Schroeder et al., 2001). Due to their  diverse physiological roles, 
and altered expression in various cancers, it is proposed that fatty acid binding 
proteins can play a role in tumourigenesis (Jing et al., 2000). Studies by Lawrie 
et.al (Lawrie et al., 2004) describe significantly decreased levels of fatty acid 
binding protein 1 expression in colorectal cancers, especially at the adenoma 
stage of tumour development. Their findings are in contrast to my observations. 
The high expression levels of fatty acid binding protein-1 noted in the Dukes’ B 
stage tumour expressing lamins A/C is intriguing. No definitive explanation can be 
given for this observation. However one possible theory to explain this finding is 
that A-type lamins are known markers for differentiation as is FABP 1, and hence 
their expression predominantly in the differentiated compartment of the colonic 
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crypts is to be expected. It is feasible to propose that the presence of lamin A/C in 
colorectal tumours imposes a more differentiated phenotype and thereby 
preserves the expression of fatty acid binding protein 1 in these tissues. 
 
 
 
 
 
5.5 Summary 
 
In summary then, I profiled the expression patterns of A-type lamins and their 
associated binding partners, Emerin and LAP2α, in crypts from the colon and 
rectum. A unique finding is the expression of lamin A in the putative stem cell 
niche area. The obvious questions here are ‘Does lamin A play a role in 
maintaining the stem cell niche? Can lamin A/C be a marker for stem cells? What 
are the underlying mechanisms resulting in this expression?’ In an attempt to 
answer these questions and many more, I identified potential mechanisms that 
can explain why lamin A/C is expressed in the stem cell niche area and also the 
intricate interactions of A-type lamins and their binding partners with known 
signalling mechanism at work in the crypts. A definitive link between Wnt signalling 
and lamin A/C is theoretically possible through Emerin. In addition, the 
retinoblastoma – E2F pathway is also potentially implicated in maintaining 
homeostasis in the crypts and can play a key role in the stem cell niche area. 
Looking at the role of A-type lamins in colorectal cancers, it is noted that lamin A/C 
expression in cancer cells imparts a poor prognosis, irrespective of stage or 
differentiation status. Further experimental work and microarray analysis yield 
indicative information as to the potential mechanisms responsible for A-type 
lamins imparting a poor prognosis in colorectal cancers. Of key interest are the 
observations that tumours expressing lamin A/C have a more motile and less 
adherent phenotype due to up regulation of T-plastin and down regulation of E-
325 | P a g e  
 
cadherin. These tumours also exhibit a general up regulation of genes involved in 
stem cell differentiation, especially in the Dukes’ C stage of the tumour; and a 
down regulation of genes involved in apoptosis and inhibition of tumour 
suppressor genes. 
Concentrating on the Dukes’ B stage tumour, I note significant differences 
between the nuclear lamin A/C expressing tumours and tumours not expressing 
lamin A/C. In the tumour sample expressing lamin A/C, there appears to be a 
general up regulation of genes involved with inhibition of apoptosis, cell cycle 
progression / proliferation and growth, oncogenes, stem cell differentiation and 
Wnt signalling pathways. These observations also add further insight as to why 
lamin A/C expressing tumours can potentially be more aggressive.  
In studying individual key genes showing significant change, I note with interest 
the significant role BMP / TGFβ signalling might play in the group of cancers 
expressing lamin A/C. Similarly, up regulation of IGF2 in the lamin A/C expressing 
tumour sample hints towards involvement of the hedgehog signalling pathway. 
The Wnt signalling pathway is also implicated in the lamin A/C expressing tumour 
sample. Another unique gene up regulated significantly in the lamin A/C 
expressing tumour is CKB. The product of this gene, CKB protein appeared to 
hold good promise as a prognostic indicator in colorectal cancers in conjunction 
with lamin A/C.  
An answer to the question of “Is colorectal cancer primarily a stem cell problem or 
not?” is still not clear. However, from my observations, there appear to be key 
changes taking place mostly in the Dukes’ B group of tumours only, this can 
potentially indicate that colorectal cancers do adopt a more stem cell like 
phenotype at this stage and not before, thereby favouring a top down 
morphogenesis of colorectal cancer. It is stressed at this point that additional 
samples or pooled samples from multiple patients are needed to carry out further 
confirmatory studies. My results are based on single samples from individual 
patients. I will conclude this work by proposing that “Lamin A/C expressing 
tumours appear to be motile, more invasive and less adherent and adopt a stem 
cell like phenotype which can impart an adverse outcome in this group of patients”. 
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